[{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1414517229476093957"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-07-12T10:11:20.000Z","author_id":"116716199","text":"RT @EU_Health: To vaccinate as many people as possible is crucial to end the pandemic.\n\nTwo-time kidney transplant patient Borislava explai‚Ä¶","id":"1414527790435737602","conversation_id":"1414527790435737602","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1413830368734728192"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":93,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-07-12T07:52:38.000Z","author_id":"116716199","text":"RT @EU_Commission: Full vaccination is the way out of the pandemic.\n\nWe have made remarkable progress, but let's not relax our efforts: we‚Ä¶","id":"1414492883399348229","conversation_id":"1414492883399348229","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1414488019944493058"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-07-12T07:52:12.000Z","author_id":"116716199","text":"RT @EU_HaDEA: European Reference Networks #ERN are networks of üá™üá∫ #healthcare providers, focusing on complex or rare diseases and condition‚Ä¶","id":"1414492777937883140","conversation_id":"1414492777937883140","entities":{"mentions":[{"start":3,"end":12,"username":"EU_HaDEA","id":"1399614058496679936"}],"hashtags":[{"start":42,"end":46,"tag":"ERN"},{"start":66,"end":77,"tag":"healthcare"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":29,"quote_count":1},"created_at":"2021-07-09T15:14:37.000Z","author_id":"116716199","text":"EMA's safety committee, the #PRAC, finds no evidence linking Zynteglo to blood cancer.\nhttps://t.co/kSS16P4ML6\n\n#SaftyOfMedicines #Pharmacovigilance","id":"1413516948697194497","conversation_id":"1413516948697194497","entities":{"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"PRAC"},{"start":112,"end":129,"tag":"SaftyOfMedicines"},{"start":130,"end":148,"tag":"Pharmacovigilance"}],"urls":[{"start":87,"end":110,"url":"https://t.co/kSS16P4ML6","expanded_url":"https://www.ema.europa.eu/en/news/ema-finds-no-evidence-linking-viral-vector-zynteglo-blood-cancer","display_url":"ema.europa.eu/en/news/ema-fi‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":76,"reply_count":3,"like_count":111,"quote_count":16},"created_at":"2021-07-09T14:44:40.000Z","author_id":"116716199","text":"EMA has recommended that people with a history of capillary leak syndrome must not be vaccinated with #COVID19vaccine Janssen.\nhttps://t.co/YghuIPRgEf\n\n#healthcare #COVID19vaccine","id":"1413509413973934080","conversation_id":"1413509413973934080","entities":{"mentions":{},"hashtags":[{"start":102,"end":117,"tag":"COVID19vaccine"},{"start":152,"end":163,"tag":"healthcare"},{"start":164,"end":179,"tag":"COVID19vaccine"}],"urls":[{"start":127,"end":150,"url":"https://t.co/YghuIPRgEf","expanded_url":"https://www.ema.europa.eu/en/news/ema-advises-against-use-covid-19-vaccine-janssen-people-history-capillary-leak-syndrome","display_url":"ema.europa.eu/en/news/ema-ad‚Ä¶"}],"annotations":[{"start":118,"end":124,"probability":0.7928,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":143,"reply_count":11,"like_count":192,"quote_count":19},"created_at":"2021-07-09T13:50:48.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) has concluded that very rare cases of myocarditis and pericarditis can occur following vaccination with mRNA vaccines:https://t.co/RijRbF2GAT https://t.co/eFaj2U22FK","id":"1413495858474201094","conversation_id":"1413495858474201094","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"}],"urls":[{"start":149,"end":172,"url":"https://t.co/RijRbF2GAT","expanded_url":"https://www.ema.europa.eu/en/news/comirnaty-spikevax-possible-link-very-rare-cases-myocarditis-pericarditis","display_url":"ema.europa.eu/en/news/comirn‚Ä¶"},{"start":173,"end":196,"url":"https://t.co/eFaj2U22FK","expanded_url":"https://twitter.com/EMA_News/status/1413495858474201094/photo/1","display_url":"pic.twitter.com/eFaj2U22FK"}],"annotations":{}},"attachments":{"media_keys":["3_1413495240967671816"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":33,"quote_count":5},"created_at":"2021-07-09T11:43:31.000Z","author_id":"116716199","text":"During its July meeting, EMA‚Äôs safety committee (#PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines, including #COVID19vaccines. \nRead more:https://t.co/wAokMsDSW7 https://t.co/bQI6h1t9YZ","id":"1413463826599665664","conversation_id":"1413463826599665664","entities":{"mentions":{},"hashtags":[{"start":49,"end":54,"tag":"PRAC"},{"start":187,"end":203,"tag":"COVID19vaccines"}],"urls":[{"start":216,"end":239,"url":"https://t.co/wAokMsDSW7","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-5-8-july-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":240,"end":263,"url":"https://t.co/bQI6h1t9YZ","expanded_url":"https://twitter.com/EMA_News/status/1413463826599665664/photo/1","display_url":"pic.twitter.com/bQI6h1t9YZ"}],"annotations":{}},"attachments":{"media_keys":["3_1413463401192378369"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":18,"quote_count":0},"created_at":"2021-07-06T09:47:12.000Z","author_id":"116716199","text":"In 2020, we saw the highest number of positive opinions received by #SMEs for a marketing authorisation for human medicines üíä in the üá™üá∫. Half of these medicines are targeting #RareDiseases. \nüëâhttps://t.co/lFvh2RaPhx #SMEOfficeEMA","id":"1412347390498050049","conversation_id":"1412347390498050049","entities":{"mentions":{},"hashtags":[{"start":68,"end":73,"tag":"SMEs"},{"start":175,"end":188,"tag":"RareDiseases"},{"start":216,"end":229,"tag":"SMEOfficeEMA"}],"urls":[{"start":192,"end":215,"url":"https://t.co/lFvh2RaPhx","expanded_url":"https://ema.europa.eu/en/news/success-rate-marketing-authorisation-applications-smes-doubles-between-2016-2020","display_url":"ema.europa.eu/en/news/succes‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":1,"like_count":17,"quote_count":0},"created_at":"2021-07-06T09:34:41.000Z","author_id":"116716199","text":"More than 4 in 10 medicines for animal use developed by #SMEs and granted with a positive opinion for a marketing authorisation in the üá™üá∫ benefited from EMA‚Äôs scientific advice. #veterinary #SMEOfficeEMA \nüëâhttps://t.co/UaLNnFpLBo https://t.co/InJXKlzv9k","id":"1412344238029815809","conversation_id":"1412344238029815809","entities":{"mentions":{},"hashtags":[{"start":56,"end":61,"tag":"SMEs"},{"start":178,"end":189,"tag":"veterinary"},{"start":190,"end":203,"tag":"SMEOfficeEMA"}],"urls":[{"start":206,"end":229,"url":"https://t.co/UaLNnFpLBo","expanded_url":"https://www.ema.europa.eu/en/news/success-rate-marketing-authorisation-applications-smes-doubles-between-2016-2020","display_url":"ema.europa.eu/en/news/succes‚Ä¶"},{"start":230,"end":253,"url":"https://t.co/InJXKlzv9k","expanded_url":"https://twitter.com/EMA_News/status/1412344238029815809/video/1","display_url":"pic.twitter.com/InJXKlzv9k"}],"annotations":{}},"attachments":{"media_keys":["7_1412344082534486018"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":1,"like_count":19,"quote_count":0},"created_at":"2021-07-06T08:30:17.000Z","author_id":"116716199","text":"#DidYouKnow? 14% of all scientific advice for #COVID19 developments were from #SMEs registered with EMA. #SMEOfficeEMA \nüëâhttps://t.co/UaLNnFpLBo","id":"1412328033277591554","conversation_id":"1412328033277591554","entities":{"mentions":{},"hashtags":[{"start":0,"end":11,"tag":"DidYouKnow"},{"start":46,"end":54,"tag":"COVID19"},{"start":78,"end":83,"tag":"SMEs"},{"start":105,"end":118,"tag":"SMEOfficeEMA"}],"urls":[{"start":121,"end":144,"url":"https://t.co/UaLNnFpLBo","expanded_url":"https://www.ema.europa.eu/en/news/success-rate-marketing-authorisation-applications-smes-doubles-between-2016-2020","display_url":"ema.europa.eu/en/news/succes‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":5,"like_count":28,"quote_count":0},"created_at":"2021-07-06T07:54:14.000Z","author_id":"116716199","text":"What are the key achievements of SMEs in medicine development? Find out in our #SME Office Report 2016-2020. \n\nThe success rate of SMEs applying for a marketing authorisation application for human medicinesüíä has doubled! \n\nRead more: \nüëâhttps://t.co/UaLNnFpLBo #SMEOfficeEMA https://t.co/gGBm8ULbh1","id":"1412318961375617027","conversation_id":"1412318961375617027","entities":{"mentions":{},"hashtags":[{"start":79,"end":83,"tag":"SME"},{"start":260,"end":273,"tag":"SMEOfficeEMA"}],"urls":[{"start":236,"end":259,"url":"https://t.co/UaLNnFpLBo","expanded_url":"https://www.ema.europa.eu/en/news/success-rate-marketing-authorisation-applications-smes-doubles-between-2016-2020","display_url":"ema.europa.eu/en/news/succes‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/gGBm8ULbh1","expanded_url":"https://twitter.com/EMA_News/status/1412318961375617027/photo/1","display_url":"pic.twitter.com/gGBm8ULbh1"}],"annotations":{}},"attachments":{"media_keys":["16_1412318660635602944"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":1,"like_count":12,"quote_count":1},"created_at":"2021-07-02T16:02:36.000Z","author_id":"116716199","text":"During its June 2021 meeting, the #CHMP reviewed 4 recommendations for eligibility to PRIME. All of them were denied. \n\nRead more about the individual outcomes adopted this month: https://t.co/yXGayFxX8k\n\n#PRIMEschemeEU https://t.co/TMbCEanp8H","id":"1410992312801452033","conversation_id":"1410992312801452033","entities":{"mentions":{},"hashtags":[{"start":34,"end":39,"tag":"CHMP"},{"start":205,"end":219,"tag":"PRIMEschemeEU"}],"urls":[{"start":180,"end":203,"url":"https://t.co/yXGayFxX8k","expanded_url":"https://www.ema.europa.eu/en/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-21-24-june-2021_en.pdf","display_url":"ema.europa.eu/en/documents/c‚Ä¶"},{"start":220,"end":243,"url":"https://t.co/TMbCEanp8H","expanded_url":"https://twitter.com/EMA_News/status/1410992312801452033/photo/1","display_url":"pic.twitter.com/TMbCEanp8H"}],"annotations":{}},"attachments":{"media_keys":["3_1410991734838943753"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":63,"reply_count":11,"like_count":142,"quote_count":9},"created_at":"2021-07-02T15:28:07.000Z","author_id":"116716199","text":"EMA has approved a scale-up of the manufacturing capacity at the site in Leiden, the Netherlands for the production of COVID-19 Vaccine Janssen, a #COVID19vaccine developed by Janssen - Cilag International NV. https://t.co/xR9GpOiS7d\n#vaccineswork #COVID19 https://t.co/m2wIwVVoQB","id":"1410983632974585856","conversation_id":"1410983632974585856","entities":{"mentions":{},"hashtags":[{"start":147,"end":162,"tag":"COVID19vaccine"},{"start":234,"end":247,"tag":"vaccineswork"},{"start":248,"end":256,"tag":"COVID19"}],"urls":[{"start":210,"end":233,"url":"https://t.co/xR9GpOiS7d","expanded_url":"https://www.ema.europa.eu/en/news/increased-manufacturing-capacity-covid-19-vaccine-janssen","display_url":"ema.europa.eu/en/news/increa‚Ä¶"},{"start":257,"end":280,"url":"https://t.co/m2wIwVVoQB","expanded_url":"https://twitter.com/EMA_News/status/1410983632974585856/photo/1","display_url":"pic.twitter.com/m2wIwVVoQB"}],"annotations":[{"start":0,"end":2,"probability":0.6643,"type":"Organization","normalized_text":"EMA"},{"start":73,"end":78,"probability":0.9687,"type":"Place","normalized_text":"Leiden"},{"start":85,"end":95,"probability":0.8325,"type":"Place","normalized_text":"Netherlands"},{"start":176,"end":182,"probability":0.6404,"type":"Person","normalized_text":"Janssen"},{"start":186,"end":207,"probability":0.5309,"type":"Place","normalized_text":"Cilag International NV"}]},"attachments":{"media_keys":["3_1410983182921568256"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":2,"like_count":32,"quote_count":3},"created_at":"2021-07-01T16:32:24.000Z","author_id":"116716199","text":"Our #Patients and Consumers Working Party #PCWP is meeting the @CTTI_Trials/@US_FDA Patient Engagement Collaborative (PEC) for the 1st time. \n\nThey will share experiences on patient information and discuss engaging young people in regulators' work. \nüëâhttps://t.co/sW7YgDQyAJ https://t.co/dXEgHSelqB","id":"1410637420224303105","conversation_id":"1410637420224303105","entities":{"mentions":[{"start":63,"end":75,"username":"CTTI_Trials","id":"755163601"},{"start":76,"end":83,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":4,"end":13,"tag":"Patients"},{"start":42,"end":47,"tag":"PCWP"}],"urls":[{"start":251,"end":274,"url":"https://t.co/sW7YgDQyAJ","expanded_url":"https://www.ema.europa.eu/en/events/meeting-cttifda-patient-engagement-collaborative-pec-ema-patients-consumers-working-party-pcwp","display_url":"ema.europa.eu/en/events/meet‚Ä¶"},{"start":275,"end":298,"url":"https://t.co/dXEgHSelqB","expanded_url":"https://twitter.com/EMA_News/status/1410637420224303105/photo/1","display_url":"pic.twitter.com/dXEgHSelqB"},{"start":275,"end":298,"url":"https://t.co/dXEgHSelqB","expanded_url":"https://twitter.com/EMA_News/status/1410637420224303105/photo/1","display_url":"pic.twitter.com/dXEgHSelqB"}],"annotations":{}},"attachments":{"media_keys":["3_1410637258869325831","3_1410637258907078663"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":2,"like_count":23,"quote_count":1},"created_at":"2021-07-01T12:39:05.000Z","author_id":"116716199","text":"Watch the tweets posted during EMA's fourth regular press briefing on 1 July 2021 on #COVID19 vaccines and treatments. #EMAPresser https://t.co/EcZ197E1or","id":"1410578705295056899","conversation_id":"1410578705295056899","entities":{"mentions":{},"hashtags":[{"start":85,"end":93,"tag":"COVID19"},{"start":119,"end":130,"tag":"EMAPresser"}],"urls":[{"start":131,"end":154,"url":"https://t.co/EcZ197E1or","expanded_url":"https://twitter.com/i/events/1410576700660912131","display_url":"twitter.com/i/events/14105‚Ä¶"}],"annotations":[{"start":31,"end":33,"probability":0.5229,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":10,"like_count":31,"quote_count":2},"created_at":"2021-07-01T12:16:45.000Z","author_id":"116716199","text":"All 5 treatments selected by the @EU_Commission under its Therapeutics Strategy are currently under EMA's rolling review, which will continue over the summer. First opinions are expected later this year. #EMAPresser","id":"1410573084680130565","conversation_id":"1410573084680130565","entities":{"mentions":[{"start":33,"end":47,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":204,"end":215,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":1,"like_count":58,"quote_count":2},"created_at":"2021-07-01T12:16:15.000Z","author_id":"116716199","text":"Healthcare professionals should report any #SideEffects in people having #COVID19vaccines. Any new data that become available will be assessed by EMA's safety committee. #PRAC #EMAPresser","id":"1410572958108635139","conversation_id":"1410572958108635139","entities":{"mentions":{},"hashtags":[{"start":43,"end":55,"tag":"SideEffects"},{"start":73,"end":89,"tag":"COVID19vaccines"},{"start":170,"end":175,"tag":"PRAC"},{"start":176,"end":187,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":1,"like_count":106,"quote_count":4},"created_at":"2021-07-01T12:15:08.000Z","author_id":"116716199","text":"EMA will review data on the safety and immune response in people who have received a 3rd dose, or a 2nd dose in the case of the #Janssen #COVID19 vaccine. These data should be collected over the summer. #EMAPresser","id":"1410572678591881220","conversation_id":"1410572678591881220","entities":{"mentions":{},"hashtags":[{"start":128,"end":136,"tag":"Janssen"},{"start":137,"end":145,"tag":"COVID19"},{"start":203,"end":214,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4761,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":70,"reply_count":15,"like_count":186,"quote_count":27},"created_at":"2021-07-01T12:14:38.000Z","author_id":"116716199","text":"EMA is in touch with vaccine developers to discuss the potential use of a booster dose and to determine the best timing and the best strategy. At this stage it is unclear whether booster doses will be necessary for the #COVID19vaccines to maintain their protection. #EMAPresser","id":"1410572553907748868","conversation_id":"1410572553907748868","entities":{"mentions":{},"hashtags":[{"start":219,"end":235,"tag":"COVID19vaccines"},{"start":266,"end":277,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4652,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":98,"reply_count":10,"like_count":221,"quote_count":26},"created_at":"2021-07-01T12:13:18.000Z","author_id":"116716199","text":"Currently EMA can't make a recommendation on use of different #COVID19vaccines for the 2 doses. Interim results from studies in üá™üá∏ üá©üá™ &amp; üá¨üáß show good immune response &amp; no safety concerns. More data are awaited shortly. EMA is reviewing data as they become available. #EMAPresser","id":"1410572216601919500","conversation_id":"1410572216601919500","entities":{"mentions":{},"hashtags":[{"start":62,"end":78,"tag":"COVID19vaccines"},{"start":274,"end":285,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":5,"like_count":116,"quote_count":7},"created_at":"2021-07-01T12:04:46.000Z","author_id":"116716199","text":"EMA has requested all vaccine developers to investigate if their vaccine provides protection against emerging new virus variants. All studies are examined by EMA to conclude on the level of protection that current #COVID19vaccines offer against new variants. #EMAPresser","id":"1410570071580229638","conversation_id":"1410570071580229638","entities":{"mentions":{},"hashtags":[{"start":214,"end":230,"tag":"COVID19vaccines"},{"start":259,"end":270,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5623,"type":"Organization","normalized_text":"EMA"},{"start":158,"end":160,"probability":0.6117,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":2,"like_count":42,"quote_count":2},"created_at":"2021-07-01T12:04:28.000Z","author_id":"116716199","text":"Speeding up vaccination &amp; maintaining #PublicHealth measures remain essential tools to fight #COVID19. It is important to ensure that vulnerable and elderly people complete their vaccination course ASAP to protect them from further spread of the delta variant. #EMAPresser","id":"1410569994312765442","conversation_id":"1410569994312765442","entities":{"mentions":{},"hashtags":[{"start":42,"end":55,"tag":"PublicHealth"},{"start":97,"end":105,"tag":"COVID19"},{"start":265,"end":276,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":511,"reply_count":49,"like_count":1064,"quote_count":89},"created_at":"2021-07-01T12:03:49.000Z","author_id":"116716199","text":"It seems that the 4 vaccines authorised in the EU üá™üá∫ protect against all strains, including the delta variant. First real-world data suggest that:\n‚û°Ô∏è2 doses of vaccines protect against the delta variant\n‚û°Ô∏èantibodies from the approved vaccines neutralise this variant. #EMAPresser","id":"1410569830831476736","conversation_id":"1410569830831476736","entities":{"mentions":{},"hashtags":[{"start":268,"end":279,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":23,"quote_count":0},"created_at":"2021-07-01T12:01:12.000Z","author_id":"116716199","text":"Watch live üî¥\n\nWe are now starting the fourth regular press briefing on #COVID19 vaccines and treatments. \n\nDon‚Äôt miss our tweets during the press briefing. Follow #EMAPresser. \n\nüëâhttps://t.co/DgjakTyggZ","id":"1410569171902119940","conversation_id":"1410569171902119940","entities":{"mentions":{},"hashtags":[{"start":71,"end":79,"tag":"COVID19"},{"start":163,"end":174,"tag":"EMAPresser"}],"urls":[{"start":179,"end":202,"url":"https://t.co/DgjakTyggZ","expanded_url":"https://youtu.be/1sdIXHwN7Xc","display_url":"youtu.be/1sdIXHwN7Xc"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":4,"like_count":36,"quote_count":1},"created_at":"2021-07-01T11:45:04.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA‚Äôs fourth regular press briefing on #COVID19 vaccines and treatments will be broadcast live üî¥ today, 1 July 2021, 14:00 CEST  #EMAPresser\n\nhttps://t.co/cFsBOOBaEX https://t.co/dEorugVkGO","id":"1410565114512674822","conversation_id":"1410565114512674822","entities":{"mentions":{},"hashtags":[{"start":42,"end":50,"tag":"COVID19"},{"start":132,"end":143,"tag":"EMAPresser"}],"urls":[{"start":145,"end":168,"url":"https://t.co/cFsBOOBaEX","expanded_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-1","display_url":"ema.europa.eu/en/events/ema-‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-1"},{"start":169,"end":192,"url":"https://t.co/dEorugVkGO","expanded_url":"https://twitter.com/EMA_News/status/1410565114512674822/photo/1","display_url":"pic.twitter.com/dEorugVkGO"}],"annotations":{}},"attachments":{"media_keys":["3_1410565060045459456"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1410487799233617923"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":352,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-07-01T10:32:06.000Z","author_id":"116716199","text":"RT @EU_Commission: We are bringing back the spirit of an open Europe. \n\nAs of today, EU citizens can get their #EUCOVIDcertificate issued a‚Ä¶","id":"1410546749127671817","conversation_id":"1410546749127671817","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":111,"end":130,"tag":"EUCOVIDcertificate"}],"urls":{},"annotations":[{"start":62,"end":67,"probability":0.9324,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1410218165582417923"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-30T12:48:12.000Z","author_id":"116716199","text":"RT @SKyriakidesEU: Pleased to launch the Knowledge Centre on #Cancer with @GabrielMariya. \n\nAs our first #EUCancerPlan flagship it will be‚Ä¶","id":"1410218614226096131","conversation_id":"1410218614226096131","entities":{"mentions":[{"start":3,"end":17,"username":"SKyriakidesEU","id":"2476130260"},{"start":74,"end":88,"username":"GabrielMariya","id":"2162942852"}],"hashtags":[{"start":61,"end":68,"tag":"Cancer"},{"start":105,"end":118,"tag":"EUCancerPlan"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":43,"reply_count":4,"like_count":78,"quote_count":4},"created_at":"2021-06-30T09:37:51.000Z","author_id":"116716199","text":"#Antibiotic consumption data in food-producing animals collected by EMA confirm that the measures taken by national authorities and @EFSA_EU , @ECDC_EU and EMA are effective. #AMR #AntimicrobialResistance https://t.co/UXUFz4y4bO https://t.co/Vj5IJBdUdq","id":"1410170709406593028","conversation_id":"1410170709406593028","entities":{"mentions":[{"start":132,"end":140,"username":"EFSA_EU","id":"84582815"},{"start":143,"end":151,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":0,"end":11,"tag":"Antibiotic"},{"start":175,"end":179,"tag":"AMR"},{"start":180,"end":204,"tag":"AntimicrobialResistance"}],"urls":[{"start":205,"end":228,"url":"https://t.co/UXUFz4y4bO","expanded_url":"https://www.ema.europa.eu/en/news/use-antibiotics-animals-decreasing","display_url":"ema.europa.eu/en/news/use-an‚Ä¶"},{"start":229,"end":252,"url":"https://t.co/Vj5IJBdUdq","expanded_url":"https://twitter.com/EMA_News/status/1410170709406593028/photo/1","display_url":"pic.twitter.com/Vj5IJBdUdq"}],"annotations":[{"start":68,"end":70,"probability":0.4359,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1410170025877684225"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":2,"like_count":42,"quote_count":4},"created_at":"2021-06-30T09:20:21.000Z","author_id":"116716199","text":"üì¢ @EFSA_EU - EMA - @ECDC_EU report: \nUse of #antibiotics is now lower in food-producing animals than in humans. \nThis is an important finding as the report identifies links between #antimicrobial consumption in animals and #AMR in bacteria from humans \nüëâhttps://t.co/UXUFz4y4bO https://t.co/gTpmJrvmuL","id":"1410166306440159234","conversation_id":"1410166306440159234","entities":{"mentions":[{"start":2,"end":10,"username":"EFSA_EU","id":"84582815"},{"start":19,"end":27,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":44,"end":56,"tag":"antibiotics"},{"start":181,"end":195,"tag":"antimicrobial"},{"start":223,"end":227,"tag":"AMR"}],"urls":[{"start":254,"end":277,"url":"https://t.co/UXUFz4y4bO","expanded_url":"https://www.ema.europa.eu/en/news/use-antibiotics-animals-decreasing","display_url":"ema.europa.eu/en/news/use-an‚Ä¶"},{"start":278,"end":301,"url":"https://t.co/gTpmJrvmuL","expanded_url":"https://twitter.com/EMA_News/status/1410166306440159234/photo/1","display_url":"pic.twitter.com/gTpmJrvmuL"}],"annotations":{}},"attachments":{"media_keys":["3_1410166196083859460"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":31,"like_count":83,"quote_count":17},"created_at":"2021-06-30T08:17:57.000Z","author_id":"116716199","text":"#COVID19vaccines where are we now? \nRolling reviews in progress, no new applications submitted, authorisations completed. https://t.co/8d5ZAVS8J0","id":"1410150601506365440","conversation_id":"1410150601506365440","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":122,"end":145,"url":"https://t.co/8d5ZAVS8J0","expanded_url":"https://twitter.com/EMA_News/status/1410150601506365440/photo/1","display_url":"pic.twitter.com/8d5ZAVS8J0"}],"annotations":{}},"attachments":{"media_keys":["3_1410150027540975621"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1408416636084707335"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":221,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-25T13:57:49.000Z","author_id":"116716199","text":"RT @WHO: Here is why you should get vaccinated even if you have had #COVID19 üëá","id":"1408424191754391560","conversation_id":"1408424191754391560","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":68,"end":76,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":53,"reply_count":7,"like_count":109,"quote_count":8},"created_at":"2021-06-25T13:19:59.000Z","author_id":"116716199","text":"EMA has approved an additional manufacturing site for the production of #COVID19vaccine Janssen, developed by Janssen - Cilag International NV: https://t.co/ZJShTCEIXE\n\n#vaccineswork #COVID19 https://t.co/UtFRfDbXT6","id":"1408414673695879181","conversation_id":"1408414673695879181","entities":{"mentions":{},"hashtags":[{"start":72,"end":87,"tag":"COVID19vaccine"},{"start":169,"end":182,"tag":"vaccineswork"},{"start":183,"end":191,"tag":"COVID19"}],"urls":[{"start":144,"end":167,"url":"https://t.co/ZJShTCEIXE","expanded_url":"https://www.ema.europa.eu/en/news/additional-manufacturing-site-covid-19-vaccine-janssen","display_url":"ema.europa.eu/en/news/additi‚Ä¶"},{"start":192,"end":215,"url":"https://t.co/UtFRfDbXT6","expanded_url":"https://twitter.com/EMA_News/status/1408414673695879181/photo/1","display_url":"pic.twitter.com/UtFRfDbXT6"}],"annotations":[{"start":0,"end":2,"probability":0.7628,"type":"Organization","normalized_text":"EMA"},{"start":88,"end":94,"probability":0.6861,"type":"Person","normalized_text":"Janssen"},{"start":110,"end":116,"probability":0.7861,"type":"Person","normalized_text":"Janssen"},{"start":120,"end":141,"probability":0.5725,"type":"Place","normalized_text":"Cilag International NV"}]},"attachments":{"media_keys":["3_1408413943702429700"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":2,"like_count":43,"quote_count":3},"created_at":"2021-06-25T12:35:49.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) has recommended the first cell-based gene therapy to treat adult patients with relapsed and refractory multiple myeloma for approval in the EU. \nhttps://t.co/nA57GVSRkf","id":"1408403558089871368","conversation_id":"1408403558089871368","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"}],"urls":[{"start":185,"end":208,"url":"https://t.co/nA57GVSRkf","expanded_url":"https://www.ema.europa.eu/en/news/first-cell-based-gene-therapy-treat-adult-patients-multiple-myeloma","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":1,"like_count":25,"quote_count":0},"created_at":"2021-06-25T12:09:30.000Z","author_id":"116716199","text":"EMA's human medicines committee #CHMP has recommended for approval a new #medicine for a condition that impairs bone growth and causes dwarfism:https://t.co/qrAfIyIDlO","id":"1408396934390374400","conversation_id":"1408396934390374400","entities":{"mentions":{},"hashtags":[{"start":32,"end":37,"tag":"CHMP"},{"start":73,"end":82,"tag":"medicine"}],"urls":[{"start":144,"end":167,"url":"https://t.co/qrAfIyIDlO","expanded_url":"https://www.ema.europa.eu/en/news/new-treatment-people-dwarfism","display_url":"ema.europa.eu/en/news/new-tr‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":3,"like_count":28,"quote_count":0},"created_at":"2021-06-25T10:38:56.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 8 #medicines for approval at its June 2021 meeting:https://t.co/0knfWrPF6t https://t.co/c76ofHDVhF","id":"1408374144287248390","conversation_id":"1408374144287248390","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":102,"end":125,"url":"https://t.co/0knfWrPF6t","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-june-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":126,"end":149,"url":"https://t.co/c76ofHDVhF","expanded_url":"https://twitter.com/EMA_News/status/1408374144287248390/photo/1","display_url":"pic.twitter.com/c76ofHDVhF"}],"annotations":[{"start":0,"end":2,"probability":0.4632,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1408373427564597252"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1408326744474537986"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":31,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-25T07:34:19.000Z","author_id":"116716199","text":"RT @EU_Health: Hello @CPME_EUROPA, @PGEU and @EFNBrussels! üëã\n\nIt's 6 months after the first #COVID19 vaccinations were administered in the‚Ä¶","id":"1408327682882998273","conversation_id":"1408327682882998273","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":21,"end":33,"username":"CPME_EUROPA","id":"440810430"},{"start":35,"end":40,"username":"PGEU","id":"459292439"},{"start":45,"end":57,"username":"EFNBrussels","id":"2813358969"}],"hashtags":[{"start":92,"end":100,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1407694848673583108"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-25T07:29:33.000Z","author_id":"116716199","text":"RT @ECDC_EU: #ECDC Director Andrea Ammon:\n\n\"Now is the time to walk the extra mile.\nWe have several #COVID19 vaccines available and every s‚Ä¶","id":"1408326481030299649","conversation_id":"1408326481030299649","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":18,"tag":"ECDC"},{"start":100,"end":108,"tag":"COVID19"}],"urls":{},"annotations":[{"start":28,"end":39,"probability":0.7723,"type":"Person","normalized_text":"Andrea Ammon"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":104,"reply_count":14,"like_count":272,"quote_count":26},"created_at":"2021-06-22T12:49:46.000Z","author_id":"116716199","text":"EMA has approved additional manufacturing sites for the production of Comirnaty, the #COVID19vaccine developed by BioNTech and Pfizer. https://t.co/kFXSVB6rRn\n\n#VaccinesWork #CovidVaccines https://t.co/sKSBaBkrzu","id":"1407319905511354373","conversation_id":"1407319905511354373","entities":{"mentions":{},"hashtags":[{"start":85,"end":100,"tag":"COVID19vaccine"},{"start":160,"end":173,"tag":"VaccinesWork"},{"start":174,"end":188,"tag":"CovidVaccines"}],"urls":[{"start":135,"end":158,"url":"https://t.co/kFXSVB6rRn","expanded_url":"https://www.ema.europa.eu/en/news/two-additional-manufacturing-sites-biontechpfizers-covid-19-vaccine","display_url":"ema.europa.eu/en/news/two-ad‚Ä¶"},{"start":189,"end":212,"url":"https://t.co/sKSBaBkrzu","expanded_url":"https://twitter.com/EMA_News/status/1407319905511354373/photo/1","display_url":"pic.twitter.com/sKSBaBkrzu"}],"annotations":[{"start":0,"end":2,"probability":0.8403,"type":"Organization","normalized_text":"EMA"},{"start":70,"end":78,"probability":0.4058,"type":"Place","normalized_text":"Comirnaty"},{"start":114,"end":121,"probability":0.6193,"type":"Organization","normalized_text":"BioNTech"},{"start":127,"end":132,"probability":0.5075,"type":"Organization","normalized_text":"Pfizer"}]},"attachments":{"media_keys":["3_1407319008886542338"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":9,"like_count":29,"quote_count":0},"created_at":"2021-06-21T14:18:22.000Z","author_id":"116716199","text":"What's on the agenda of the June meeting of EMA's human medicines committee (#CHMP): https://t.co/tAsFDKm0eK","id":"1406979814712659968","conversation_id":"1406979814712659968","entities":{"mentions":{},"hashtags":[{"start":77,"end":82,"tag":"CHMP"}],"urls":[{"start":85,"end":108,"url":"https://t.co/tAsFDKm0eK","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-21-24-june-2021-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":7,"like_count":24,"quote_count":0},"created_at":"2021-06-18T14:48:57.000Z","author_id":"116716199","text":"üì¢The highlights of EMA‚Äôs Management Board meeting are now available ‚ÄºÔ∏è  \n\nRead more about the Agency‚Äôs activities in response to the #COVID19 pandemic, the annual activity report for 2020, and progress with the #clinicaltrial information system. https://t.co/Zwk4Y7Ugzt https://t.co/gUmMEvtsZo","id":"1405900343876202500","conversation_id":"1405900343876202500","entities":{"mentions":{},"hashtags":[{"start":133,"end":141,"tag":"COVID19"},{"start":211,"end":225,"tag":"clinicaltrial"}],"urls":[{"start":246,"end":269,"url":"https://t.co/Zwk4Y7Ugzt","expanded_url":"https://www.ema.europa.eu/en/news/highlights-management-board-june-2021-meeting","display_url":"ema.europa.eu/en/news/highli‚Ä¶"},{"start":270,"end":293,"url":"https://t.co/gUmMEvtsZo","expanded_url":"https://twitter.com/EMA_News/status/1405900343876202500/photo/1","display_url":"pic.twitter.com/gUmMEvtsZo"}],"annotations":[{"start":20,"end":22,"probability":0.6586,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1405899234252050437"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":22,"like_count":104,"quote_count":14},"created_at":"2021-06-18T13:52:58.000Z","author_id":"116716199","text":"#COVID19vaccines where are we now? \nRolling reviews in progress, no new applications submitted, authorisations completed. https://t.co/v4iv7F1EY0","id":"1405886259197849603","conversation_id":"1405886259197849603","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":122,"end":145,"url":"https://t.co/v4iv7F1EY0","expanded_url":"https://twitter.com/EMA_News/status/1405886259197849603/photo/1","display_url":"pic.twitter.com/v4iv7F1EY0"}],"annotations":{}},"attachments":{"media_keys":["3_1405886034215424005"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":4,"like_count":23,"quote_count":0},"created_at":"2021-06-17T14:58:14.000Z","author_id":"116716199","text":"See the live tweets posted during EMA's technical press briefing held on 17 June 2021. #EMAPresser\nhttps://t.co/bL5HvcVlhI","id":"1405540292585869316","conversation_id":"1405540292585869316","entities":{"mentions":{},"hashtags":[{"start":87,"end":98,"tag":"EMAPresser"}],"urls":[{"start":99,"end":122,"url":"https://t.co/bL5HvcVlhI","expanded_url":"https://twitter.com/i/events/1405531852333477891","display_url":"twitter.com/i/events/14055‚Ä¶"}],"annotations":[{"start":34,"end":36,"probability":0.5223,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":33,"like_count":101,"quote_count":35},"created_at":"2021-06-17T14:12:05.000Z","author_id":"116716199","text":"We have 4 vaccines under rolling review: Curevac, Novavax, Sinovac (Vero Cell) and the Sputnik vaccine.\nFor these vaccines, the rolling review continues until EMA has sufficient evidence for a formal marketing authorisation application. #EMAPresser https://t.co/5I3In4RcjI","id":"1405528681242525715","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":237,"end":248,"tag":"EMAPresser"}],"urls":[{"start":249,"end":272,"url":"https://t.co/5I3In4RcjI","expanded_url":"https://twitter.com/EMA_News/status/1405528681242525715/photo/1","display_url":"pic.twitter.com/5I3In4RcjI"}],"annotations":[{"start":87,"end":93,"probability":0.5279,"type":"Organization","normalized_text":"Sputnik"}]},"attachments":{"media_keys":["3_1405528327511633922"]},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":35,"reply_count":2,"like_count":47,"quote_count":7},"created_at":"2021-06-17T14:09:26.000Z","author_id":"116716199","text":"Currently, the authorised #COVID19vaccines seem to protect against all the strains that are dominant in the üá™üá∫. EMA will remain very vigilant. #EMAPresser","id":"1405528012955684869","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":26,"end":42,"tag":"COVID19vaccines"},{"start":143,"end":154,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":55,"quote_count":7},"created_at":"2021-06-17T14:08:51.000Z","author_id":"116716199","text":"EMA has started evaluating an application to extend the use of #COVID19Vaccine Moderna to include young people aged 12 to 17. The outcome of the evaluation is expected inüóìÔ∏è July unless more information is needed. #EMAPresser","id":"1405527865618157570","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":63,"end":78,"tag":"COVID19Vaccine"},{"start":213,"end":224,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4624,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":2,"like_count":56,"quote_count":2},"created_at":"2021-06-17T14:07:08.000Z","author_id":"116716199","text":"#PRAC is analysing concerns with myocarditis and pericarditis reported after vaccination with mRNA #COVID19vaccines. So far, there is not enough data to establish a causal relationship. Safety monitoring will continue. #EMAPresser","id":"1405527433554497536","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"PRAC"},{"start":99,"end":115,"tag":"COVID19vaccines"},{"start":219,"end":230,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":2,"like_count":40,"quote_count":11},"created_at":"2021-06-17T14:06:26.000Z","author_id":"116716199","text":"EMA's safety committee, #PRAC, concluded last week that capillary leak syndrome should be added as a new #SideEffect of #Vaxzevria (previously #COVID19Vaccine AstraZeneca). People who previously had this syndrome must not be vaccinated with the vaccine. #EMAPresser","id":"1405527256814919692","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":105,"end":116,"tag":"SideEffect"},{"start":120,"end":130,"tag":"Vaxzevria"},{"start":143,"end":158,"tag":"COVID19Vaccine"},{"start":254,"end":265,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":42,"quote_count":2},"created_at":"2021-06-17T14:04:58.000Z","author_id":"116716199","text":"Production capacity for authorised vaccines is continuously being scaled up. A recent example is the approval of a new finished product site for Moderna‚Äôs #COVID19Vaccine in Monts, üá´üá∑. This is expected to boost the supply of COVID-19 vaccines in the EU. #EMAPresser","id":"1405526888274010119","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":155,"end":170,"tag":"COVID19Vaccine"},{"start":254,"end":265,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":145,"end":151,"probability":0.2864,"type":"Organization","normalized_text":"Moderna"},{"start":174,"end":184,"probability":0.5281,"type":"Place","normalized_text":"Monts, üá´üá∑"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":24,"quote_count":0},"created_at":"2021-06-17T14:04:25.000Z","author_id":"116716199","text":"We are doing everything possible to safeguard supplies for EU citizens. The EU will continue to receive vaccines containing the active substance from another manufacturer based in Leiden, NL, which is currently expanding its manufacturing capacity. #EMAPresser","id":"1405526748960202762","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":249,"end":260,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":59,"end":60,"probability":0.5418,"type":"Organization","normalized_text":"EU"},{"start":76,"end":77,"probability":0.7488,"type":"Organization","normalized_text":"EU"},{"start":180,"end":189,"probability":0.7094,"type":"Place","normalized_text":"Leiden, NL"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":1,"like_count":21,"quote_count":1},"created_at":"2021-06-17T14:03:56.000Z","author_id":"116716199","text":"EMA has taken steps to safeguard the quality of Janssen's #COVID19Vaccine. Approximately 17 million doses containing the active substance, made around the same time as a contamination occurred at the US manufacturing site, are currently not released onto the EU market #EMAPresser","id":"1405526628051034114","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":58,"end":73,"tag":"COVID19Vaccine"},{"start":269,"end":280,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.2926,"type":"Person","normalized_text":"EMA"},{"start":48,"end":54,"probability":0.8179,"type":"Person","normalized_text":"Janssen"},{"start":200,"end":201,"probability":0.9496,"type":"Place","normalized_text":"US"},{"start":259,"end":260,"probability":0.5039,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1405525984963559445"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":1,"like_count":31,"quote_count":2},"created_at":"2021-06-17T14:03:05.000Z","author_id":"116716199","text":"The #CureVac vaccine is under rolling review. The data from the clinical trial will be evaluated, once the final analysis has been performed and the complete dataset has been submitted. Only then it will be possible to define next steps. #EMAPresser https://t.co/risZxWgimq","id":"1405526415659782156","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":4,"end":12,"tag":"CureVac"},{"start":238,"end":249,"tag":"EMAPresser"}],"urls":[{"start":250,"end":273,"url":"https://t.co/risZxWgimq","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-curevacs-covid-19-vaccine-cvncov","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":14,"like_count":45,"quote_count":1},"created_at":"2021-06-17T14:01:22.000Z","author_id":"116716199","text":"Watch liveüî¥\n\nWe are now starting the third regular press briefing on #COVID19 vaccines and treatments. \n\nDon‚Äôt miss our tweets during the press briefing. Follow #EMAPresser\n\nhttps://t.co/YU1oB7fhCr","id":"1405525984963559445","conversation_id":"1405525984963559445","entities":{"mentions":{},"hashtags":[{"start":69,"end":77,"tag":"COVID19"},{"start":161,"end":172,"tag":"EMAPresser"}],"urls":[{"start":174,"end":197,"url":"https://t.co/YU1oB7fhCr","expanded_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-0","display_url":"ema.europa.eu/en/events/ema-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":5,"like_count":51,"quote_count":3},"created_at":"2021-06-17T13:33:21.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA‚Äôs third regular press conference on #COVID19 vaccines and treatments will be broadcast live üî¥today, June 17, from 16:00 CEST https://t.co/YU1oB7fhCr\n\n#EMAPresser https://t.co/AA3DaMXNMR","id":"1405518931838726151","conversation_id":"1405518931838726151","entities":{"mentions":{},"hashtags":[{"start":43,"end":51,"tag":"COVID19"},{"start":157,"end":168,"tag":"EMAPresser"}],"urls":[{"start":132,"end":155,"url":"https://t.co/YU1oB7fhCr","expanded_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19-0","display_url":"ema.europa.eu/en/events/ema-‚Ä¶"},{"start":169,"end":192,"url":"https://t.co/AA3DaMXNMR","expanded_url":"https://twitter.com/EMA_News/status/1405518931838726151/photo/1","display_url":"pic.twitter.com/AA3DaMXNMR"}],"annotations":{}},"attachments":{"media_keys":["3_1405518203267153927"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1404841715341660163"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-16T07:42:32.000Z","author_id":"116716199","text":"RT @EU_Health: During this pandemic, a wide range of EU initiatives were delivered in record time\n\nWe have identified specific areas where‚Ä¶","id":"1405068259133644800","conversation_id":"1405068259133644800","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":[{"start":53,"end":54,"probability":0.8397,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1404751361913274369"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-16T07:41:31.000Z","author_id":"116716199","text":"RT @EFSA_EU: Find out how we can reduce the use of #antimicrobials in food-producing animals.\nhttps://t.co/WozhFChoDe","id":"1405068004954681349","conversation_id":"1405068004954681349","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":51,"end":66,"tag":"antimicrobials"}],"urls":[{"start":94,"end":117,"url":"https://t.co/WozhFChoDe","expanded_url":"https://bit.ly/2SsT04c","display_url":"bit.ly/2SsT04c"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":6,"like_count":50,"quote_count":5},"created_at":"2021-06-14T14:24:25.000Z","author_id":"116716199","text":"2020 #AnnualReportEMA has been published! Learn more about EMA's major achievements in 2020, key figures and contributions to public health in Europe. \nüëâhttps://t.co/RwLw6674S6 https://t.co/zeJT5mLk4A","id":"1404444620772319245","conversation_id":"1404444620772319245","entities":{"mentions":{},"hashtags":[{"start":5,"end":21,"tag":"AnnualReportEMA"}],"urls":[{"start":153,"end":176,"url":"https://t.co/RwLw6674S6","expanded_url":"https://www.ema.europa.eu/en/annual-report-2020/","display_url":"ema.europa.eu/en/annual-repo‚Ä¶"},{"start":177,"end":200,"url":"https://t.co/zeJT5mLk4A","expanded_url":"https://twitter.com/EMA_News/status/1404444620772319245/photo/1","display_url":"pic.twitter.com/zeJT5mLk4A"}],"annotations":[{"start":143,"end":148,"probability":0.9936,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1404444301925494786"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":3,"like_count":37,"quote_count":1},"created_at":"2021-06-14T09:24:39.000Z","author_id":"116716199","text":"Are you a veterinarian?\n\nEMA and @FVEurope are hosting a joint webinar on EMA‚Äôs categorisation of #antibiotics for animal üêÆüêìüêù use in the üá™üá∫.\n\nRegister before üóìÔ∏è21 June: \nüëâhttps://t.co/wgzE31of1X\n\n#AnimalHealth #VeterinaryMedicine #AMEGcategorisation #AMR https://t.co/e4Jn8yiCOv","id":"1404369182477668352","conversation_id":"1404369182477668352","entities":{"mentions":[{"start":33,"end":42,"username":"FVEurope","id":"1549866445"}],"hashtags":[{"start":98,"end":110,"tag":"antibiotics"},{"start":196,"end":209,"tag":"AnimalHealth"},{"start":210,"end":229,"tag":"VeterinaryMedicine"},{"start":230,"end":249,"tag":"AMEGcategorisation"},{"start":250,"end":254,"tag":"AMR"}],"urls":[{"start":171,"end":194,"url":"https://t.co/wgzE31of1X","expanded_url":"https://www.ema.europa.eu/en/events/webinar-emas-categorisation-antibiotics-used-animals#event-summary-section","display_url":"ema.europa.eu/en/events/webi‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/events/webinar-emas-categorisation-antibiotics-used-animals#event-summary-section"},{"start":255,"end":278,"url":"https://t.co/e4Jn8yiCOv","expanded_url":"https://twitter.com/EMA_News/status/1404369182477668352/photo/1","display_url":"pic.twitter.com/e4Jn8yiCOv"}],"annotations":{}},"attachments":{"media_keys":["3_1404368913606090759"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":810,"reply_count":98,"like_count":1887,"quote_count":239},"created_at":"2021-06-13T13:45:28.000Z","author_id":"116716199","text":"Misinformation is making the rounds today. This is the situation: Benefit/risk balance of AstraZeneca #COVID19 vaccine is positive and it remains authorised for all populations.","id":"1404072431766151172","conversation_id":"1404072431766151172","entities":{"mentions":{},"hashtags":[{"start":102,"end":110,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":5,"like_count":37,"quote_count":2},"created_at":"2021-06-11T15:49:14.000Z","author_id":"116716199","text":"During its June meeting, EMA‚Äôs safety committee (#PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines, including #COVID19vaccines. \n\nRead more üëá\nhttps://t.co/E9fyz8c4l2 https://t.co/7yTi4npbBR","id":"1403378800822558728","conversation_id":"1403378800822558728","entities":{"mentions":{},"hashtags":[{"start":49,"end":54,"tag":"PRAC"},{"start":187,"end":203,"tag":"COVID19vaccines"}],"urls":[{"start":219,"end":242,"url":"https://t.co/E9fyz8c4l2","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-7-10-june-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":243,"end":266,"url":"https://t.co/7yTi4npbBR","expanded_url":"https://twitter.com/EMA_News/status/1403378800822558728/photo/1","display_url":"pic.twitter.com/7yTi4npbBR"}],"annotations":{}},"attachments":{"media_keys":["3_1403377902478053381"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":3,"like_count":40,"quote_count":8},"created_at":"2021-06-11T14:57:37.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Authorities in üá™üá∫ take steps to safeguard the quality of the #COVID19Vaccine Janssen https://t.co/CIAEivPdEx https://t.co/sw3zHKBuV3","id":"1403365810949738506","conversation_id":"1403365810949738506","entities":{"mentions":{},"hashtags":[{"start":64,"end":79,"tag":"COVID19Vaccine"}],"urls":[{"start":88,"end":111,"url":"https://t.co/CIAEivPdEx","expanded_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-authorities-eu-take-steps-safeguard-vaccine-quality","display_url":"ema.europa.eu/en/news/covid-‚Ä¶"},{"start":112,"end":135,"url":"https://t.co/sw3zHKBuV3","expanded_url":"https://twitter.com/EMA_News/status/1403365810949738506/photo/1","display_url":"pic.twitter.com/sw3zHKBuV3"}],"annotations":[{"start":18,"end":21,"probability":0.8144,"type":"Place","normalized_text":"üá™üá∫"},{"start":82,"end":88,"probability":0.5977,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1403365640505892864"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":1,"like_count":29,"quote_count":0},"created_at":"2021-06-11T13:57:02.000Z","author_id":"116716199","text":"EMA has endorsed a statement published today by International Coalition of Medicines Regulatory Authorities (#ICMRA) to outline objectives and benefits of building a collective capability between regulators for pharmaceutical quality knowledge management\nhttps://t.co/8p9dgo6GTH https://t.co/Suuim8D8Yy","id":"1403350565644607489","conversation_id":"1403350565644607489","entities":{"mentions":{},"hashtags":[{"start":109,"end":115,"tag":"ICMRA"}],"urls":[{"start":255,"end":278,"url":"https://t.co/8p9dgo6GTH","expanded_url":"http://www.icmra.info/drupal/strategicinitatives/pqkms/statement","display_url":"icmra.info/drupal/strateg‚Ä¶"},{"start":279,"end":302,"url":"https://t.co/Suuim8D8Yy","expanded_url":"https://twitter.com/EMA_News/status/1403350565644607489/photo/1","display_url":"pic.twitter.com/Suuim8D8Yy"}],"annotations":[{"start":0,"end":2,"probability":0.4513,"type":"Organization","normalized_text":"EMA"},{"start":48,"end":106,"probability":0.5705,"type":"Organization","normalized_text":"International Coalition of Medicines Regulatory Authorities"}]},"attachments":{"media_keys":["3_1403347692953157633"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":134,"reply_count":8,"like_count":370,"quote_count":24},"created_at":"2021-06-11T12:51:38.000Z","author_id":"116716199","text":"EMA has approved new manufacturing capacity for Moderna #COVID19vaccine, including a manufacturing site in Monts, France. This will increase the supply of the vaccine in the European Union.\n\nhttps://t.co/Qk91zJRa8T https://t.co/GWnaoIpzxz","id":"1403334108135239687","conversation_id":"1403334108135239687","entities":{"mentions":{},"hashtags":[{"start":56,"end":71,"tag":"COVID19vaccine"}],"urls":[{"start":191,"end":214,"url":"https://t.co/Qk91zJRa8T","expanded_url":"https://www.ema.europa.eu/en/news/additional-manufacturing-capacity-modernas-covid-19-vaccine","display_url":"ema.europa.eu/en/news/additi‚Ä¶"},{"start":215,"end":238,"url":"https://t.co/GWnaoIpzxz","expanded_url":"https://twitter.com/EMA_News/status/1403334108135239687/photo/1","display_url":"pic.twitter.com/GWnaoIpzxz"}],"annotations":[{"start":0,"end":2,"probability":0.7399,"type":"Organization","normalized_text":"EMA"},{"start":107,"end":119,"probability":0.4773,"type":"Place","normalized_text":"Monts, France"}]},"attachments":{"media_keys":["3_1403333800214548482"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":5,"like_count":49,"quote_count":2},"created_at":"2021-06-11T11:27:08.000Z","author_id":"116716199","text":"International regulators and @WHO published a statement to help #HealthcareProfessionals to increase confidence in #COVID19vaccines and answer questions from patients about the development, regulatory review and safety monitoring of these #vaccines. \n\nhttps://t.co/saklG2uHzm https://t.co/IOJ3AZ3F0U","id":"1403312842229567489","conversation_id":"1403312842229567489","entities":{"mentions":[{"start":29,"end":33,"username":"WHO","id":"14499829"}],"hashtags":[{"start":64,"end":88,"tag":"HealthcareProfessionals"},{"start":115,"end":131,"tag":"COVID19vaccines"},{"start":239,"end":248,"tag":"vaccines"}],"urls":[{"start":252,"end":275,"url":"https://t.co/saklG2uHzm","expanded_url":"https://www.ema.europa.eu/en/news/international-regulators-who-address-need-boost-covid-19-vaccine-confidence","display_url":"ema.europa.eu/en/news/intern‚Ä¶"},{"start":276,"end":299,"url":"https://t.co/IOJ3AZ3F0U","expanded_url":"https://twitter.com/EMA_News/status/1403312842229567489/photo/1","display_url":"pic.twitter.com/IOJ3AZ3F0U"}],"annotations":{}},"attachments":{"media_keys":["3_1403312581222318082"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":97,"reply_count":7,"like_count":167,"quote_count":14},"created_at":"2021-06-08T15:16:02.000Z","author_id":"116716199","text":"EMA starts evaluating the use of #COVID19Vaccine Moderna in young people aged 12 to 17. The vaccine is currently used for preventing #COVID19 in people aged 18 and older. \nhttps://t.co/G1q6lQmz8V https://t.co/5G1SOUya3c","id":"1402283284483252227","conversation_id":"1402283284483252227","entities":{"mentions":{},"hashtags":[{"start":33,"end":48,"tag":"COVID19Vaccine"},{"start":133,"end":141,"tag":"COVID19"}],"urls":[{"start":172,"end":195,"url":"https://t.co/G1q6lQmz8V","expanded_url":"https://www.ema.europa.eu/en/news/ema-evaluating-use-covid-19-vaccine-moderna-young-people-aged-12-17","display_url":"ema.europa.eu/en/news/ema-ev‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/ema-evaluating-use-covid-19-vaccine-moderna-young-people-aged-12-17"},{"start":196,"end":219,"url":"https://t.co/5G1SOUya3c","expanded_url":"https://twitter.com/EMA_News/status/1402283284483252227/photo/1","display_url":"pic.twitter.com/5G1SOUya3c"}],"annotations":{}},"attachments":{"media_keys":["3_1402282537741860869"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":54,"reply_count":1,"like_count":69,"quote_count":7},"created_at":"2021-06-08T08:03:33.000Z","author_id":"116716199","text":"EMA is advising #HealthcareProfessionals in the üá™üá∫ to consider recommendations by learned societies when assessing people with symptoms of #thrombosis with thrombocytopenia syndrome (TTS) following vaccination with Vaxzevria and #COVID19Vaccine Janssen. \nhttps://t.co/l0f2wHIt0Y https://t.co/M2VRhiV9AL","id":"1402174444819341312","conversation_id":"1402174444819341312","entities":{"mentions":{},"hashtags":[{"start":16,"end":40,"tag":"HealthcareProfessionals"},{"start":139,"end":150,"tag":"thrombosis"},{"start":229,"end":244,"tag":"COVID19Vaccine"}],"urls":[{"start":255,"end":278,"url":"https://t.co/l0f2wHIt0Y","expanded_url":"https://www.ema.europa.eu/en/news/ema-raises-awareness-clinical-care-recommendations-manage-suspected-thrombosis-thrombocytopenia","display_url":"ema.europa.eu/en/news/ema-ra‚Ä¶"},{"start":279,"end":302,"url":"https://t.co/M2VRhiV9AL","expanded_url":"https://twitter.com/EMA_News/status/1402174444819341312/photo/1","display_url":"pic.twitter.com/M2VRhiV9AL"}],"annotations":[{"start":0,"end":2,"probability":0.3506,"type":"Organization","normalized_text":"EMA"},{"start":217,"end":225,"probability":0.5401,"type":"Person","normalized_text":"Vaxzevria"},{"start":247,"end":253,"probability":0.7457,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1402174251315171328"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":1,"like_count":30,"quote_count":1},"created_at":"2021-06-07T15:20:35.000Z","author_id":"116716199","text":"Save the date! EMA is hosting virtual workshops on the draft of the EU common standard for electronic product information (ePI).\n\nRegister now to join the workshops on 5 and 8 July 2021: https://t.co/V4twDXTrVH\n\n#ePI4Medicines #EMAwebinars https://t.co/4pmFyGMKie","id":"1401922038768545806","conversation_id":"1401922038768545806","entities":{"mentions":{},"hashtags":[{"start":212,"end":226,"tag":"ePI4Medicines"},{"start":227,"end":239,"tag":"EMAwebinars"}],"urls":[{"start":187,"end":210,"url":"https://t.co/V4twDXTrVH","expanded_url":"https://www.ema.europa.eu/en/events/epi-information-workshop-exploratory-workshop","display_url":"ema.europa.eu/en/events/epi-‚Ä¶"},{"start":240,"end":263,"url":"https://t.co/4pmFyGMKie","expanded_url":"https://twitter.com/EMA_News/status/1401922038768545806/photo/1","display_url":"pic.twitter.com/4pmFyGMKie"}],"annotations":[{"start":15,"end":17,"probability":0.3662,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1401920948530466819"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":1,"like_count":16,"quote_count":1},"created_at":"2021-06-07T14:47:33.000Z","author_id":"116716199","text":"Share your views! The public consultation on the EU common standard draft for electronic product information (ePI) is now open!\n\nhttps://t.co/01bUpSckul \n\n#ePI4Medicines https://t.co/22Xp1bJioO","id":"1401913725926445057","conversation_id":"1401913725926445057","entities":{"mentions":{},"hashtags":[{"start":155,"end":169,"tag":"ePI4Medicines"}],"urls":[{"start":129,"end":152,"url":"https://t.co/01bUpSckul","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/product-information-requirements#electronic-product-information-initiative-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":170,"end":193,"url":"https://t.co/22Xp1bJioO","expanded_url":"https://twitter.com/EMA_News/status/1401913725926445057/photo/1","display_url":"pic.twitter.com/22Xp1bJioO"}],"annotations":{}},"attachments":{"media_keys":["3_1401909023318945798"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1401063737562390528"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-07T10:53:55.000Z","author_id":"116716199","text":"RT @EU_Health: On #WorldEnvironmentDay let's remember:\n\nThe fight against #AntiMicrobialResistance must be based on a holistic one health a‚Ä¶","id":"1401854932991590400","conversation_id":"1401854932991590400","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":18,"end":38,"tag":"WorldEnvironmentDay"},{"start":74,"end":98,"tag":"AntiMicrobialResistance"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1401516219337871361"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":435,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-06-07T10:53:38.000Z","author_id":"116716199","text":"RT @EU_Commission: The EU Gateway for the EU Digital COVID Certificate is up and running.\n\nThis system allows to verify certificates in a s‚Ä¶","id":"1401854859826057217","conversation_id":"1401854859826057217","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":[{"start":23,"end":32,"probability":0.6053,"type":"Organization","normalized_text":"EU Gateway"},{"start":42,"end":69,"probability":0.2977,"type":"Other","normalized_text":"EU Digital COVID Certificate"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":4,"like_count":26,"quote_count":3},"created_at":"2021-06-04T14:16:47.000Z","author_id":"116716199","text":"At the 6th #ICMRA workshop on observational research, medicines regulators from around the üåç discussed the importance of global collaboration on #RealWorldEvidence for regulatory decision-making on #COVID19 treatments and vaccines. \n\nFind out more: https://t.co/8lOBGxqlMa https://t.co/je0cIBKdJD","id":"1400818819103404041","conversation_id":"1400818819103404041","entities":{"mentions":{},"hashtags":[{"start":11,"end":17,"tag":"ICMRA"},{"start":145,"end":163,"tag":"RealWorldEvidence"},{"start":198,"end":206,"tag":"COVID19"}],"urls":[{"start":249,"end":272,"url":"https://t.co/8lOBGxqlMa","expanded_url":"https://bit.ly/2THgHG5","display_url":"bit.ly/2THgHG5","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/advancing-international-collaboration-covid-19-real-world-evidence-observational-studies"},{"start":273,"end":296,"url":"https://t.co/je0cIBKdJD","expanded_url":"https://twitter.com/EMA_News/status/1400818819103404041/photo/1","display_url":"pic.twitter.com/je0cIBKdJD"}],"annotations":{}},"attachments":{"media_keys":["3_1400818325828034564"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":24,"quote_count":2},"created_at":"2021-06-04T09:24:49.000Z","author_id":"116716199","text":"üì¢Call for tender for the Coordination Center of #DARWINEU!\n\nThis initiative will provide timely and reliable evidence on the use, safety and effectiveness of üíä and vaccines from real world #healthcare databases in the üá™üá∫.\n\nMore details here: https://t.co/LwILP040kz https://t.co/ylC9ula0B6","id":"1400745346993696771","conversation_id":"1400745346993696771","entities":{"mentions":{},"hashtags":[{"start":48,"end":57,"tag":"DARWINEU"},{"start":189,"end":200,"tag":"healthcare"}],"urls":[{"start":242,"end":265,"url":"https://t.co/LwILP040kz","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/big-data/data-analysis-real-world-interrogation-network-darwin-eu#coordination-centre-section","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":266,"end":289,"url":"https://t.co/ylC9ula0B6","expanded_url":"https://twitter.com/EMA_News/status/1400745346993696771/photo/1","display_url":"pic.twitter.com/ylC9ula0B6"}],"annotations":{}},"attachments":{"media_keys":["3_1400745169289453568"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":2,"like_count":66,"quote_count":3},"created_at":"2021-06-04T08:40:27.000Z","author_id":"116716199","text":"EMA is establishing the Data Analysis and Real World Interrogation Network #DARWINEU. \n\nIt will provide timely and reliable evidence on the use, safety and effectiveness of üíä and vaccines from real world #healthcare databases in the üá™üá∫.\n\nRead more: üëâhttps://t.co/i8pqg8R750 https://t.co/qZco1fnveL","id":"1400734179986481153","conversation_id":"1400734179986481153","entities":{"mentions":{},"hashtags":[{"start":75,"end":84,"tag":"DARWINEU"},{"start":204,"end":215,"tag":"healthcare"}],"urls":[{"start":250,"end":273,"url":"https://t.co/i8pqg8R750","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/big-data/data-analysis-real-world-interrogation-network-darwin-eu","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/qZco1fnveL","expanded_url":"https://twitter.com/EMA_News/status/1400734179986481153/photo/1","display_url":"pic.twitter.com/qZco1fnveL"}],"annotations":[{"start":0,"end":2,"probability":0.454,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1400734002978430977"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":2,"like_count":44,"quote_count":3},"created_at":"2021-06-03T15:31:52.000Z","author_id":"116716199","text":"EU regulators have adopted a reflection paper with a set of recommendations to support forecasting of demand for human #medicines across the #EU and at the national level: https://t.co/6ZqMShWRcA https://t.co/0GePArTxiu","id":"1400475326526918662","conversation_id":"1400475326526918662","entities":{"mentions":{},"hashtags":[{"start":119,"end":129,"tag":"medicines"},{"start":141,"end":144,"tag":"EU"}],"urls":[{"start":172,"end":195,"url":"https://t.co/6ZqMShWRcA","expanded_url":"https://bit.ly/3wRrSu0","display_url":"bit.ly/3wRrSu0"},{"start":196,"end":219,"url":"https://t.co/0GePArTxiu","expanded_url":"https://twitter.com/EMA_News/status/1400475326526918662/photo/1","display_url":"pic.twitter.com/0GePArTxiu"}],"annotations":[{"start":0,"end":1,"probability":0.5862,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1400475028278452226"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":53,"reply_count":23,"like_count":101,"quote_count":14},"created_at":"2021-06-03T15:16:03.000Z","author_id":"116716199","text":"#COVID19vaccines where are we now? \nRolling reviews in progress, no new applications submitted, authorisations completed. https://t.co/NkIX9iss3q","id":"1400471346291916801","conversation_id":"1400471346291916801","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":122,"end":145,"url":"https://t.co/NkIX9iss3q","expanded_url":"https://twitter.com/EMA_News/status/1400471346291916801/photo/1","display_url":"pic.twitter.com/NkIX9iss3q"}],"annotations":{}},"attachments":{"media_keys":["3_1400470976085823490"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":1,"like_count":30,"quote_count":4},"created_at":"2021-06-02T08:07:47.000Z","author_id":"116716199","text":"We need to include European #AnimalHealth data in the #EUhealthdataspace. Find out more about other policy opportunities in this area.\n\nWatch liveüî¥ EMA‚Äôs first #Veterinary Big Data stakeholder forum: \nüëâhttps://t.co/ImwCzI0EO7 #BigData https://t.co/h7h4hPR6fA","id":"1400001181913595911","conversation_id":"1400001181913595911","entities":{"mentions":{},"hashtags":[{"start":28,"end":41,"tag":"AnimalHealth"},{"start":54,"end":72,"tag":"EUhealthdataspace"},{"start":160,"end":171,"tag":"Veterinary"},{"start":226,"end":234,"tag":"BigData"}],"urls":[{"start":202,"end":225,"url":"https://t.co/ImwCzI0EO7","expanded_url":"https://www.ema.europa.eu/en/events/veterinary-big-data-stakeholder-forum","display_url":"ema.europa.eu/en/events/vete‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/events/veterinary-big-data-stakeholder-forum"},{"start":235,"end":258,"url":"https://t.co/h7h4hPR6fA","expanded_url":"https://twitter.com/EMA_News/status/1400001181913595911/photo/1","display_url":"pic.twitter.com/h7h4hPR6fA"}],"annotations":{}},"attachments":{"media_keys":["3_1400000849875722243"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":46,"reply_count":5,"like_count":204,"quote_count":8},"created_at":"2021-06-02T07:41:06.000Z","author_id":"116716199","text":"EMA recommends the approval of additional manufacturing and filling lines at Pfizer's vaccine manufacturing site in Puurs, Belgium. \nüëâhttps://t.co/sSzEXYvM4s https://t.co/HN2jJUJIiC","id":"1399994467931901953","conversation_id":"1399994467931901953","entities":{"mentions":{},"hashtags":{},"urls":[{"start":134,"end":157,"url":"https://t.co/sSzEXYvM4s","expanded_url":"https://www.ema.europa.eu/en/news/additional-manufacturing-capacity-biontechpfizers-covid-19-vaccine","display_url":"ema.europa.eu/en/news/additi‚Ä¶"},{"start":158,"end":181,"url":"https://t.co/HN2jJUJIiC","expanded_url":"https://twitter.com/EMA_News/status/1399994467931901953/photo/1","display_url":"pic.twitter.com/HN2jJUJIiC"}],"annotations":[{"start":0,"end":2,"probability":0.7467,"type":"Organization","normalized_text":"EMA"},{"start":77,"end":82,"probability":0.8302,"type":"Organization","normalized_text":"Pfizer"},{"start":116,"end":129,"probability":0.4246,"type":"Place","normalized_text":"Puurs, Belgium"}]},"attachments":{"media_keys":["3_1399994451431464960"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":2,"like_count":22,"quote_count":1},"created_at":"2021-06-01T12:26:37.000Z","author_id":"116716199","text":"#Veterinary Big Data is changing the focus from treating animals to preventing disease. \n\nJoin the conversation! Participate in EMA‚Äôs Veterinary #BigData stakeholder forum on 1-2 June.\n\nüî¥ Link to the live broadcast: https://t.co/TbHGUF6Rju https://t.co/978cPj0dF9","id":"1399703931543080963","conversation_id":"1399703931543080963","entities":{"mentions":{},"hashtags":[{"start":0,"end":11,"tag":"Veterinary"},{"start":145,"end":153,"tag":"BigData"}],"urls":[{"start":216,"end":239,"url":"https://t.co/TbHGUF6Rju","expanded_url":"https://bit.ly/3vHtTsv","display_url":"bit.ly/3vHtTsv"},{"start":240,"end":263,"url":"https://t.co/978cPj0dF9","expanded_url":"https://twitter.com/EMA_News/status/1399703931543080963/photo/1","display_url":"pic.twitter.com/978cPj0dF9"}],"annotations":{}},"attachments":{"media_keys":["3_1399703752555352065"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":3,"like_count":37,"quote_count":3},"created_at":"2021-06-01T09:52:19.000Z","author_id":"116716199","text":"EMA and @EUnetHTA have published a report on their achievements since 2017. Whilst the current activities of the network are drawing to a close, the collaboration between EMA and the European HTA community will continue: https://t.co/GYeiQ9DCWb\n\n#PublicHealth #EUnetHTA #HTA https://t.co/x91RcOP98R","id":"1399665100710105090","conversation_id":"1399665100710105090","entities":{"mentions":[{"start":8,"end":17,"username":"EUnetHTA","id":"56493220"}],"hashtags":[{"start":246,"end":259,"tag":"PublicHealth"},{"start":260,"end":269,"tag":"EUnetHTA"},{"start":270,"end":274,"tag":"HTA"}],"urls":[{"start":221,"end":244,"url":"https://t.co/GYeiQ9DCWb","expanded_url":"https://bit.ly/3p98gif","display_url":"bit.ly/3p98gif"},{"start":275,"end":298,"url":"https://t.co/x91RcOP98R","expanded_url":"https://twitter.com/EMA_News/status/1399665100710105090/photo/1","display_url":"pic.twitter.com/x91RcOP98R"}],"annotations":{}},"attachments":{"media_keys":["3_1399664887866003456"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398288378634833928"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":1,"like_count":7,"quote_count":0},"created_at":"2021-05-28T14:45:29.000Z","author_id":"116716199","text":"@fluglehrer The press briefing can be watched here: https://t.co/hmeZKyr9Y6","id":"1398289329185775620","conversation_id":"1398286775123128321","entities":{"mentions":[{"start":0,"end":11,"username":"fluglehrer","id":"8954232"}],"hashtags":{},"urls":[{"start":52,"end":75,"url":"https://t.co/hmeZKyr9Y6","expanded_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19","display_url":"ema.europa.eu/en/events/ema-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"8954232"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398288803220099073"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":16,"like_count":55,"quote_count":7},"created_at":"2021-05-28T14:43:57.000Z","author_id":"116716199","text":"There is currently insufficient evidence that inhaled corticosteroids are beneficial for people with #COVID19 who are not in hospital. EMA is advising against their use in COVID-19 patients before more definitive evidence is available. #EMAPresser","id":"1398288942710067206","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":101,"end":109,"tag":"COVID19"},{"start":236,"end":247,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398288547971469319"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":5,"like_count":72,"quote_count":1},"created_at":"2021-05-28T14:43:24.000Z","author_id":"116716199","text":"4 antiviral monoclonal antibodies are currently under rolling review by EMA. We are confident that some of these reviews will result in authorised treatments against #COVID19 by the third or fourth quarter of 2021. #EMAPresser","id":"1398288803220099073","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":166,"end":174,"tag":"COVID19"},{"start":215,"end":226,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":72,"end":74,"probability":0.4546,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398288331096657928"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":10,"like_count":32,"quote_count":2},"created_at":"2021-05-28T14:42:23.000Z","author_id":"116716199","text":"#COVID19 treatments are urgently needed. EMA is working with the @EU_Commission on the Therapeutics Strategy. Follow EMA's website for updates: https://t.co/YZCZKoHur0","id":"1398288547971469319","conversation_id":"1398286775123128321","entities":{"mentions":[{"start":65,"end":79,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":0,"end":8,"tag":"COVID19"}],"urls":[{"start":144,"end":167,"url":"https://t.co/YZCZKoHur0","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-treatments","display_url":"ema.europa.eu/en/human-regul‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398288035373015040"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":7,"like_count":75,"quote_count":11},"created_at":"2021-05-28T14:41:31.000Z","author_id":"116716199","text":"EMA is in touch with #COVID19vaccine developers to discuss variant strains and how to approach a possible booster dose. Preliminary data on the duration of immunity doesn't show the need for a third dose currently, but more evidence is needed. #EMAPresser","id":"1398288331096657928","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":21,"end":36,"tag":"COVID19vaccine"},{"start":244,"end":255,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4179,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398287900647829506"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":2,"like_count":44,"quote_count":1},"created_at":"2021-05-28T14:40:21.000Z","author_id":"116716199","text":"It is important to increase the #COVID19vaccines supply to support vaccination rollout in the üá™üá∫. EMA is working to authorise the expansion of manufacturing capacity and update the authorised storage conditions for the already authorised vaccines. #EMAPresser","id":"1398288035373015040","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":32,"end":48,"tag":"COVID19vaccines"},{"start":248,"end":259,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398287552818319362"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":3,"like_count":39,"quote_count":1},"created_at":"2021-05-28T14:39:49.000Z","author_id":"116716199","text":"EMA continually monitors the safety &amp; effectiveness of #Comirnaty in both children and adults. #EMAPresser","id":"1398287900647829506","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":59,"end":69,"tag":"Comirnaty"},{"start":99,"end":110,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398287202099073025"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":90,"reply_count":5,"like_count":166,"quote_count":18},"created_at":"2021-05-28T14:38:26.000Z","author_id":"116716199","text":"The recommended use of the Comirnaty #COVID19vaccine in children from 12 to 15 will be the same as it is in people aged 16 and above. It is administered as two injections in the muscles of the arm, at least 3 weeks apart. #EMAPresser","id":"1398287552818319362","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":37,"end":52,"tag":"COVID19vaccine"},{"start":222,"end":233,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1398286775123128321"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":327,"reply_count":71,"like_count":536,"quote_count":157},"created_at":"2021-05-28T14:37:02.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee #CHMP has today approved an application to extend the use of the Pfizer/BioNTech #COVID19vaccine (Comirnaty) to include children aged 12 to 15. #EMAPresser","id":"1398287202099073025","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":32,"end":37,"tag":"CHMP"},{"start":113,"end":128,"tag":"COVID19vaccine"},{"start":176,"end":187,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5516,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":12,"like_count":109,"quote_count":3},"created_at":"2021-05-28T14:35:20.000Z","author_id":"116716199","text":"Watch live üî¥ \n\nWe are now starting the second regular press briefing on #COVID19 vaccines and treatments. \n\nDon‚Äôt miss our tweets during the press briefing. Follow #EMAPresser.","id":"1398286775123128321","conversation_id":"1398286775123128321","entities":{"mentions":{},"hashtags":[{"start":72,"end":80,"tag":"COVID19"},{"start":164,"end":175,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":9,"like_count":81,"quote_count":7},"created_at":"2021-05-28T14:04:15.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA‚Äôs second regular press conference on #COVID19 vaccines and treatments will be broadcast live üî¥today, 28 May, from 16:30 to 17:00 CEST. #EMAPresser\nüëâhttps://t.co/hmeZKyr9Y6 https://t.co/LXlQfNQlRv","id":"1398278951164952579","conversation_id":"1398278951164952579","entities":{"mentions":{},"hashtags":[{"start":44,"end":52,"tag":"COVID19"},{"start":142,"end":153,"tag":"EMAPresser"}],"urls":[{"start":155,"end":178,"url":"https://t.co/hmeZKyr9Y6","expanded_url":"https://www.ema.europa.eu/en/events/ema-regular-press-briefing-covid-19","display_url":"ema.europa.eu/en/events/ema-‚Ä¶"},{"start":179,"end":202,"url":"https://t.co/LXlQfNQlRv","expanded_url":"https://twitter.com/EMA_News/status/1398278951164952579/photo/1","display_url":"pic.twitter.com/LXlQfNQlRv"}],"annotations":{}},"attachments":{"media_keys":["3_1398278829538435075"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":62,"reply_count":9,"like_count":91,"quote_count":7},"created_at":"2021-05-27T13:57:27.000Z","author_id":"116716199","text":"There is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19 who are not in hospital:https://t.co/yfZN5jWAkK https://t.co/u5lmvsrJq7","id":"1397914854262857741","conversation_id":"1397914854262857741","entities":{"mentions":{},"hashtags":{},"urls":[{"start":134,"end":157,"url":"https://t.co/yfZN5jWAkK","expanded_url":"https://bit.ly/3fswYa4","display_url":"bit.ly/3fswYa4"},{"start":158,"end":181,"url":"https://t.co/u5lmvsrJq7","expanded_url":"https://twitter.com/EMA_News/status/1397914854262857741/photo/1","display_url":"pic.twitter.com/u5lmvsrJq7"}],"annotations":{}},"attachments":{"media_keys":["3_1397914577585639431"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1397498399314874369"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-26T10:34:55.000Z","author_id":"116716199","text":"RT @EU_Health: As of today, the regulation on medical devices (MDR) is fully applicable.\n\nThe new rules will:\nüîéprovide more transparency fo‚Ä¶","id":"1397501493872406528","conversation_id":"1397501493872406528","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1397467092220268545"}],"possibly_sensitive":false,"lang":"und","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-26T09:27:41.000Z","author_id":"116716199","text":"RT @EU_Health: #MentalHealthMatters #MentalHealthEU https://t.co/hytwqaT7MD","id":"1397484574549106688","conversation_id":"1397484574549106688","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":35,"tag":"MentalHealthMatters"},{"start":36,"end":51,"tag":"MentalHealthEU"}],"urls":[{"start":52,"end":75,"url":"https://t.co/hytwqaT7MD","expanded_url":"https://twitter.com/eupatientsforum/status/1397224691991973897","display_url":"twitter.com/eupatientsforu‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1397089279411687430"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":78,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-26T07:47:52.000Z","author_id":"116716199","text":"RT @EU_Health: Let‚Äôs turn the tide against cancer.\n\nThe #EUCancerPlan sets out a new approach to cancer prevention, diagnosis, treatment &amp;‚Ä¶","id":"1397459457488179200","conversation_id":"1397459457488179200","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":56,"end":69,"tag":"EUCancerPlan"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":8,"like_count":32,"quote_count":3},"created_at":"2021-05-21T13:07:44.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 8 #medicines for approval at its May 2021 meeting:https://t.co/Rp8Oy7p2c0 https://t.co/FrCZ54ktZa","id":"1395728013216686085","conversation_id":"1395728013216686085","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":101,"end":124,"url":"https://t.co/Rp8Oy7p2c0","expanded_url":"https://bit.ly/3yvJMUI","display_url":"bit.ly/3yvJMUI"},{"start":125,"end":148,"url":"https://t.co/FrCZ54ktZa","expanded_url":"https://twitter.com/EMA_News/status/1395728013216686085/photo/1","display_url":"pic.twitter.com/FrCZ54ktZa"}],"annotations":[{"start":0,"end":2,"probability":0.4557,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1395727827874557957"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":4,"like_count":14,"quote_count":0},"created_at":"2021-05-21T12:50:34.000Z","author_id":"116716199","text":"EMA‚Äôs human medicine committee #CHMP has recommended for approval a new #medicine for #obesity caused by rare genetic disorders: https://t.co/sqUqlPq5gM","id":"1395723694111141890","conversation_id":"1395723694111141890","entities":{"mentions":{},"hashtags":[{"start":31,"end":36,"tag":"CHMP"},{"start":72,"end":81,"tag":"medicine"},{"start":86,"end":94,"tag":"obesity"}],"urls":[{"start":129,"end":152,"url":"https://t.co/sqUqlPq5gM","expanded_url":"https://bit.ly/3ftDr3m","display_url":"bit.ly/3ftDr3m"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":3,"like_count":37,"quote_count":4},"created_at":"2021-05-21T12:44:46.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) has recommended the first gene therapy for children with a rare inherited neurological disease (cerebral adrenoleukodystrophy) for approval in the EU: https://t.co/120a8Jj6Tl","id":"1395722235667787776","conversation_id":"1395722235667787776","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"}],"urls":[{"start":191,"end":214,"url":"https://t.co/120a8Jj6Tl","expanded_url":"https://bit.ly/3woZAXz","display_url":"bit.ly/3woZAXz"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":1,"like_count":41,"quote_count":2},"created_at":"2021-05-21T12:40:44.000Z","author_id":"116716199","text":"EMA‚Äôs human medicine committee (#CHMP) has recommended granting a marketing authorisation in the EU for the first treatment for a rare liver disease (progressive familial intrahepatic cholestasis) in patients aged 6 months or older: https://t.co/o7H6Lrb1LK","id":"1395721219908022280","conversation_id":"1395721219908022280","entities":{"mentions":{},"hashtags":[{"start":32,"end":37,"tag":"CHMP"}],"urls":[{"start":233,"end":256,"url":"https://t.co/o7H6Lrb1LK","expanded_url":"https://bit.ly/3oCYtRn","display_url":"bit.ly/3oCYtRn"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1395640944154849281"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":57,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-21T11:16:20.000Z","author_id":"116716199","text":"RT @EU_opendata: üîî TODAY is your last chance to submit a proposal for the #EUopendatadays! Speak at the #EUdataviz conference or compete in‚Ä¶","id":"1395699978572648454","conversation_id":"1395699978572648454","entities":{"mentions":[{"start":3,"end":15,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":74,"end":89,"tag":"EUopendatadays"},{"start":104,"end":114,"tag":"EUdataviz"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":65,"reply_count":20,"like_count":114,"quote_count":14},"created_at":"2021-05-20T16:46:08.000Z","author_id":"116716199","text":"#COVID19vaccines where are we now? \n\nRolling reviews in progress, no new applications submitted, authorisations completed. https://t.co/dXueJHydry","id":"1395420589674881024","conversation_id":"1395420589674881024","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":123,"end":146,"url":"https://t.co/dXueJHydry","expanded_url":"https://twitter.com/EMA_News/status/1395420589674881024/photo/1","display_url":"pic.twitter.com/dXueJHydry"}],"annotations":{}},"attachments":{"media_keys":["3_1395419925058048002"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":113,"reply_count":12,"like_count":281,"quote_count":30},"created_at":"2021-05-18T10:28:22.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee #CHMP recommended to change the storage period of unopened frozen vials of #Covid19vaccine Comirnaty. \n\nStored in a fridge at 2-8¬∞C, the #vaccine can be kept for up to 31 days, instead of 5 days: https://t.co/IDfKHz42AP https://t.co/QViUgA9646","id":"1394600743777312768","conversation_id":"1394600743777312768","entities":{"mentions":{},"hashtags":[{"start":32,"end":37,"tag":"CHMP"},{"start":107,"end":122,"tag":"Covid19vaccine"},{"start":169,"end":177,"tag":"vaccine"}],"urls":[{"start":228,"end":251,"url":"https://t.co/IDfKHz42AP","expanded_url":"https://bit.ly/3eXsY1c","display_url":"bit.ly/3eXsY1c"},{"start":252,"end":275,"url":"https://t.co/QViUgA9646","expanded_url":"https://twitter.com/EMA_News/status/1394600743777312768/photo/1","display_url":"pic.twitter.com/QViUgA9646"}],"annotations":{}},"attachments":{"media_keys":["3_1394597907517562883"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":11,"like_count":38,"quote_count":0},"created_at":"2021-05-18T08:55:20.000Z","author_id":"116716199","text":"What's on the agenda of the May meeting of EMA's human medicines committee (#CHMP): https://t.co/p6UfN3Wupr","id":"1394577330643812354","conversation_id":"1394577330643812354","entities":{"mentions":{},"hashtags":[{"start":76,"end":81,"tag":"CHMP"}],"urls":[{"start":84,"end":107,"url":"https://t.co/p6UfN3Wupr","expanded_url":"https://bit.ly/3hzE7af","display_url":"bit.ly/3hzE7af"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1386710049565859845"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":4,"like_count":44,"quote_count":3},"created_at":"2021-05-17T14:38:21.000Z","author_id":"116716199","text":"The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (@ICH_news) is holding a free global public web conference on 18-19 May to provide an update on a major revision to the ICH E6 Guideline for Good Clinical Practice https://t.co/vWmGKo7Rws","id":"1394301265388130304","conversation_id":"1394301265388130304","entities":{"mentions":[{"start":105,"end":114,"username":"ICH_news","id":"305434870"}],"hashtags":{},"urls":[{"start":268,"end":291,"url":"https://t.co/vWmGKo7Rws","expanded_url":"https://twitter.com/ICH_news/status/1386710049565859845","display_url":"twitter.com/ICH_news/statu‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1392421924660207621"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":86,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-17T07:55:36.000Z","author_id":"116716199","text":"RT @ECDC_EU: #DoYouKnow\nthat we have a new page with all of the current knowledge on the #SARSCoV2 variants of concern/variants of interest‚Ä¶","id":"1394199912200425473","conversation_id":"1394199912200425473","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":23,"tag":"DoYouKnow"},{"start":89,"end":98,"tag":"SARSCoV2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1394173335077011459"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-17T07:55:14.000Z","author_id":"116716199","text":"RT @EU_Health: We have to be better prepared to deal with future pandemics.\n\nThis Friday, üóìÔ∏è on 21 May, we will co-host with @g20org Italy‚Ä¶","id":"1394199818382286850","conversation_id":"1394199818382286850","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":125,"end":132,"username":"g20org","id":"925441731331543040"}],"hashtags":{},"urls":{},"annotations":[{"start":134,"end":138,"probability":0.6287,"type":"Place","normalized_text":"Italy"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":10,"like_count":23,"quote_count":0},"created_at":"2021-05-12T13:24:46.000Z","author_id":"116716199","text":"See the live tweets posted during EMA's technical press briefing held on 12 May 2021. #EMAPresser \nhttps://t.co/iSpxOhDX9y","id":"1392470808258301952","conversation_id":"1392470808258301952","entities":{"mentions":{},"hashtags":[{"start":86,"end":97,"tag":"EMAPresser"}],"urls":[{"start":99,"end":122,"url":"https://t.co/iSpxOhDX9y","expanded_url":"https://twitter.com/i/events/1392460897994649600","display_url":"twitter.com/i/events/13924‚Ä¶"}],"annotations":[{"start":34,"end":36,"probability":0.4859,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":57,"reply_count":7,"like_count":195,"quote_count":5},"created_at":"2021-05-12T12:37:20.000Z","author_id":"116716199","text":"EMA is also reviewing an application to extend the use of the vaccine #Comirnaty to include young people aged 12 to 15. #EMAPresser","id":"1392458871478833154","conversation_id":"1392458871478833154","entities":{"mentions":{},"hashtags":[{"start":70,"end":80,"tag":"Comirnaty"},{"start":120,"end":131,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.3781,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":9,"like_count":41,"quote_count":3},"created_at":"2021-05-12T12:33:50.000Z","author_id":"116716199","text":"To get informed about #COVID19vaccines, look at the authoritative sources from regulatory agencies to avoid being exposed to fake news. #EMAPresser","id":"1392457989764829186","conversation_id":"1392457989764829186","entities":{"mentions":{},"hashtags":[{"start":22,"end":38,"tag":"COVID19vaccines"},{"start":136,"end":147,"tag":"EMAPresser"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":5,"like_count":51,"quote_count":3},"created_at":"2021-05-12T12:24:03.000Z","author_id":"116716199","text":"At the moment, EMA has very limited data regarding pregnant women and #COVID19vaccines. We are closely monitoring the data that is emerging. #EMAPresser","id":"1392455527796461568","conversation_id":"1392455527796461568","entities":{"mentions":{},"hashtags":[{"start":70,"end":86,"tag":"COVID19vaccines"},{"start":141,"end":152,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":15,"end":17,"probability":0.4717,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":280,"reply_count":31,"like_count":856,"quote_count":66},"created_at":"2021-05-12T12:13:36.000Z","author_id":"116716199","text":"EMA is monitoring very closely the data on the Indian variant. We are seeing promising evidence that mRNA vaccines would be able to neutralise this variant. #EMAPresser","id":"1392452899230437376","conversation_id":"1392452899230437376","entities":{"mentions":{},"hashtags":[{"start":157,"end":168,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5248,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":2,"like_count":48,"quote_count":1},"created_at":"2021-05-12T12:10:16.000Z","author_id":"116716199","text":"EMA has frequent and regular interactions with developers of üíäüíâ. We have given scientific advice for 30 vaccines under development and over 50 therapeutics. We have interacted with developers of 250 vaccines &amp; therapeutics since the beginning of #COVID19. #EMAPresser","id":"1392452062512885772","conversation_id":"1392452062512885772","entities":{"mentions":{},"hashtags":[{"start":250,"end":258,"tag":"COVID19"},{"start":260,"end":271,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.4075,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":83,"reply_count":24,"like_count":185,"quote_count":13},"created_at":"2021-05-12T12:07:12.000Z","author_id":"116716199","text":"The EU is the only region that has 4 safe and effective #COVID19vaccines authorised (Pfizer/BioNTech, Moderna, AstraZeneca, Janssen). 4 other vaccines are under EMA‚Äôs rolling review (Curevac, Novavax, Sputnik V and Sinovac). #EMAPresser","id":"1392451287908823047","conversation_id":"1392451287908823047","entities":{"mentions":{},"hashtags":[{"start":56,"end":72,"tag":"COVID19vaccines"},{"start":225,"end":236,"tag":"EMAPresser"}],"urls":{},"annotations":[{"start":4,"end":5,"probability":0.5805,"type":"Organization","normalized_text":"EU"},{"start":124,"end":130,"probability":0.6105,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":3,"like_count":27,"quote_count":3},"created_at":"2021-05-12T11:33:50.000Z","author_id":"116716199","text":"üî¥ LIVE\nToday at 14h00 CEST, EMA is holding a press briefing to provide updates on its activities in the context of the #COVID19 pandemic: \n\nWatch it here: https://t.co/AzaFlRgINx\n\n#EMAPresser https://t.co/p4vzi4hSsO","id":"1392442890450837504","conversation_id":"1392442890450837504","entities":{"mentions":{},"hashtags":[{"start":119,"end":127,"tag":"COVID19"},{"start":180,"end":191,"tag":"EMAPresser"}],"urls":[{"start":155,"end":178,"url":"https://t.co/AzaFlRgINx","expanded_url":"https://bit.ly/3y46TWg","display_url":"bit.ly/3y46TWg"},{"start":192,"end":215,"url":"https://t.co/p4vzi4hSsO","expanded_url":"https://twitter.com/EMA_News/status/1392442890450837504/photo/1","display_url":"pic.twitter.com/p4vzi4hSsO"}],"annotations":[{"start":17,"end":31,"probability":0.2108,"type":"Place","normalized_text":"14h00 CEST, EMA"}]},"attachments":{"media_keys":["3_1392442768367276037"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1392366688390287361"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-12T09:28:18.000Z","author_id":"116716199","text":"RT @esno_web: Today it's International Nursing Day, we wish all an inspiring day with much of activities and posts on social media. #IND202‚Ä¶","id":"1392411301910024193","conversation_id":"1392411301910024193","entities":{"mentions":[{"start":3,"end":12,"username":"esno_web","id":"1185837546"}],"hashtags":{},"urls":{},"annotations":[{"start":25,"end":49,"probability":0.6881,"type":"Other","normalized_text":"International Nursing Day"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1388388233285885954"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-05-10T08:12:24.000Z","author_id":"116716199","text":"RT @my_ueg: Today marks the start of Digestive Health Month 2021! We're excited to share information throughout May on a range of chronic d‚Ä¶","id":"1391667424190152704","conversation_id":"1391667424190152704","entities":{"mentions":[{"start":3,"end":10,"username":"my_ueg","id":"487344065"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":2,"like_count":35,"quote_count":3},"created_at":"2021-05-07T16:30:19.000Z","author_id":"116716199","text":"The International Coalition of Medicines Regulatory Authorities (#ICMRA) and @WHO are urging pharmaceutical companies to provide wider access to clinical data for new #medicines and #vaccines. \n\nCheck out their joint statement: https://t.co/SDq1DH7UAX https://t.co/aIWuHZUNDX","id":"1390705566302019587","conversation_id":"1390705566302019587","entities":{"mentions":[{"start":77,"end":81,"username":"WHO","id":"14499829"}],"hashtags":[{"start":65,"end":71,"tag":"ICMRA"},{"start":167,"end":177,"tag":"medicines"},{"start":182,"end":191,"tag":"vaccines"}],"urls":[{"start":228,"end":251,"url":"https://t.co/SDq1DH7UAX","expanded_url":"https://bit.ly/3vOBm8L","display_url":"bit.ly/3vOBm8L"},{"start":252,"end":275,"url":"https://t.co/aIWuHZUNDX","expanded_url":"https://twitter.com/EMA_News/status/1390705566302019587/photo/1","display_url":"pic.twitter.com/aIWuHZUNDX"}],"annotations":[{"start":4,"end":62,"probability":0.2054,"type":"Organization","normalized_text":"International Coalition of Medicines Regulatory Authorities"}]},"attachments":{"media_keys":["3_1390705273485078532"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":5,"like_count":93,"quote_count":3},"created_at":"2021-05-07T14:11:39.000Z","author_id":"116716199","text":"EMA, the European Commission's DG Sante, and ANVISA Brazil have signed a confidentiality arrangement, allowing the exchange of non-public information to enhance cooperation for the benefit of public health. \n\nRead more here: https://t.co/M9OtUBMqoB\n\n#healthcare #medicine https://t.co/ZKMuLR8jns","id":"1390670667524288518","conversation_id":"1390670667524288518","entities":{"mentions":{},"hashtags":[{"start":250,"end":261,"tag":"healthcare"},{"start":262,"end":271,"tag":"medicine"}],"urls":[{"start":225,"end":248,"url":"https://t.co/M9OtUBMqoB","expanded_url":"https://bit.ly/33v57iJ","display_url":"bit.ly/33v57iJ"},{"start":272,"end":295,"url":"https://t.co/ZKMuLR8jns","expanded_url":"https://twitter.com/EMA_News/status/1390670667524288518/photo/1","display_url":"pic.twitter.com/ZKMuLR8jns"}],"annotations":[{"start":52,"end":57,"probability":0.6273,"type":"Place","normalized_text":"Brazil"}]},"attachments":{"media_keys":["3_1390670078924967940"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":71,"reply_count":8,"like_count":146,"quote_count":7},"created_at":"2021-05-07T12:53:45.000Z","author_id":"116716199","text":"EMA has started a rolling review of data on sotrovimab (also known as VIR-7831 and GSK4182136) a monoclonal antibody developed by GlaxoSmithKline and Vir Biotechnology, for the treatment of #COVID19.\n\nFollow the announcement here:https://t.co/CqQNl6A4g3 https://t.co/wk6Qmw4yvf","id":"1390651064303632402","conversation_id":"1390651064303632402","entities":{"mentions":{},"hashtags":[{"start":190,"end":198,"tag":"COVID19"}],"urls":[{"start":230,"end":253,"url":"https://t.co/CqQNl6A4g3","expanded_url":"https://bit.ly/3tyujzO","display_url":"bit.ly/3tyujzO"},{"start":254,"end":277,"url":"https://t.co/wk6Qmw4yvf","expanded_url":"https://twitter.com/EMA_News/status/1390651064303632402/photo/1","display_url":"pic.twitter.com/wk6Qmw4yvf"}],"annotations":[{"start":0,"end":2,"probability":0.3872,"type":"Organization","normalized_text":"EMA"},{"start":130,"end":144,"probability":0.8021,"type":"Organization","normalized_text":"GlaxoSmithKline"},{"start":150,"end":166,"probability":0.6773,"type":"Organization","normalized_text":"Vir Biotechnology"}]},"attachments":{"media_keys":["3_1390650789169967108"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":10,"like_count":31,"quote_count":3},"created_at":"2021-05-07T11:02:27.000Z","author_id":"116716199","text":"During its May meeting, EMA‚Äôs safety committee (#PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines, including #COVID19vaccines. Read more: https://t.co/DPLqMXAW68 https://t.co/fUdYjr5w9V","id":"1390623056624816132","conversation_id":"1390623056624816132","entities":{"mentions":{},"hashtags":[{"start":48,"end":53,"tag":"PRAC"},{"start":186,"end":202,"tag":"COVID19vaccines"}],"urls":[{"start":215,"end":238,"url":"https://t.co/DPLqMXAW68","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶","images":[{"url":"https://pbs.twimg.com/news_img/1477901564807417856/xjWy3Td4?format=png&name=orig","width":842,"height":1102},{"url":"https://pbs.twimg.com/news_img/1477901564807417856/xjWy3Td4?format=png&name=150x150","width":150,"height":150}],"status":200,"title":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021 - European Medicines Agency","description":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 3-6 May 2021","unwound_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021"},{"start":239,"end":262,"url":"https://t.co/fUdYjr5w9V","expanded_url":"https://twitter.com/EMA_News/status/1390623056624816132/photo/1","display_url":"pic.twitter.com/fUdYjr5w9V","images":{}}],"annotations":{}},"attachments":{"media_keys":["3_1390622997443194882"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1390266702655541249"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":5,"like_count":22,"quote_count":0},"created_at":"2021-05-06T14:26:12.000Z","author_id":"116716199","text":"Today, EMA‚Äôs Deputy Executive Director No√´l Wathion is joining @SKyriakidesEU in the new @EU_Commission #podcast Europe Calling. \n\nTune in now üëá https://t.co/KdZPyN8cUp","id":"1390311943618060291","conversation_id":"1390311943618060291","entities":{"mentions":[{"start":63,"end":77,"username":"SKyriakidesEU","id":"2476130260"},{"start":89,"end":103,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":104,"end":112,"tag":"podcast"}],"urls":[{"start":145,"end":168,"url":"https://t.co/KdZPyN8cUp","expanded_url":"https://twitter.com/EC_AVService/status/1390266702655541249","display_url":"twitter.com/EC_AVService/s‚Ä¶"}],"annotations":[{"start":7,"end":9,"probability":0.3454,"type":"Organization","normalized_text":"EMA"},{"start":30,"end":50,"probability":0.4875,"type":"Person","normalized_text":"Director No√´l Wathion"},{"start":113,"end":118,"probability":0.4932,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":71,"reply_count":22,"like_count":124,"quote_count":10},"created_at":"2021-05-06T14:06:56.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, no new applications submitted, authorisations completed https://t.co/fve6O9OuQe","id":"1390307095661015055","conversation_id":"1390307095661015055","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":122,"end":145,"url":"https://t.co/fve6O9OuQe","expanded_url":"https://twitter.com/EMA_News/status/1390307095661015055/photo/1","display_url":"pic.twitter.com/fve6O9OuQe"}],"annotations":{}},"attachments":{"media_keys":["3_1390306963972448265"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":5,"like_count":64,"quote_count":0},"created_at":"2021-05-04T10:57:15.000Z","author_id":"116716199","text":"We have just published our academia collaboration action plan that sets out how EMA intends to create closer ties with academics and researchers in the next two and a half years. \n\nThe action plan üëâ https://t.co/TJr1hgdzha https://t.co/Ec3sQcr71C","id":"1389534581834100739","conversation_id":"1389534581834100739","entities":{"mentions":{},"hashtags":{},"urls":[{"start":199,"end":222,"url":"https://t.co/TJr1hgdzha","expanded_url":"https://bit.ly/33qQM7j","display_url":"bit.ly/33qQM7j"},{"start":223,"end":246,"url":"https://t.co/Ec3sQcr71C","expanded_url":"https://twitter.com/EMA_News/status/1389534581834100739/photo/1","display_url":"pic.twitter.com/Ec3sQcr71C"}],"annotations":[{"start":80,"end":82,"probability":0.6233,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1389534417639677953"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":334,"reply_count":41,"like_count":448,"quote_count":84},"created_at":"2021-05-04T09:34:08.000Z","author_id":"116716199","text":"!! EMA human medicines committee (#CHMP) has started a rolling review of #COVID19vaccine (Vero Cell) Inactivated, developed by Sinovac Life Sciences Co., Ltd.\n\nLink to the announcement üëâhttps://t.co/DK7qcNGLbu https://t.co/fsq6TNVzjF","id":"1389513666672869376","conversation_id":"1389513666672869376","entities":{"mentions":{},"hashtags":[{"start":34,"end":39,"tag":"CHMP"},{"start":73,"end":88,"tag":"COVID19vaccine"}],"urls":[{"start":186,"end":209,"url":"https://t.co/DK7qcNGLbu","expanded_url":"https://bit.ly/3egBwQz","display_url":"bit.ly/3egBwQz"},{"start":210,"end":233,"url":"https://t.co/fsq6TNVzjF","expanded_url":"https://twitter.com/EMA_News/status/1389513666672869376/photo/1","display_url":"pic.twitter.com/fsq6TNVzjF"}],"annotations":[{"start":127,"end":157,"probability":0.5197,"type":"Organization","normalized_text":"Sinovac Life Sciences Co., Ltd."}]},"attachments":{"media_keys":["3_1389513075636809738"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":133,"reply_count":7,"like_count":277,"quote_count":23},"created_at":"2021-05-03T15:00:55.000Z","author_id":"116716199","text":"EMA human medicine committee (#CHMP) is evaluating the use of the #COVID19vaccine Comirnaty (currently for ages 16+) in young people aged 12 to 15.\n\nThe review is currently ongoing: https://t.co/jy0GVhTnX7\n\n#medicine #COVID19 #vaccine https://t.co/V16mPlmm0m","id":"1389233516467081222","conversation_id":"1389233516467081222","entities":{"mentions":{},"hashtags":[{"start":30,"end":35,"tag":"CHMP"},{"start":66,"end":81,"tag":"COVID19vaccine"},{"start":207,"end":216,"tag":"medicine"},{"start":217,"end":225,"tag":"COVID19"},{"start":226,"end":234,"tag":"vaccine"}],"urls":[{"start":182,"end":205,"url":"https://t.co/jy0GVhTnX7","expanded_url":"https://bit.ly/3nPCypJ","display_url":"bit.ly/3nPCypJ"},{"start":235,"end":258,"url":"https://t.co/V16mPlmm0m","expanded_url":"https://twitter.com/EMA_News/status/1389233516467081222/photo/1","display_url":"pic.twitter.com/V16mPlmm0m"}],"annotations":{}},"attachments":{"media_keys":["3_1389232821164822528"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":56,"reply_count":22,"like_count":329,"quote_count":9},"created_at":"2021-04-30T13:59:18.000Z","author_id":"116716199","text":"Executive Director Emer Cooke received her #COVID19 vaccine today. üëç\n\nBy expediting the development and approval of safe and effective treatments and vaccines, EMA is contributing to global efforts to save lives during the pandemic. \n\n#SafeVaccines https://t.co/J3tg3omBmZ","id":"1388130845781807106","conversation_id":"1388130845781807106","entities":{"mentions":{},"hashtags":[{"start":43,"end":51,"tag":"COVID19"},{"start":235,"end":248,"tag":"SafeVaccines"}],"urls":[{"start":249,"end":272,"url":"https://t.co/J3tg3omBmZ","expanded_url":"https://twitter.com/EMA_News/status/1388130845781807106/photo/1","display_url":"pic.twitter.com/J3tg3omBmZ"}],"annotations":[{"start":19,"end":28,"probability":0.7559,"type":"Person","normalized_text":"Emer Cooke"},{"start":161,"end":163,"probability":0.5766,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1388130571981934593"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387780992476274688"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T15:03:06.000Z","author_id":"116716199","text":"RT @ECDC_EU: How many Europeans have been vaccinated against #COVID19 so far? How does it look in the specific age groups?\n\nFind all the in‚Ä¶","id":"1387784512902467593","conversation_id":"1387784512902467593","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":61,"end":69,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":49,"reply_count":3,"like_count":81,"quote_count":5},"created_at":"2021-04-29T14:29:18.000Z","author_id":"116716199","text":"EMA started evaluating Olumiant (baricitinib) in #COVID19 patients from 10 years of age who require supplemental oxygen üëâhttps://t.co/sIMh9m7Qzv\n\n#medicine #pharmaceutical https://t.co/k5H4tw7TVT","id":"1387776007667691529","conversation_id":"1387776007667691529","entities":{"mentions":{},"hashtags":[{"start":49,"end":57,"tag":"COVID19"},{"start":146,"end":155,"tag":"medicine"},{"start":156,"end":171,"tag":"pharmaceutical"}],"urls":[{"start":121,"end":144,"url":"https://t.co/sIMh9m7Qzv","expanded_url":"https://bit.ly/3nvwBOy","display_url":"bit.ly/3nvwBOy"},{"start":172,"end":195,"url":"https://t.co/k5H4tw7TVT","expanded_url":"https://twitter.com/EMA_News/status/1387776007667691529/photo/1","display_url":"pic.twitter.com/k5H4tw7TVT"}],"annotations":{}},"attachments":{"media_keys":["3_1387775693665280002"]}},{"source":"Moments Internal Auth","referenced_tweets":{},"possibly_sensitive":false,"lang":"und","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T14:21:09.000Z","author_id":"116716199","text":"https://t.co/FvTdeZUh8y","id":"1387773957210841095","conversation_id":"1387773957210841095","entities":{"mentions":{},"hashtags":{},"urls":[{"start":0,"end":23,"url":"https://t.co/FvTdeZUh8y","expanded_url":"https://twitter.com/EMA_News/status/1387773957210841095/photo/1","display_url":"pic.twitter.com/FvTdeZUh8y"}],"annotations":{}},"attachments":{"media_keys":["3_1387773952559390735"]}},{"source":"Moments Internal Auth","referenced_tweets":{},"possibly_sensitive":false,"lang":"und","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T14:19:44.000Z","author_id":"116716199","text":"https://t.co/W8HiaIkUMB","id":"1387773599386320905","conversation_id":"1387773599386320905","entities":{"mentions":{},"hashtags":{},"urls":[{"start":0,"end":23,"url":"https://t.co/W8HiaIkUMB","expanded_url":"https://twitter.com/EMA_News/status/1387773599386320905/photo/1","display_url":"pic.twitter.com/W8HiaIkUMB"}],"annotations":{}},"attachments":{"media_keys":["3_1387773588246253570"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387768733918277641"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T14:00:36.000Z","author_id":"116716199","text":"RT @EU_Health: @ECDC_EU @TwitterGov @EMA_News And in closing, let's share the simple message that #VaccinesWork \n\nThe pandemic may have foc‚Ä¶","id":"1387768783595528195","conversation_id":"1387768783595528195","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":15,"end":23,"username":"ECDC_EU","id":"204752573"},{"start":24,"end":35,"username":"TwitterGov","id":"222953824"},{"start":36,"end":45,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":98,"end":111,"tag":"VaccinesWork"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387768056869531657"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T13:57:58.000Z","author_id":"116716199","text":"RT @ECDC_EU: @EU_Health @TwitterGov @EMA_News We also set up the \"#COVID19 Vaccine Tracker\", an interactive dashboard that allows to monito‚Ä¶","id":"1387768122116087808","conversation_id":"1387768122116087808","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":13,"end":23,"username":"EU_Health","id":"606325697"},{"start":24,"end":35,"username":"TwitterGov","id":"222953824"},{"start":36,"end":45,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":66,"end":74,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387767342353063944"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T13:55:02.000Z","author_id":"116716199","text":"RT @EU_Health: @TwitterGov @ECDC_EU @EMA_News It can be difficult to assess the accuracy of information on COVID-19. Checking your sources‚Ä¶","id":"1387767383608242182","conversation_id":"1387767383608242182","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":15,"end":26,"username":"TwitterGov","id":"222953824"},{"start":27,"end":35,"username":"ECDC_EU","id":"204752573"},{"start":36,"end":45,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387765398972555275"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T13:47:22.000Z","author_id":"116716199","text":"RT @ECDC_EU: @EMA_News @TwitterGov @EU_Health Remember this is a new virus. We need more information on how efficient the vaccines are in r‚Ä¶","id":"1387765455365058561","conversation_id":"1387765455365058561","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":13,"end":22,"username":"EMA_News","id":"116716199"},{"start":23,"end":34,"username":"TwitterGov","id":"222953824"},{"start":35,"end":45,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1387764876836225035"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":1,"like_count":28,"quote_count":0},"created_at":"2021-04-29T13:45:53.000Z","author_id":"116716199","text":"@TwitterGov @EU_Health @ECDC_EU It's difficult to say for the moment as more data is needed, but we are monitoring this very carefully. \nWe have asked researchers and vaccine manufacturers to gather more information and submit it to us for assessment.","id":"1387765082239741955","conversation_id":"1387761777518260233","entities":{"mentions":[{"start":0,"end":11,"username":"TwitterGov","id":"222953824"},{"start":12,"end":22,"username":"EU_Health","id":"606325697"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"222953824"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1387764200798314507"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":1,"like_count":27,"quote_count":0},"created_at":"2021-04-29T13:43:23.000Z","author_id":"116716199","text":"@EU_Health @TwitterGov @ECDC_EU The safety of #COVID19vaccines is stronger with everybody's participation!\nPlease report any suspected side effect to your doctor, national authority in your country or the vaccine manufacturer  https://t.co/vJaSpm1GMq","id":"1387764452477620231","conversation_id":"1387761777518260233","entities":{"mentions":[{"start":0,"end":10,"username":"EU_Health","id":"606325697"},{"start":11,"end":22,"username":"TwitterGov","id":"222953824"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":46,"end":62,"tag":"COVID19vaccines"}],"urls":[{"start":227,"end":250,"url":"https://t.co/vJaSpm1GMq","expanded_url":"https://www.hma.eu/nationalcontacts_hum.html","display_url":"hma.eu/nationalcontac‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1387764027737190400"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":1,"like_count":33,"quote_count":0},"created_at":"2021-04-29T13:42:23.000Z","author_id":"116716199","text":"@EU_Health @TwitterGov @ECDC_EU Most side effects are identified before a vaccine is licensed. Some side effects are so rare, they may only show up once millions of people have received the vaccine.\nThe EU's safety monitoring system is set up to rapidly detect and deal with possible safety concerns.","id":"1387764200798314507","conversation_id":"1387761777518260233","entities":{"mentions":[{"start":0,"end":10,"username":"EU_Health","id":"606325697"},{"start":11,"end":22,"username":"TwitterGov","id":"222953824"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":{},"annotations":[{"start":203,"end":204,"probability":0.4842,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"606325697"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1387763127677329408"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":30,"quote_count":0},"created_at":"2021-04-29T13:38:38.000Z","author_id":"116716199","text":"@TwitterGov @EU_Health @ECDC_EU All vaccines are rigorously tested for quality, safety and efficacy in large clinical trials with tens of thousands of participants before they can be used in the EU. \nAfter authorisation, we closely monitor, review evidence and take quick action, when needed.","id":"1387763257323237390","conversation_id":"1387761777518260233","entities":{"mentions":[{"start":0,"end":11,"username":"TwitterGov","id":"222953824"},{"start":12,"end":22,"username":"EU_Health","id":"606325697"},{"start":23,"end":31,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"222953824"},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387761777518260233"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-29T13:33:13.000Z","author_id":"116716199","text":"RT @TwitterGov: Hi @EU_Health, @EMA_News, and @ECDC_EU üëã\n\nIt's #WorldImmunizationWeek what better time to talk about COVID-19 vaccines?‚Ä¶","id":"1387761894375755788","conversation_id":"1387761894375755788","entities":{"mentions":[{"start":3,"end":14,"username":"TwitterGov","id":"222953824"},{"start":19,"end":29,"username":"EU_Health","id":"606325697"},{"start":31,"end":40,"username":"EMA_News","id":"116716199"},{"start":46,"end":54,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":63,"end":85,"tag":"WorldImmunizationWeek"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1387666016692576256"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":1,"like_count":35,"quote_count":0},"created_at":"2021-04-29T11:11:43.000Z","author_id":"116716199","text":"Follow our conversation with @TwitterGov, @EU_Health and @ECDC_EU on #COVID19vaccines today at 3:30 PM (CEST)!\n\n#VaccinesWork \n#EuropeanImmunizationWeek\n#WorldImmunizationWeek https://t.co/lUOmJjEzCR","id":"1387726284638273541","conversation_id":"1387726284638273541","entities":{"mentions":[{"start":29,"end":40,"username":"TwitterGov","id":"222953824"},{"start":42,"end":52,"username":"EU_Health","id":"606325697"},{"start":57,"end":65,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":69,"end":85,"tag":"COVID19vaccines"},{"start":112,"end":125,"tag":"VaccinesWork"},{"start":127,"end":152,"tag":"EuropeanImmunizationWeek"},{"start":153,"end":175,"tag":"WorldImmunizationWeek"}],"urls":[{"start":176,"end":199,"url":"https://t.co/lUOmJjEzCR","expanded_url":"https://twitter.com/EU_Health/status/1387666016692576256","display_url":"twitter.com/EU_Health/stat‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1387400684249702408"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-28T14:16:50.000Z","author_id":"116716199","text":"RT @EUnetHTA: The last EMA-EUnetHTA Bilateral Meeting under Joint Action 3 was held today, concluding collaboration that began with the fir‚Ä¶","id":"1387410482785669127","conversation_id":"1387410482785669127","entities":{"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"}],"hashtags":{},"urls":{},"annotations":[{"start":23,"end":73,"probability":0.1774,"type":"Other","normalized_text":"EMA-EUnetHTA Bilateral Meeting under Joint Action 3"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1387286377084166144"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":2,"like_count":66,"quote_count":3},"created_at":"2021-04-28T13:59:02.000Z","author_id":"116716199","text":"For over 200 years, vaccines have saved millions of lives from deadly infectious diseases.\n\nVaccines also allow people to come together without the fear of getting ill, this improves the quality of life and their wellbeing. \n\nFind out how #VaccinesWork :https://t.co/1lly7d5rrp https://t.co/4NAl8OPDnq","id":"1387406004090978308","conversation_id":"1387406004090978308","entities":{"mentions":{},"hashtags":[{"start":239,"end":252,"tag":"VaccinesWork"}],"urls":[{"start":254,"end":277,"url":"https://t.co/1lly7d5rrp","expanded_url":"https://bit.ly/2QvUwBC","display_url":"bit.ly/2QvUwBC","status":200,"title":"European Vaccination Information Portal / Home page | European Vaccination Information Portal","description":"The European Commission authorised the first COVID-19 vaccine on 21 December 2020, after an evaluation by the European Medicines Agency (EMA) and consultation with the EU Member States. A vaccine stimulates an immune response, and a ‚Äòmemory‚Äô of the body to a specific disease, without causing the disease. Key facts on HPV, symptoms, complications, risk factors, how it spreads, prevention, and treatment. Key facts on Influenza, symptoms, complications, risk factors, how it spreads, prevention, and treatment.","unwound_url":"https://vaccination-info.eu/en"},{"start":278,"end":301,"url":"https://t.co/4NAl8OPDnq","expanded_url":"https://twitter.com/EU_Health/status/1387286377084166144","display_url":"twitter.com/EU_Health/stat‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1387075047903440910"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":40,"quote_count":0},"created_at":"2021-04-28T13:49:49.000Z","author_id":"116716199","text":"As we dive deeply into #EuropeanImmunizationWeek, we must remember that #vaccineswork. Vaccination is our way towards ending the #COVID19 pandemic and saving lives üåé \n\nVisit EMA‚Äôs website to get reliable information on #COVID19vaccines: https://t.co/bY95nHrSPu https://t.co/BddyxcZCsZ","id":"1387403683625947142","conversation_id":"1387403683625947142","entities":{"mentions":{},"hashtags":[{"start":23,"end":48,"tag":"EuropeanImmunizationWeek"},{"start":72,"end":85,"tag":"vaccineswork"},{"start":129,"end":137,"tag":"COVID19"},{"start":219,"end":235,"tag":"COVID19vaccines"}],"urls":[{"start":237,"end":260,"url":"https://t.co/bY95nHrSPu","expanded_url":"https://bit.ly/3xr8Uvz","display_url":"bit.ly/3xr8Uvz"},{"start":261,"end":284,"url":"https://t.co/BddyxcZCsZ","expanded_url":"https://twitter.com/ECDC_EU/status/1387075047903440910","display_url":"twitter.com/ECDC_EU/status‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1385531946634252289"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-28T11:06:51.000Z","author_id":"116716199","text":"RT @EU_Health: Today, our lives are defined by COVID-19\n\nWhat does this mean for our mental health &amp; for those providing care?\n\nJoin us on‚Ä¶","id":"1387362673336229889","conversation_id":"1387362673336229889","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":67,"reply_count":9,"like_count":108,"quote_count":4},"created_at":"2021-04-26T14:05:18.000Z","author_id":"116716199","text":"EMA and @ECDC_EU today kicked off a new initiative aimed at strengthening post-marketing monitoring of the safety, effectiveness and impact of #COVID19 vaccines in the EU/EEA. Read more: üëâhttps://t.co/bSL8VHRkLL https://t.co/O5nl6mPEGs","id":"1386682805908918274","conversation_id":"1386682805908918274","entities":{"mentions":[{"start":8,"end":16,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":143,"end":151,"tag":"COVID19"}],"urls":[{"start":188,"end":211,"url":"https://t.co/bSL8VHRkLL","expanded_url":"https://www.ema.europa.eu/en/news/ema-ecdc-join-forces-enhanced-post-marketing-monitoring-covid-19-vaccines-europe","display_url":"ema.europa.eu/en/news/ema-ec‚Ä¶"},{"start":212,"end":235,"url":"https://t.co/O5nl6mPEGs","expanded_url":"https://twitter.com/EMA_News/status/1386682805908918274/photo/1","display_url":"pic.twitter.com/O5nl6mPEGs"}],"annotations":{}},"attachments":{"media_keys":["3_1386682691601506305"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":3,"like_count":34,"quote_count":1},"created_at":"2021-04-26T13:09:18.000Z","author_id":"116716199","text":"Thank you to all #healthcare professionals involved in EMA activities in 2020. \n\nSee highlights of involvement üëâhttps://t.co/pdBZOd6mUD\n\nRead more on how healthcare professionals are involved in #regulation of #medicines üëâ https://t.co/PS90xKOPQq https://t.co/k9g4pX9tcH","id":"1386668711461933058","conversation_id":"1386668711461933058","entities":{"mentions":{},"hashtags":[{"start":17,"end":28,"tag":"healthcare"},{"start":195,"end":206,"tag":"regulation"},{"start":210,"end":220,"tag":"medicines"}],"urls":[{"start":112,"end":135,"url":"https://t.co/pdBZOd6mUD","expanded_url":"https://bit.ly/2QVPYEg","display_url":"bit.ly/2QVPYEg"},{"start":223,"end":246,"url":"https://t.co/PS90xKOPQq","expanded_url":"https://bit.ly/3gFCvve","display_url":"bit.ly/3gFCvve"},{"start":247,"end":270,"url":"https://t.co/k9g4pX9tcH","expanded_url":"https://twitter.com/EMA_News/status/1386668711461933058/photo/1","display_url":"pic.twitter.com/k9g4pX9tcH"}],"annotations":{}},"attachments":{"media_keys":["3_1386668612379942916"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":31,"reply_count":4,"like_count":69,"quote_count":2},"created_at":"2021-04-26T10:52:30.000Z","author_id":"116716199","text":"Thank you to all #patients involved in EMA activities during 2020. \n\nSee highlights of involvement üëâhttps://t.co/2hLBgN4Fhs \n\nDid you know that patients participate in #regulation of #medicines Read more here üëâ https://t.co/u265oFLrv1 https://t.co/ZEyVnrviNV","id":"1386634284333740038","conversation_id":"1386634284333740038","entities":{"mentions":{},"hashtags":[{"start":17,"end":26,"tag":"patients"},{"start":168,"end":179,"tag":"regulation"},{"start":183,"end":193,"tag":"medicines"}],"urls":[{"start":100,"end":123,"url":"https://t.co/2hLBgN4Fhs","expanded_url":"https://bit.ly/3aD1Hyo","display_url":"bit.ly/3aD1Hyo"},{"start":211,"end":234,"url":"https://t.co/u265oFLrv1","expanded_url":"https://bit.ly/3sSjyrt","display_url":"bit.ly/3sSjyrt"},{"start":235,"end":258,"url":"https://t.co/ZEyVnrviNV","expanded_url":"https://twitter.com/EMA_News/status/1386634284333740038/photo/1","display_url":"pic.twitter.com/ZEyVnrviNV"}],"annotations":{}},"attachments":{"media_keys":["3_1386634125243715584"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1386563441553444864"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":282,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-26T07:41:59.000Z","author_id":"116716199","text":"RT @EU_Commission: European Immunization Week is here.\n\nAs vaccinations against #COVID19 are taking place, vaccine production has also been‚Ä¶","id":"1386586340880523264","conversation_id":"1386586340880523264","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":80,"end":88,"tag":"COVID19"}],"urls":{},"annotations":[{"start":19,"end":44,"probability":0.3866,"type":"Other","normalized_text":"European Immunization Week"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1386559414958706691"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":213,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-04-26T07:29:14.000Z","author_id":"116716199","text":"RT @EU_Health: #Covid19 focused our attention on vaccination\n\nBut for more than 200 years vaccines have protected billions of people from d‚Ä¶","id":"1386583130207932416","conversation_id":"1386583130207932416","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":23,"tag":"Covid19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":8,"like_count":48,"quote_count":4},"created_at":"2021-04-23T18:31:24.000Z","author_id":"116716199","text":"Did you miss the press briefing on further assessment of data on Vaxzevria, the #COVID19vaccine from AstraZeneca? You can watch it on EMA's YouTube channel: https://t.co/GfovqACcEP","id":"1385662606707499011","conversation_id":"1385662606707499011","entities":{"mentions":{},"hashtags":[{"start":80,"end":95,"tag":"COVID19vaccine"}],"urls":[{"start":157,"end":180,"url":"https://t.co/GfovqACcEP","expanded_url":"https://www.youtube.com/watch?v=HeEecXcOtAw","display_url":"youtube.com/watch?v=HeEecX‚Ä¶"}],"annotations":[{"start":65,"end":73,"probability":0.4126,"type":"Organization","normalized_text":"Vaxzevria"},{"start":101,"end":111,"probability":0.4688,"type":"Organization","normalized_text":"AstraZeneca"},{"start":140,"end":146,"probability":0.4926,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":2,"like_count":19,"quote_count":0},"created_at":"2021-04-23T16:01:01.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 8 #medicines for approval at its April 2021. üëâhttps://t.co/FjJUjU9EM8 https://t.co/shA01BP3kw","id":"1385624759761874944","conversation_id":"1385624759761874944","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":97,"end":120,"url":"https://t.co/FjJUjU9EM8","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2021"},{"start":121,"end":144,"url":"https://t.co/shA01BP3kw","expanded_url":"https://twitter.com/EMA_News/status/1385624759761874944/photo/1","display_url":"pic.twitter.com/shA01BP3kw"}],"annotations":[{"start":0,"end":2,"probability":0.4457,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1385624614152327177"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":7,"like_count":71,"quote_count":2},"created_at":"2021-04-23T14:13:42.000Z","author_id":"116716199","text":"Peter Arlett, Head of Data Analytics and Methods: ‚ÄúOur work goes on. The safety of all the #COVID19vaccines is our top priority and all new data will be evaluated immediately and the public will be kept up to date.‚Äù","id":"1385597756442566661","conversation_id":"1385597756442566661","entities":{"mentions":{},"hashtags":[{"start":91,"end":107,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":0,"end":11,"probability":0.9911,"type":"Person","normalized_text":"Peter Arlett"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":54,"reply_count":11,"like_count":102,"quote_count":10},"created_at":"2021-04-23T14:13:13.000Z","author_id":"116716199","text":"Peter Arlett, Head of Data Analytics and Methods: ‚ÄúThe benefits of AstraZeneca vaccine outweigh the risks. The work introduced today puts the very rare blood clots into the context of #COVID19 hospitalisations prevented, intensive-care admissions prevented and deaths prevented.‚Äù","id":"1385597634107383815","conversation_id":"1385597634107383815","entities":{"mentions":{},"hashtags":[{"start":184,"end":192,"tag":"COVID19"}],"urls":{},"annotations":[{"start":0,"end":11,"probability":0.9789,"type":"Person","normalized_text":"Peter Arlett"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":118,"reply_count":6,"like_count":172,"quote_count":56},"created_at":"2021-04-23T14:10:09.000Z","author_id":"116716199","text":"No√´l Wathion, EMA‚Äôs Deputy Executive Director: \"CHMP has recommended to continue giving a second dose of Vaxzevria 4 to 12 weeks after giving the first one in line with the product information.\"","id":"1385596859285131264","conversation_id":"1385596859285131264","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":11,"probability":0.6397,"type":"Person","normalized_text":"No√´l Wathion"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":2,"like_count":32,"quote_count":0},"created_at":"2021-04-23T14:08:54.000Z","author_id":"116716199","text":"No√´l Wathion, EMA‚Äôs Deputy Executive Director: ‚ÄúEMA will continue to assess further information as it becomes available from ECDC, from the Member States, from the company to decide if its current conclusions should be changed in the light of further scientific evidence.‚Äù","id":"1385596547472269314","conversation_id":"1385596547472269314","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":11,"probability":0.8285,"type":"Person","normalized_text":"No√´l Wathion"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":49,"quote_count":7},"created_at":"2021-04-23T14:08:01.000Z","author_id":"116716199","text":"No√´l Wathion, EMA‚Äôs Deputy Executive Director: ‚ÄúOverall, the data show that the benefits of vaccination increase with age and with increasing levels of infection in the community.‚Äù","id":"1385596325916463111","conversation_id":"1385596325916463111","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":11,"probability":0.7671,"type":"Person","normalized_text":"No√´l Wathion"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":2,"like_count":37,"quote_count":1},"created_at":"2021-04-23T14:02:03.000Z","author_id":"116716199","text":"We are starting the press briefing on further assessment of data on Vaxzevria, the #COVID19vaccine from AstraZeneca: https://t.co/D7EZUYvtrg","id":"1385594824426938372","conversation_id":"1385594824426938372","entities":{"mentions":{},"hashtags":[{"start":83,"end":98,"tag":"COVID19vaccine"}],"urls":[{"start":117,"end":140,"url":"https://t.co/D7EZUYvtrg","expanded_url":"https://youtu.be/HeEecXcOtAw","display_url":"youtu.be/HeEecXcOtAw"}],"annotations":[{"start":68,"end":76,"probability":0.4362,"type":"Organization","normalized_text":"Vaxzevria"},{"start":104,"end":114,"probability":0.4157,"type":"Organization","normalized_text":"AstraZeneca"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":126,"reply_count":7,"like_count":163,"quote_count":42},"created_at":"2021-04-23T13:59:41.000Z","author_id":"116716199","text":"Analysis of data on Vaxzevria (formerly #COVID19vaccine AstraZeneca) puts risks of very rare blood clots in the context of benefits for different age groups and different rates of infection inform national decisions on vaccine roll-out üëâ https://t.co/crHJnVEksn https://t.co/9XUQEt2OKO","id":"1385594225249632261","conversation_id":"1385594225249632261","entities":{"mentions":{},"hashtags":[{"start":40,"end":55,"tag":"COVID19vaccine"}],"urls":[{"start":238,"end":261,"url":"https://t.co/crHJnVEksn","expanded_url":"https://bit.ly/2QtYzyb","display_url":"bit.ly/2QtYzyb"},{"start":262,"end":285,"url":"https://t.co/9XUQEt2OKO","expanded_url":"https://twitter.com/EMA_News/status/1385594225249632261/photo/1","display_url":"pic.twitter.com/9XUQEt2OKO"}],"annotations":[{"start":20,"end":28,"probability":0.616,"type":"Organization","normalized_text":"Vaxzevria"}]},"attachments":{"media_keys":["3_1385594139954368512"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":4,"like_count":54,"quote_count":7},"created_at":"2021-04-23T13:52:26.000Z","author_id":"116716199","text":"!! A press briefing following the further assessment of #COVID19Vaccine Vaxzevria by our human medicines committee (#CHMP) is planned at 16:00 CET today \nüëâhttps://t.co/oDe9DGjOGK","id":"1385592402593959937","conversation_id":"1385592402593959937","entities":{"mentions":{},"hashtags":[{"start":56,"end":71,"tag":"COVID19Vaccine"},{"start":116,"end":121,"tag":"CHMP"}],"urls":[{"start":155,"end":178,"url":"https://t.co/oDe9DGjOGK","expanded_url":"https://bit.ly/2QVNjus","display_url":"bit.ly/2QVNjus"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":204,"reply_count":14,"like_count":581,"quote_count":48},"created_at":"2021-04-23T12:48:08.000Z","author_id":"116716199","text":"EMA has approved manufacturing changes that will increase capacity and supply of Pfizer/BioNTech &amp; Moderna #COVID19vaccines in the EU \nüëâhttps://t.co/qBqoQTWcm9 https://t.co/QFUCOHqs99","id":"1385576219798867968","conversation_id":"1385576219798867968","entities":{"mentions":{},"hashtags":[{"start":111,"end":127,"tag":"COVID19vaccines"}],"urls":[{"start":140,"end":163,"url":"https://t.co/qBqoQTWcm9","expanded_url":"https://bit.ly/3dI2v7i","display_url":"bit.ly/3dI2v7i"},{"start":164,"end":187,"url":"https://t.co/QFUCOHqs99","expanded_url":"https://twitter.com/EMA_News/status/1385576219798867968/photo/1","display_url":"pic.twitter.com/QFUCOHqs99"}],"annotations":[{"start":0,"end":2,"probability":0.8229,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1385576210378407937"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":85,"reply_count":17,"like_count":148,"quote_count":21},"created_at":"2021-04-22T15:02:53.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, no new applications submitted, authorisations completed https://t.co/VUrFWth9Xg","id":"1385247742797230083","conversation_id":"1385247742797230083","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":122,"end":145,"url":"https://t.co/VUrFWth9Xg","expanded_url":"https://twitter.com/EMA_News/status/1385247742797230083/photo/1","display_url":"pic.twitter.com/VUrFWth9Xg"}],"annotations":{}},"attachments":{"media_keys":["3_1385246372178300930"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":13,"like_count":76,"quote_count":8},"created_at":"2021-04-20T17:29:02.000Z","author_id":"116716199","text":"Did you miss our press briefing on EMA's safety committee (#PRAC) review of #COVID19Vaccine Janssen and cases of blood clots? You can watch it on EMA's YouTube channel:\nhttps://t.co/H4xlcn1Cok","id":"1384559748956278792","conversation_id":"1384559748956278792","entities":{"mentions":{},"hashtags":[{"start":59,"end":64,"tag":"PRAC"},{"start":76,"end":91,"tag":"COVID19Vaccine"}],"urls":[{"start":169,"end":192,"url":"https://t.co/H4xlcn1Cok","expanded_url":"https://youtu.be/C9mY0_yz2io","display_url":"youtu.be/C9mY0_yz2io"}],"annotations":[{"start":92,"end":98,"probability":0.4647,"type":"Person","normalized_text":"Janssen"},{"start":152,"end":158,"probability":0.5541,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":58,"reply_count":11,"like_count":116,"quote_count":7},"created_at":"2021-04-20T15:17:16.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: ‚ÄúThe #COVID19vaccine Janssen has demonstrated in clinical trials and it is highly effective in preventing infections caused by #COVID19.‚Äù","id":"1384526586599383040","conversation_id":"1384526586599383040","entities":{"mentions":{},"hashtags":[{"start":32,"end":47,"tag":"COVID19vaccine"},{"start":154,"end":162,"tag":"COVID19"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9568,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":3,"like_count":52,"quote_count":5},"created_at":"2021-04-20T15:15:51.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"It is important that #healthcareprofessionals and the people coming for vaccination are aware of the risks and look out for possible signs or symptoms that usually occur in the first two weeks following vaccination.‚Äù","id":"1384526232071639041","conversation_id":"1384526232071639041","entities":{"mentions":{},"hashtags":[{"start":49,"end":73,"tag":"healthcareprofessionals"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9392,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":6,"like_count":76,"quote_count":3},"created_at":"2021-04-20T15:15:21.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"At this moment it is not possible to identify clear risk factors such as gender or age.‚Äù","id":"1384526104376008705","conversation_id":"1384526104376008705","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":12,"probability":0.8998,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":2,"like_count":65,"quote_count":4},"created_at":"2021-04-20T15:14:54.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"The careful review of the cases and available evidence have led #PRAC to the conclusion that these blood clotting disorders are very rare side effects of the #COVID19vaccine Janssen.‚Äù","id":"1384525994321661954","conversation_id":"1384525994321661954","entities":{"mentions":{},"hashtags":[{"start":92,"end":97,"tag":"PRAC"},{"start":186,"end":201,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.8703,"type":"Person","normalized_text":"Sabine Straus"},{"start":202,"end":208,"probability":0.6954,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":36,"quote_count":4},"created_at":"2021-04-20T15:14:30.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"The reported cases occurred mostly in women under 60 years, within the first three weeks following vaccination.‚Äù","id":"1384525890265178114","conversation_id":"1384525890265178114","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":12,"probability":0.944,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":2,"like_count":29,"quote_count":1},"created_at":"2021-04-20T15:12:11.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúPRAC‚Äôs scientific assessment provides health authorities responsible for vaccination campaigns in the Member States with the important information they need to take decisions based on their national situation.‚Äù","id":"1384525310289485839","conversation_id":"1384525310289485839","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9904,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":60,"reply_count":5,"like_count":171,"quote_count":6},"created_at":"2021-04-20T15:11:36.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúWhen vaccines are rolled-out to large numbers of people, very rare events can occur that were not identified in the clinical trials. Our role is to detect and analyse these risks and their impact on the benefit/risk profile of the vaccine.‚Äù","id":"1384525163094548482","conversation_id":"1384525163094548482","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9905,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":3,"like_count":40,"quote_count":0},"created_at":"2021-04-20T15:11:13.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúOur investigations will continue. We will be imposing studies on Janssen to look further into the data. EMA has also commissioned research into the cases of thrombosis in #COVID19 disease through two research consortiums.‚Äù","id":"1384525066793271303","conversation_id":"1384525066793271303","entities":{"mentions":{},"hashtags":[{"start":206,"end":214,"tag":"COVID19"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9912,"type":"Person","normalized_text":"Emer Cooke"},{"start":100,"end":106,"probability":0.7534,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":2,"like_count":54,"quote_count":4},"created_at":"2021-04-20T15:06:05.000Z","author_id":"116716199","text":"We are starting the press briefing on EMA‚Äôs safety committee (#PRAC) review of #COVID19vaccine Janssen and cases of blood clots: https://t.co/H4xlcn1Cok","id":"1384523772909268995","conversation_id":"1384523772909268995","entities":{"mentions":{},"hashtags":[{"start":62,"end":67,"tag":"PRAC"},{"start":79,"end":94,"tag":"COVID19vaccine"}],"urls":[{"start":129,"end":152,"url":"https://t.co/H4xlcn1Cok","expanded_url":"https://youtu.be/C9mY0_yz2io","display_url":"youtu.be/C9mY0_yz2io"}],"annotations":[{"start":38,"end":40,"probability":0.469,"type":"Organization","normalized_text":"EMA"},{"start":95,"end":101,"probability":0.6031,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":568,"reply_count":34,"like_count":762,"quote_count":268},"created_at":"2021-04-20T14:14:14.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) recommends adding ‚Äòvery rare cases of unusual blood clots with low blood platelets‚Äô to the list of side effects for Janssen #vaccine. \n\nOverall benefit-risk remains positive.  \nüëâhttps://t.co/hNusE5blWm https://t.co/5kX1ECgogz","id":"1384510725268385794","conversation_id":"1384510725268385794","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":155,"end":163,"tag":"vaccine"}],"urls":[{"start":209,"end":232,"url":"https://t.co/hNusE5blWm","expanded_url":"https://bit.ly/3arvkCL","display_url":"bit.ly/3arvkCL"},{"start":233,"end":256,"url":"https://t.co/5kX1ECgogz","expanded_url":"https://twitter.com/EMA_News/status/1384510725268385794/photo/1","display_url":"pic.twitter.com/5kX1ECgogz"}],"annotations":[{"start":147,"end":153,"probability":0.8755,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1384510389749174274"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":130,"reply_count":4,"like_count":170,"quote_count":28},"created_at":"2021-04-20T13:15:44.000Z","author_id":"116716199","text":"‚ÄºÔ∏è A press briefing on EMA‚Äôs safety committee (PRAC) review of #COVID19Vaccine Janssen and blood clots is planned at 5:00 PM CET today\n\nFollow live on YouTube: https://t.co/H4xlcn1Cok","id":"1384496001453547521","conversation_id":"1384496001453547521","entities":{"mentions":{},"hashtags":[{"start":63,"end":78,"tag":"COVID19Vaccine"}],"urls":[{"start":160,"end":183,"url":"https://t.co/H4xlcn1Cok","expanded_url":"https://youtu.be/C9mY0_yz2io","display_url":"youtu.be/C9mY0_yz2io"}],"annotations":[{"start":23,"end":25,"probability":0.5247,"type":"Organization","normalized_text":"EMA"},{"start":79,"end":85,"probability":0.5575,"type":"Person","normalized_text":"Janssen"},{"start":151,"end":157,"probability":0.5777,"type":"Organization","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":9,"like_count":33,"quote_count":1},"created_at":"2021-04-19T08:21:40.000Z","author_id":"116716199","text":"What's on the agenda of the April meeting of EMA's human medicines committee (#CHMP): https://t.co/S6nTsNDF5B","id":"1384059612991692800","conversation_id":"1384059612991692800","entities":{"mentions":{},"hashtags":[{"start":78,"end":83,"tag":"CHMP"}],"urls":[{"start":86,"end":109,"url":"https://t.co/S6nTsNDF5B","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-19-22-april-2021-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":9,"like_count":82,"quote_count":7},"created_at":"2021-04-16T15:32:05.000Z","author_id":"116716199","text":"EMA and Heads of Medicines Agencies (HMA) are organising a joint #workshop on artificial intelligence (#AI) in #medicines regulation. Join to hear views from stakeholders and experts about ongoing actions and potential gaps. \n\nüëâFollow live broadcast: https://t.co/W0rzENbZQu https://t.co/EtHHIGce6Z","id":"1383080764326227977","conversation_id":"1383080764326227977","entities":{"mentions":{},"hashtags":[{"start":65,"end":74,"tag":"workshop"},{"start":103,"end":106,"tag":"AI"},{"start":111,"end":121,"tag":"medicines"}],"urls":[{"start":251,"end":274,"url":"https://t.co/W0rzENbZQu","expanded_url":"https://www.ema.europa.eu/en/events/joint-hmaema-workshop-artificial-intelligence-medicines-regulation","display_url":"ema.europa.eu/en/events/join‚Ä¶"},{"start":275,"end":298,"url":"https://t.co/EtHHIGce6Z","expanded_url":"https://twitter.com/EMA_News/status/1383080764326227977/photo/1","display_url":"pic.twitter.com/EtHHIGce6Z"}],"annotations":[{"start":8,"end":34,"probability":0.5148,"type":"Organization","normalized_text":"Heads of Medicines Agencies"}]},"attachments":{"media_keys":["3_1383080560298446849"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":80,"reply_count":37,"like_count":132,"quote_count":15},"created_at":"2021-04-15T14:39:49.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed. https://t.co/gjOttj6ce3","id":"1382705224327036931","conversation_id":"1382705224327036931","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":116,"end":139,"url":"https://t.co/gjOttj6ce3","expanded_url":"https://twitter.com/EMA_News/status/1382705224327036931/photo/1","display_url":"pic.twitter.com/gjOttj6ce3"}],"annotations":{}},"attachments":{"media_keys":["3_1382705109667307534"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":143,"reply_count":24,"like_count":229,"quote_count":28},"created_at":"2021-04-14T15:07:56.000Z","author_id":"116716199","text":"Update on AstraZeneca #COVID19vaccine: EMA to provide further context on risk of very rare blood clots with low blood platelets that occurred after vaccination. Read more: https://t.co/GPc4veMHlg https://t.co/1FpEQxbrE9","id":"1382349911568580609","conversation_id":"1382349911568580609","entities":{"mentions":{},"hashtags":[{"start":22,"end":37,"tag":"COVID19vaccine"}],"urls":[{"start":172,"end":195,"url":"https://t.co/GPc4veMHlg","expanded_url":"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-provide-further-context-risk-very-rare-blood-clots-low-blood","display_url":"ema.europa.eu/en/news/astraz‚Ä¶"},{"start":196,"end":219,"url":"https://t.co/1FpEQxbrE9","expanded_url":"https://twitter.com/EMA_News/status/1382349911568580609/photo/1","display_url":"pic.twitter.com/1FpEQxbrE9"}],"annotations":{}},"attachments":{"media_keys":["3_1382349843172065282"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":140,"reply_count":18,"like_count":229,"quote_count":24},"created_at":"2021-04-14T13:57:03.000Z","author_id":"116716199","text":"Update on #COVID19vaccine Janssen: assessment of very rare cases of unusual blood clots with low platelets continues. EMA is expediting this evaluation and currently expects to issue a recommendation next week. Read more: https://t.co/uzwQSf2cXt https://t.co/Ki27oIdcIQ","id":"1382332071750860803","conversation_id":"1382332071750860803","entities":{"mentions":{},"hashtags":[{"start":10,"end":25,"tag":"COVID19vaccine"}],"urls":[{"start":222,"end":245,"url":"https://t.co/uzwQSf2cXt","expanded_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-janssen-assessment-very-rare-cases-unusual-blood-clots-low-platelets-continues","display_url":"ema.europa.eu/en/news/covid-‚Ä¶"},{"start":246,"end":269,"url":"https://t.co/Ki27oIdcIQ","expanded_url":"https://twitter.com/EMA_News/status/1382332071750860803/photo/1","display_url":"pic.twitter.com/Ki27oIdcIQ"}],"annotations":[{"start":26,"end":32,"probability":0.6237,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1382331834533609474"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":23,"like_count":68,"quote_count":5},"created_at":"2021-04-09T11:47:22.000Z","author_id":"116716199","text":"During its April meeting, EMA‚Äôs safety committee, the #PRAC, carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines, including #COVID19vaccines. Read more: \nüëâhttps://t.co/BSurWDTBs4 https://t.co/zFau6OmBuL","id":"1380487497013166084","conversation_id":"1380487497013166084","entities":{"mentions":{},"hashtags":[{"start":54,"end":59,"tag":"PRAC"},{"start":192,"end":208,"tag":"COVID19vaccines"}],"urls":[{"start":223,"end":246,"url":"https://t.co/BSurWDTBs4","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-6-9-april-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/zFau6OmBuL","expanded_url":"https://twitter.com/EMA_News/status/1380487497013166084/photo/1","display_url":"pic.twitter.com/zFau6OmBuL"}],"annotations":{}},"attachments":{"media_keys":["3_1380487433305874433"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":93,"reply_count":37,"like_count":152,"quote_count":15},"created_at":"2021-04-08T13:30:00.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/7U100MMqtJ","id":"1380150940552941569","conversation_id":"1380150940552941569","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/7U100MMqtJ","expanded_url":"https://twitter.com/EMA_News/status/1380150940552941569/photo/1","display_url":"pic.twitter.com/7U100MMqtJ"}],"annotations":{}},"attachments":{"media_keys":["3_1380148074241216519"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":85,"reply_count":63,"like_count":127,"quote_count":17},"created_at":"2021-04-07T15:23:36.000Z","author_id":"116716199","text":"Did you miss our press briefing on EMA‚Äôs safety committee (#PRAC) conclusion on the review of #COVID19Vaccine AstraZeneca and cases of blood clots? You can watch it on EMA‚Äôs YouTube channel: https://t.co/BpYBxkk9E6","id":"1379817138932883458","conversation_id":"1379817138932883458","entities":{"mentions":{},"hashtags":[{"start":59,"end":64,"tag":"PRAC"},{"start":94,"end":109,"tag":"COVID19Vaccine"}],"urls":[{"start":191,"end":214,"url":"https://t.co/BpYBxkk9E6","expanded_url":"https://www.youtube.com/watch?v=R44xKGOZ0kQ","display_url":"youtube.com/watch?v=R44xKG‚Ä¶"}],"annotations":[{"start":35,"end":37,"probability":0.3625,"type":"Organization","normalized_text":"EMA"},{"start":174,"end":180,"probability":0.5985,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":63,"reply_count":22,"like_count":81,"quote_count":8},"created_at":"2021-04-07T14:15:49.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: ‚ÄúIt is of great importance that #healthcareprofessionals and the people coming for vaccination are aware of these risks and look out for possible signs or symptoms that usually occur in the first two weeks following vaccination.‚Äù","id":"1379800082321657860","conversation_id":"1379800082321657860","entities":{"mentions":{},"hashtags":[{"start":59,"end":83,"tag":"healthcareprofessionals"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9267,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":14,"like_count":51,"quote_count":1},"created_at":"2021-04-07T14:15:28.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: ‚ÄúFurther research and analysis of this important issue will take place. The #PRAC will continue to assess all evidence that becomes available on this issue while the vaccination campaigns continue.‚Äù","id":"1379799991573708802","conversation_id":"1379799991573708802","entities":{"mentions":{},"hashtags":[{"start":103,"end":108,"tag":"PRAC"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9543,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":121,"reply_count":28,"like_count":153,"quote_count":51},"created_at":"2021-04-07T14:15:08.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: ‚ÄúAlthough most of the cases occurred in people under 60 years and in women, due to different ways the vaccine in being use in different countries, the #PRAC did not conclude that age and gender were clear risk factors for these very rare side effects.‚Äù","id":"1379799908371341312","conversation_id":"1379799908371341312","entities":{"mentions":{},"hashtags":[{"start":178,"end":183,"tag":"PRAC"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.8553,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":70,"reply_count":8,"like_count":98,"quote_count":13},"created_at":"2021-04-07T14:14:48.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: ‚ÄúNo specific risk factors could be identified, based on the current data. The #PRAC is not recommending any specific measures to reduce the risk.‚Äù","id":"1379799824267087874","conversation_id":"1379799824267087874","entities":{"mentions":{},"hashtags":[{"start":105,"end":110,"tag":"PRAC"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9381,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":4,"like_count":76,"quote_count":13},"created_at":"2021-04-07T14:13:03.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"The #PRAC carried out a detailed review of 62 cases of cerebral venous sinus thrombosis and 24 cases of splanchnic vein thrombosis in the EU drug safety database (EudraVigilance) as of 22 March 2021, 18 of which were fatal.\"","id":"1379799386687950851","conversation_id":"1379799386687950851","entities":{"mentions":{},"hashtags":[{"start":32,"end":37,"tag":"PRAC"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.7827,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":5,"like_count":40,"quote_count":1},"created_at":"2021-04-07T14:12:23.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \" The #PRAC has conducted a very thorough review of the reports of rare and unusual blood clotting events in combination with low platelets, with the help of an ad hoc expert group that looked at the data in great detail.‚Äù","id":"1379799216315379714","conversation_id":"1379799216315379714","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"PRAC"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9486,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":78,"reply_count":9,"like_count":121,"quote_count":18},"created_at":"2021-04-07T14:11:32.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄùThis case shows that our #pharmacovigilance system works: these very rare and unusual events were picked up, identified, analysed and we have made a clear science-based recommendation to allow the safe and effective use of the vaccine.‚Äù","id":"1379799003181821958","conversation_id":"1379799003181821958","entities":{"mentions":{},"hashtags":[{"start":60,"end":78,"tag":"pharmacovigilance"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9889,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":53,"reply_count":12,"like_count":126,"quote_count":2},"created_at":"2021-04-07T14:10:31.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúEMA will continue to monitor all the scientific evidence available on both effectiveness and safety of all the authorised COVID-19 vaccines and will issue further recommendations, if necessary, on the grounds of robust evidence.‚Äù","id":"1379798747161489412","conversation_id":"1379798747161489412","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9915,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":60,"reply_count":10,"like_count":78,"quote_count":4},"created_at":"2021-04-07T14:10:09.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúIt is important that both vaccinated people and #healthcareprofessionals are aware of the signs and symptoms of these unusual blood clotting disorders and can spot them quickly to minimise the risk.‚Äù","id":"1379798657143349248","conversation_id":"1379798657143349248","entities":{"mentions":{},"hashtags":[{"start":83,"end":107,"tag":"healthcareprofessionals"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9796,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":4,"like_count":32,"quote_count":0},"created_at":"2021-04-07T14:09:50.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: ‚ÄúEMA is working with the national competent authorities of the EU Member States and the company to make sure that these risks are proactively communicated to #healthcareprofessionals.‚Äù","id":"1379798575689965570","conversation_id":"1379798575689965570","entities":{"mentions":{},"hashtags":[{"start":192,"end":216,"tag":"healthcareprofessionals"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9918,"type":"Person","normalized_text":"Emer Cooke"},{"start":97,"end":112,"probability":0.8029,"type":"Organization","normalized_text":"EU Member States"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":232,"reply_count":20,"like_count":252,"quote_count":49},"created_at":"2021-04-07T14:08:48.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: \"The #PRAC, after an in-depth analysis, has concluded that the reported cases of unusual blood clots following vaccination with AstraZeneca #COVID19vaccine should be listed as possible side effects of the vaccine.‚Äù","id":"1379798313868873730","conversation_id":"1379798313868873730","entities":{"mentions":{},"hashtags":[{"start":39,"end":44,"tag":"PRAC"},{"start":174,"end":189,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9904,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":448,"reply_count":50,"like_count":675,"quote_count":99},"created_at":"2021-04-07T14:07:40.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: \"EMA‚Äôs expert committee on the safety of medicines (#PRAC) has confirmed that the benefits of the AstraZeneca vaccine in preventing #COVID19 overall outweigh the risks of side effects.‚Äù","id":"1379798032103915523","conversation_id":"1379798032103915523","entities":{"mentions":{},"hashtags":[{"start":86,"end":91,"tag":"PRAC"},{"start":166,"end":174,"tag":"COVID19"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9909,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":68,"reply_count":6,"like_count":80,"quote_count":14},"created_at":"2021-04-07T14:05:21.000Z","author_id":"116716199","text":"We are starting the press briefing on EMA‚Äôs safety committee (#PRAC) conclusion on review of #COVID19vaccine AstraZeneca and cases of blood clots: \nhttps://t.co/BpYBxkk9E6","id":"1379797447883554819","conversation_id":"1379797447883554819","entities":{"mentions":{},"hashtags":[{"start":62,"end":67,"tag":"PRAC"},{"start":93,"end":108,"tag":"COVID19vaccine"}],"urls":[{"start":148,"end":171,"url":"https://t.co/BpYBxkk9E6","expanded_url":"https://www.youtube.com/watch?v=R44xKGOZ0kQ","display_url":"youtube.com/watch?v=R44xKG‚Ä¶"}],"annotations":[{"start":38,"end":40,"probability":0.5486,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":819,"reply_count":67,"like_count":996,"quote_count":328},"created_at":"2021-04-07T13:53:48.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) has concluded its review of very rare cases of unusual blood clots with AstraZeneca #COVID19 vaccine. \nüëâhttps://t.co/WGsfRP8PTo https://t.co/aeyzK3bfxd","id":"1379794539456688137","conversation_id":"1379794539456688137","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":115,"end":123,"tag":"COVID19"}],"urls":[{"start":135,"end":158,"url":"https://t.co/WGsfRP8PTo","expanded_url":"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood","display_url":"ema.europa.eu/en/news/astraz‚Ä¶","status":200,"title":"AstraZeneca‚Äôs COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets - European Medicines Agency","description":"AstraZeneca‚Äôs COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low platelets","unwound_url":"https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood"},{"start":159,"end":182,"url":"https://t.co/aeyzK3bfxd","expanded_url":"https://twitter.com/EMA_News/status/1379794539456688137/photo/1","display_url":"pic.twitter.com/aeyzK3bfxd"}],"annotations":{}},"attachments":{"media_keys":["3_1379794469910888448"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":515,"reply_count":32,"like_count":769,"quote_count":131},"created_at":"2021-04-07T08:27:57.000Z","author_id":"116716199","text":"‚ÄºÔ∏è A press briefing on EMA‚Äôs safety committee (PRAC) conclusion on the review of #COVID19vaccine AstraZeneca and blood clots is planned at 4:00PM CET today. \n\nFollow live: https://t.co/BpYBxkk9E6","id":"1379712539722981376","conversation_id":"1379712539722981376","entities":{"mentions":{},"hashtags":[{"start":81,"end":96,"tag":"COVID19vaccine"}],"urls":[{"start":172,"end":195,"url":"https://t.co/BpYBxkk9E6","expanded_url":"https://www.youtube.com/watch?v=R44xKGOZ0kQ","display_url":"youtube.com/watch?v=R44xKG‚Ä¶","status":200,"unwound_url":"https://www.youtube.com/watch?v=R44xKGOZ0kQ"}],"annotations":[{"start":23,"end":25,"probability":0.6235,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":104,"reply_count":50,"like_count":196,"quote_count":15},"created_at":"2021-04-01T13:00:02.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/tIXQvFcyuI","id":"1377606681484480515","conversation_id":"1377606681484480515","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/tIXQvFcyuI","expanded_url":"https://twitter.com/EMA_News/status/1377606681484480515/photo/1","display_url":"pic.twitter.com/tIXQvFcyuI"}],"annotations":{}},"attachments":{"media_keys":["3_1377298401629462534"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":75,"reply_count":29,"like_count":128,"quote_count":16},"created_at":"2021-03-31T14:29:52.000Z","author_id":"116716199","text":"EMA's Executive Director Emer Cooke, will give an update on the investigation of AstraZeneca #COVID19vaccine and thromboembolic events during the @EUCommission press briefing today at 16:30 CET.\n\nFollow the live broadcast: https://t.co/Abm1u11i8F","id":"1377266903085891596","conversation_id":"1377266903085891596","entities":{"mentions":[{"start":146,"end":159,"username":"eucommission","id":"31389177"}],"hashtags":[{"start":93,"end":108,"tag":"COVID19vaccine"}],"urls":[{"start":223,"end":246,"url":"https://t.co/Abm1u11i8F","expanded_url":"https://audiovisual.ec.europa.eu/en/ebs/live/2?lg=INT","display_url":"audiovisual.ec.europa.eu/en/ebs/live/2?‚Ä¶","status":200,"title":"EC Audiovisual Service","description":"Live from EbS","unwound_url":"https://audiovisual.ec.europa.eu/en/ebs/live/2?lg=INT"}],"annotations":[{"start":0,"end":2,"probability":0.3647,"type":"Organization","normalized_text":"EMA"},{"start":25,"end":34,"probability":0.8364,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":135,"reply_count":12,"like_count":212,"quote_count":24},"created_at":"2021-03-31T14:11:26.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) is continuing its evaluation of very rare cases of unusual blood clots in people vaccinated with the AstraZeneca#COVID19 vaccine \nüëâ https://t.co/7fEBLZkMC5 \n\n#COVID19Vaccines #medicine","id":"1377262264407953409","conversation_id":"1377262264407953409","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":189,"end":205,"tag":"COVID19Vaccines"},{"start":206,"end":215,"tag":"medicine"}],"urls":[{"start":163,"end":186,"url":"https://t.co/7fEBLZkMC5","expanded_url":"https://bit.ly/2PHuJFM","display_url":"bit.ly/2PHuJFM"}],"annotations":[{"start":0,"end":2,"probability":0.381,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":16,"like_count":33,"quote_count":2},"created_at":"2021-03-26T16:03:43.000Z","author_id":"116716199","text":"Did you miss #EMAPublicMeeting3 on #COVID19vaccines? You can watch it on EMA's YouTube channel: https://t.co/NZop0XLh9c    \n\nShare your feedback via https://t.co/iNfuYGnDYz ‚û°Ô∏è https://t.co/KaTbyaBfSm #T488 https://t.co/Djs0GLwhfn","id":"1375478582017941504","conversation_id":"1375478582017941504","entities":{"mentions":{},"hashtags":[{"start":13,"end":31,"tag":"EMAPublicMeeting3"},{"start":35,"end":51,"tag":"COVID19vaccines"},{"start":200,"end":205,"tag":"T488"}],"urls":[{"start":96,"end":119,"url":"https://t.co/NZop0XLh9c","expanded_url":"https://youtu.be/c5YZEBwlswg","display_url":"youtu.be/c5YZEBwlswg"},{"start":149,"end":172,"url":"https://t.co/iNfuYGnDYz","expanded_url":"http://Slido.com","display_url":"Slido.com"},{"start":176,"end":199,"url":"https://t.co/KaTbyaBfSm","expanded_url":"https://bit.ly/3rlqBIF","display_url":"bit.ly/3rlqBIF"},{"start":206,"end":229,"url":"https://t.co/Djs0GLwhfn","expanded_url":"https://twitter.com/EMA_News/status/1375478582017941504/photo/1","display_url":"pic.twitter.com/Djs0GLwhfn"}],"annotations":[{"start":79,"end":85,"probability":0.6084,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":["3_1375478051501408259"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":135,"reply_count":26,"like_count":313,"quote_count":37},"created_at":"2021-03-26T14:32:59.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) has adopted several important recommendations that will increase manufacturing capacity and supply of #COVID19 vaccines from AstraZeneca, BioNTech/Pfizer and Moderna in the EU. Read more: \nüëâhttps://t.co/P4vZn0szs2 https://t.co/6BUN7XnygQ","id":"1375455749191696394","conversation_id":"1375455749191696394","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":142,"end":150,"tag":"COVID19"}],"urls":[{"start":230,"end":253,"url":"https://t.co/P4vZn0szs2","expanded_url":"https://www.ema.europa.eu/en/news/increase-vaccine-manufacturing-capacity-supply-covid-19-vaccines-astrazeneca-biontechpfizer-moderna","display_url":"ema.europa.eu/en/news/increa‚Ä¶","status":200,"title":"Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer Moderna - European Medicines Agency","description":"Increase in vaccine manufacturing capacity and supply for COVID-19 vaccines from AstraZeneca, BioNTech/Pfizer Moderna","unwound_url":"https://www.ema.europa.eu/en/news/increase-vaccine-manufacturing-capacity-supply-covid-19-vaccines-astrazeneca-biontechpfizer-moderna"},{"start":254,"end":277,"url":"https://t.co/6BUN7XnygQ","expanded_url":"https://twitter.com/EMA_News/status/1375455749191696394/photo/1","display_url":"pic.twitter.com/6BUN7XnygQ"}],"annotations":[{"start":0,"end":2,"probability":0.5312,"type":"Organization","normalized_text":"EMA"},{"start":165,"end":175,"probability":0.5706,"type":"Organization","normalized_text":"AstraZeneca"},{"start":178,"end":185,"probability":0.5169,"type":"Organization","normalized_text":"BioNTech"},{"start":187,"end":192,"probability":0.3873,"type":"Organization","normalized_text":"Pfizer"}]},"attachments":{"media_keys":["3_1375455639141498881"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":6,"like_count":73,"quote_count":3},"created_at":"2021-03-26T14:28:51.000Z","author_id":"116716199","text":"The fight against #COVID19 is a global effort involving #medicines developers, #regulators, #policymakers, #healthcare_professionals and #citizens ‚Äì we all need to work together to share important validated scientific information to combat the pandemic.","id":"1375454705875357696","conversation_id":"1375454705875357696","entities":{"mentions":{},"hashtags":[{"start":18,"end":26,"tag":"COVID19"},{"start":56,"end":66,"tag":"medicines"},{"start":79,"end":90,"tag":"regulators"},{"start":92,"end":105,"tag":"policymakers"},{"start":107,"end":132,"tag":"healthcare_professionals"},{"start":137,"end":146,"tag":"citizens"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":52,"reply_count":5,"like_count":54,"quote_count":0},"created_at":"2021-03-26T13:29:59.000Z","author_id":"116716199","text":"Read EMA‚Äôs:\n‚û°Ô∏è Key Facts on #COVID19vaccines https://t.co/eHogoaQJec \n‚û°Ô∏è Info on how #COVID19vaccines are being developed, approved &amp; monitored in the EU https://t.co/IDvxzWlRCa \n‚û°Ô∏è Info on studies needed to approve #COVID19vaccines https://t.co/XkXoiFv7Lt\n\n#EMAPublicMeeting3 https://t.co/ELjOwV1csA","id":"1375439891425853442","conversation_id":"1375439891425853442","entities":{"mentions":{},"hashtags":[{"start":28,"end":44,"tag":"COVID19vaccines"},{"start":85,"end":101,"tag":"COVID19vaccines"},{"start":220,"end":236,"tag":"COVID19vaccines"},{"start":262,"end":280,"tag":"EMAPublicMeeting3"}],"urls":[{"start":45,"end":68,"url":"https://t.co/eHogoaQJec","expanded_url":"https://bit.ly/3vN6INQ","display_url":"bit.ly/3vN6INQ"},{"start":158,"end":181,"url":"https://t.co/IDvxzWlRCa","expanded_url":"https://bit.ly/394xOGv","display_url":"bit.ly/394xOGv"},{"start":237,"end":260,"url":"https://t.co/XkXoiFv7Lt","expanded_url":"https://bit.ly/3cXAyXq","display_url":"bit.ly/3cXAyXq"},{"start":281,"end":304,"url":"https://t.co/ELjOwV1csA","expanded_url":"https://twitter.com/EMA_News/status/1375439891425853442/photo/1","display_url":"pic.twitter.com/ELjOwV1csA"}],"annotations":{}},"attachments":{"media_keys":["3_1375439529704837121"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":3,"like_count":75,"quote_count":1},"created_at":"2021-03-26T13:27:57.000Z","author_id":"116716199","text":"EMA is publishing monthly safety updates and clinical data for #COVID19 medicines in line with its exceptional transparency measures for treatments and #COVID19vaccines  #EMAPublicMeeting3","id":"1375439381666881536","conversation_id":"1375439381666881536","entities":{"mentions":{},"hashtags":[{"start":63,"end":71,"tag":"COVID19"},{"start":152,"end":168,"tag":"COVID19vaccines"},{"start":170,"end":188,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.6856,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":10,"like_count":34,"quote_count":1},"created_at":"2021-03-26T13:24:47.000Z","author_id":"116716199","text":"Feedback from the public is important to EMA and will help determine what more we can do to enhance public trust in the #COVID19vaccines and their vital role in overcoming this disease #EMAPublicMeeting3","id":"1375438582454816769","conversation_id":"1375438582454816769","entities":{"mentions":{},"hashtags":[{"start":120,"end":136,"tag":"COVID19vaccines"},{"start":185,"end":203,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":4,"like_count":35,"quote_count":1},"created_at":"2021-03-26T13:22:18.000Z","author_id":"116716199","text":"In the current dynamic situation, vaccination strategies need to be able to adapt and take the changing context into consideration #EMAPublicMeeting3","id":"1375437960397647875","conversation_id":"1375437960397647875","entities":{"mentions":{},"hashtags":[{"start":131,"end":149,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":67,"reply_count":14,"like_count":161,"quote_count":3},"created_at":"2021-03-26T13:12:04.000Z","author_id":"116716199","text":"The most effective and efficient approach to reduce hospitalisations and deaths due to #COVID19 is to prioritise vaccination of groups at highest risk of severe disease #EMAPublicMeeting3","id":"1375435384176410625","conversation_id":"1375435384176410625","entities":{"mentions":{},"hashtags":[{"start":87,"end":95,"tag":"COVID19"},{"start":169,"end":187,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":3,"like_count":35,"quote_count":2},"created_at":"2021-03-26T13:06:27.000Z","author_id":"116716199","text":"The choice of an optimal vaccination strategy depends on its goals that need to be clearly defined #EMAPublicMeeting3","id":"1375433971136352265","conversation_id":"1375433971136352265","entities":{"mentions":{},"hashtags":[{"start":99,"end":117,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":5,"like_count":56,"quote_count":2},"created_at":"2021-03-26T12:53:52.000Z","author_id":"116716199","text":"As millions of EU citizens are now receiving #COVID19vaccines over a short period of time, EMA is intensively monitoring safety to rapidly detect, assess and act on any possible issues #EMAPublicMeeting3","id":"1375430804982095872","conversation_id":"1375430804982095872","entities":{"mentions":{},"hashtags":[{"start":45,"end":61,"tag":"COVID19vaccines"},{"start":185,"end":203,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":[{"start":15,"end":16,"probability":0.5408,"type":"Organization","normalized_text":"EU"},{"start":91,"end":93,"probability":0.4549,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":2,"like_count":40,"quote_count":4},"created_at":"2021-03-26T12:43:36.000Z","author_id":"116716199","text":"The help of #patients, #healthcare_professionals and the general public in reporting #side_effects is fundamental #medicinesafety - https://t.co/skvtx8bM5N    #EMAPublicMeeting3 https://t.co/sZVAIvNYDQ","id":"1375428220762357760","conversation_id":"1375428220762357760","entities":{"mentions":{},"hashtags":[{"start":12,"end":21,"tag":"patients"},{"start":23,"end":48,"tag":"healthcare_professionals"},{"start":85,"end":98,"tag":"side_effects"},{"start":114,"end":129,"tag":"medicinesafety"},{"start":159,"end":177,"tag":"EMAPublicMeeting3"}],"urls":[{"start":132,"end":155,"url":"https://t.co/skvtx8bM5N","expanded_url":"http://www.adrreports.eu","display_url":"adrreports.eu"},{"start":178,"end":201,"url":"https://t.co/sZVAIvNYDQ","expanded_url":"https://twitter.com/EMA_News/status/1375428220762357760/photo/1","display_url":"pic.twitter.com/sZVAIvNYDQ"}],"annotations":{}},"attachments":{"media_keys":["3_1375427814938279942"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":1,"like_count":100,"quote_count":6},"created_at":"2021-03-26T12:41:07.000Z","author_id":"116716199","text":"#COVID19vaccines have shown clear evidence of efficacy in reducing #COVID19 disease with a good safety profile demonstrated in large clinical trials #EMAPublicMeeting3","id":"1375427593093185541","conversation_id":"1375427593093185541","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"},{"start":67,"end":75,"tag":"COVID19"},{"start":149,"end":167,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":15,"like_count":155,"quote_count":14},"created_at":"2021-03-26T12:26:54.000Z","author_id":"116716199","text":"Variants of the virus are emerging, and regulators are working to ensure necessary updates can be made rapidly to ensure #COVID19vaccines remain effective #EMAPublicMeeting3","id":"1375424016303931394","conversation_id":"1375424016303931394","entities":{"mentions":{},"hashtags":[{"start":121,"end":137,"tag":"COVID19vaccines"},{"start":155,"end":173,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":68,"reply_count":3,"like_count":176,"quote_count":7},"created_at":"2021-03-26T12:16:25.000Z","author_id":"116716199","text":"All #COVID19vaccines approved in the EU have shown a positive benefit-risk balance in prevention of #COVID19 disease #EMAPublicMeeting3","id":"1375421378581688320","conversation_id":"1375421378581688320","entities":{"mentions":{},"hashtags":[{"start":4,"end":20,"tag":"COVID19vaccines"},{"start":100,"end":108,"tag":"COVID19"},{"start":117,"end":135,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":[{"start":37,"end":38,"probability":0.3773,"type":"Place","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":543,"reply_count":29,"like_count":1124,"quote_count":143},"created_at":"2021-03-26T12:15:25.000Z","author_id":"116716199","text":"Preliminary real-world data suggest that vaccines not only reduce #COVID19 disease and mortality but also viral transmission; more studies are needed to confirm this effect #EMAPublicMeeting3","id":"1375421127422525446","conversation_id":"1375421127422525446","entities":{"mentions":{},"hashtags":[{"start":66,"end":74,"tag":"COVID19"},{"start":173,"end":191,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":50,"reply_count":7,"like_count":125,"quote_count":9},"created_at":"2021-03-26T12:11:20.000Z","author_id":"116716199","text":"All vaccines are important in the fight against #COVID19 https://t.co/Yt8uRLFm4r \n\n#EMAPublicMeeting3 https://t.co/ZL0cLEzEQY","id":"1375420097666428930","conversation_id":"1375420097666428930","entities":{"mentions":{},"hashtags":[{"start":48,"end":56,"tag":"COVID19"},{"start":83,"end":101,"tag":"EMAPublicMeeting3"}],"urls":[{"start":57,"end":80,"url":"https://t.co/Yt8uRLFm4r","expanded_url":"https://bit.ly/3vRAcdM","display_url":"bit.ly/3vRAcdM"},{"start":102,"end":125,"url":"https://t.co/ZL0cLEzEQY","expanded_url":"https://twitter.com/EMA_News/status/1375420097666428930/photo/1","display_url":"pic.twitter.com/ZL0cLEzEQY"}],"annotations":{}},"attachments":{"media_keys":["3_1375418376949006336"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":5,"like_count":83,"quote_count":2},"created_at":"2021-03-26T12:03:20.000Z","author_id":"116716199","text":"Four #COVID19vaccines have been approved in the EU so far and data from three more vaccines are currently being assessed using EMA‚Äôs rolling review. \n\nFollow updates on Twitter @EMA_News #EMAPublicMeeting3","id":"1375418087684595718","conversation_id":"1375418087684595718","entities":{"mentions":[{"start":177,"end":186,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":5,"end":21,"tag":"COVID19vaccines"},{"start":187,"end":205,"tag":"EMAPublicMeeting3"}],"urls":{},"annotations":[{"start":48,"end":49,"probability":0.3929,"type":"Place","normalized_text":"EU"},{"start":169,"end":175,"probability":0.7058,"type":"Product","normalized_text":"Twitter"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":3,"like_count":46,"quote_count":5},"created_at":"2021-03-26T12:01:50.000Z","author_id":"116716199","text":"A third public meeting is being held to update the public on the assessment, approval and continued safety monitoring of #COVID19vaccines and their expected impact in the community #EMAPublicMeeting3\n\nüëâhttps://t.co/S5O4eyvtgt","id":"1375417707269664775","conversation_id":"1375417707269664775","entities":{"mentions":{},"hashtags":[{"start":121,"end":137,"tag":"COVID19vaccines"},{"start":181,"end":199,"tag":"EMAPublicMeeting3"}],"urls":[{"start":202,"end":225,"url":"https://t.co/S5O4eyvtgt","expanded_url":"https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-safety-monitoring-impact-covid-19-vaccines-eu","display_url":"ema.europa.eu/en/events/publ‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":2,"like_count":57,"quote_count":5},"created_at":"2021-03-26T11:22:55.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 5 #medicines for approval at its March 2021 meeting \nüëâhttps://t.co/3Si89CcFMI https://t.co/YKKLSQORUV","id":"1375407915507548160","conversation_id":"1375407915507548160","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":105,"end":128,"url":"https://t.co/3Si89CcFMI","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-march-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":129,"end":152,"url":"https://t.co/YKKLSQORUV","expanded_url":"https://twitter.com/EMA_News/status/1375407915507548160/photo/1","display_url":"pic.twitter.com/YKKLSQORUV"}],"annotations":[{"start":0,"end":2,"probability":0.4745,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1375407707537207299"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":67,"reply_count":6,"like_count":118,"quote_count":12},"created_at":"2021-03-26T09:04:24.000Z","author_id":"116716199","text":"Remember to follow theüî¥live broadcast of the third EMA public meeting on approval, safety monitoring and impact of #COVID19vaccines in the EU üá™üá∫.\n\nüóìÔ∏è Today, 13h00 CET \n\nFollow and share our live tweets on #EMAPublicMeeting3\n\nüëâhttps://t.co/S5O4eyvtgt https://t.co/aykCU9IMPw","id":"1375373057527844865","conversation_id":"1375373057527844865","entities":{"mentions":{},"hashtags":[{"start":115,"end":131,"tag":"COVID19vaccines"},{"start":205,"end":223,"tag":"EMAPublicMeeting3"}],"urls":[{"start":226,"end":249,"url":"https://t.co/S5O4eyvtgt","expanded_url":"https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-safety-monitoring-impact-covid-19-vaccines-eu","display_url":"ema.europa.eu/en/events/publ‚Ä¶"},{"start":250,"end":273,"url":"https://t.co/aykCU9IMPw","expanded_url":"https://twitter.com/EMA_News/status/1375373057527844865/photo/1","display_url":"pic.twitter.com/aykCU9IMPw"}],"annotations":{}},"attachments":{"media_keys":["3_1375372599962828801"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":107,"reply_count":30,"like_count":201,"quote_count":16},"created_at":"2021-03-25T14:30:00.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/7cWozsCfPM","id":"1375092610180788232","conversation_id":"1375092610180788232","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/7cWozsCfPM","expanded_url":"https://twitter.com/EMA_News/status/1375092610180788232/photo/1","display_url":"pic.twitter.com/7cWozsCfPM"}],"annotations":{}},"attachments":{"media_keys":["3_1375023110953504769"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":130,"reply_count":14,"like_count":186,"quote_count":31},"created_at":"2021-03-25T13:14:06.000Z","author_id":"116716199","text":"EMA is convening an ad hoc expert group on 29 March to provide additional input into the ongoing evaluation of #COVID19vaccine AstraZeneca and blood clot cases. Check out the latest updates on the assessment of the reported cases: \nüëâhttps://t.co/bbINgXToYx","id":"1375073507726528518","conversation_id":"1375073507726528518","entities":{"mentions":{},"hashtags":[{"start":111,"end":126,"tag":"COVID19vaccine"}],"urls":[{"start":233,"end":256,"url":"https://t.co/bbINgXToYx","expanded_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-update-ongoing-evaluation-blood-clot-cases","display_url":"ema.europa.eu/en/news/covid-‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-update-ongoing-evaluation-blood-clot-cases"}],"annotations":[{"start":0,"end":2,"probability":0.5783,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":126,"reply_count":23,"like_count":179,"quote_count":25},"created_at":"2021-03-23T14:52:48.000Z","author_id":"116716199","text":"üóìÔ∏èEMA organises 3rd public meeting on Friday, 26 March 2021, to inform citizens on approval, safety monitoring and impact of #COVID19vaccines in the EU. \nüëâhttps://t.co/S5O4eydRRT https://t.co/v2Iu8Ps0pj","id":"1374373569736548353","conversation_id":"1374373569736548353","entities":{"mentions":{},"hashtags":[{"start":125,"end":141,"tag":"COVID19vaccines"}],"urls":[{"start":155,"end":178,"url":"https://t.co/S5O4eydRRT","expanded_url":"https://www.ema.europa.eu/en/events/public-stakeholder-meeting-approval-safety-monitoring-impact-covid-19-vaccines-eu","display_url":"ema.europa.eu/en/events/publ‚Ä¶"},{"start":179,"end":202,"url":"https://t.co/v2Iu8Ps0pj","expanded_url":"https://twitter.com/EMA_News/status/1374373569736548353/photo/1","display_url":"pic.twitter.com/v2Iu8Ps0pj"}],"annotations":{}},"attachments":{"media_keys":["3_1374373250633887744"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1374260372291616770"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-23T09:00:13.000Z","author_id":"116716199","text":"RT @EP_Environment: This morning in @EP_Environment \n\nüé•https://t.co/bbK4x2A46C\n\nüè•Starting with consideration of @j_kopcinska draft report o‚Ä¶","id":"1374284838212079617","conversation_id":"1374284838212079617","entities":{"mentions":[{"start":3,"end":18,"username":"EP_Environment","id":"951333319"},{"start":36,"end":51,"username":"EP_Environment","id":"951333319"},{"start":112,"end":124,"username":"j_kopcinska","id":"2767282797"}],"hashtags":{},"urls":[{"start":55,"end":78,"url":"https://t.co/bbK4x2A46C","expanded_url":"https://multimedia.europarl.europa.eu/en/committee-on-environment-public-health-and-food-safety_20210323-0900-COMMITTEE-ENVI_vd","display_url":"multimedia.europarl.europa.eu/en/committee-o‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":290,"reply_count":141,"like_count":513,"quote_count":149},"created_at":"2021-03-22T13:10:00.000Z","author_id":"116716199","text":"EMA advises against the use of ivermectin medicines for the prevention and treatment of #COVID19 outside controlled clinical trials. \nüëâhttps://t.co/mQByx8J1Li https://t.co/pZ66LaEkP7","id":"1373985312700043265","conversation_id":"1373985312700043265","entities":{"mentions":{},"hashtags":[{"start":88,"end":96,"tag":"COVID19"}],"urls":[{"start":135,"end":158,"url":"https://t.co/mQByx8J1Li","expanded_url":"https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials","display_url":"ema.europa.eu/en/news/ema-ad‚Ä¶"},{"start":159,"end":182,"url":"https://t.co/pZ66LaEkP7","expanded_url":"https://twitter.com/EMA_News/status/1373985312700043265/photo/1","display_url":"pic.twitter.com/pZ66LaEkP7"}],"annotations":[{"start":0,"end":2,"probability":0.3878,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1373985093249826817"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1372515485942710275"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-19T10:10:47.000Z","author_id":"116716199","text":"RT @ESIP_EU: On 12 March we discussed evidence-generation along the life-cycle of #medicines with @AIM_Healthcare, MEDEV and @EMA_News \nFin‚Ä¶","id":"1372853048616357890","conversation_id":"1372853048616357890","entities":{"mentions":[{"start":3,"end":11,"username":"ESIP_EU","id":"2410528153"},{"start":98,"end":113,"username":"AIM_Healthcare","id":"784869524"},{"start":125,"end":134,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":82,"end":92,"tag":"medicines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":163,"reply_count":51,"like_count":309,"quote_count":28},"created_at":"2021-03-19T09:25:54.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/cskA485pRL","id":"1372841752814612482","conversation_id":"1372841752814612482","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/cskA485pRL","expanded_url":"https://twitter.com/EMA_News/status/1372841752814612482/photo/1","display_url":"pic.twitter.com/cskA485pRL"}],"annotations":{}},"attachments":{"media_keys":["3_1372841636296851459"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":91,"reply_count":28,"like_count":168,"quote_count":16},"created_at":"2021-03-18T19:00:01.000Z","author_id":"116716199","text":"Did you miss our press briefing on the conclusion of the review of #COVID19Vaccine AstraZeneca and blood clots? You can watch it on EMA‚Äôs YouTube channel: https://t.co/lPDMFYemzs","id":"1372623843609636865","conversation_id":"1372623843609636865","entities":{"mentions":{},"hashtags":[{"start":67,"end":82,"tag":"COVID19Vaccine"}],"urls":[{"start":155,"end":178,"url":"https://t.co/lPDMFYemzs","expanded_url":"https://youtu.be/qYmP02SIQNI","display_url":"youtu.be/qYmP02SIQNI"}],"annotations":[{"start":138,"end":144,"probability":0.6199,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1624,"reply_count":193,"like_count":2266,"quote_count":457},"created_at":"2021-03-18T16:40:35.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (PRAC) concludes that the benefits of the #COVID19Vaccine AstraZeneca still outweigh its risks despite possible link to rare blood clots associated with low levels of blood platelets.\nüëâRead more: https://t.co/WCdaKqOPxB https://t.co/0NO8kh5a48","id":"1372588755085840388","conversation_id":"1372588755085840388","entities":{"mentions":{},"hashtags":[{"start":65,"end":80,"tag":"COVID19Vaccine"}],"urls":[{"start":219,"end":242,"url":"https://t.co/WCdaKqOPxB","expanded_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots","display_url":"ema.europa.eu/en/news/covid-‚Ä¶"},{"start":243,"end":266,"url":"https://t.co/0NO8kh5a48","expanded_url":"https://twitter.com/EMA_News/status/1372588755085840388/photo/1","display_url":"pic.twitter.com/0NO8kh5a48"}],"annotations":[{"start":0,"end":2,"probability":0.4546,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1372588681555509248"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":248,"reply_count":42,"like_count":385,"quote_count":102},"created_at":"2021-03-18T16:01:16.000Z","author_id":"116716199","text":"‚ÄºÔ∏è We are starting the press briefing on EMA‚Äôs safety committee (PRAC) review on the #COVID19Vaccine AstraZeneca and blood clots.\nüìΩÔ∏è Follow live on YouTube: https://t.co/lPDMFXWLHU https://t.co/XokYfS2vC3","id":"1372578862413049857","conversation_id":"1372578862413049857","entities":{"mentions":{},"hashtags":[{"start":85,"end":100,"tag":"COVID19Vaccine"}],"urls":[{"start":157,"end":180,"url":"https://t.co/lPDMFXWLHU","expanded_url":"https://youtu.be/qYmP02SIQNI","display_url":"youtu.be/qYmP02SIQNI"},{"start":181,"end":204,"url":"https://t.co/XokYfS2vC3","expanded_url":"https://twitter.com/EMA_News/status/1372578862413049857/photo/1","display_url":"pic.twitter.com/XokYfS2vC3"}],"annotations":[{"start":41,"end":43,"probability":0.646,"type":"Organization","normalized_text":"EMA"},{"start":149,"end":155,"probability":0.464,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":["3_1372578805873786886"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":356,"reply_count":34,"like_count":526,"quote_count":128},"created_at":"2021-03-18T15:13:00.000Z","author_id":"116716199","text":"‚ÄºÔ∏è A press briefing on EMA‚Äôs safety committee (PRAC) review on the #COVID19Vaccine AstraZeneca and blood clots is planned at 5:00 PM CET today (time to be confirmed).\n\nFollow live on YouTube: https://t.co/lPDMFXWLHU","id":"1372566715868020738","conversation_id":"1372566715868020738","entities":{"mentions":{},"hashtags":[{"start":67,"end":82,"tag":"COVID19Vaccine"}],"urls":[{"start":192,"end":215,"url":"https://t.co/lPDMFXWLHU","expanded_url":"https://youtu.be/qYmP02SIQNI","display_url":"youtu.be/qYmP02SIQNI"}],"annotations":[{"start":23,"end":25,"probability":0.6338,"type":"Organization","normalized_text":"EMA"},{"start":183,"end":189,"probability":0.4717,"type":"Organization","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":360,"reply_count":50,"like_count":960,"quote_count":84},"created_at":"2021-03-18T12:36:47.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (PRAC) is holding an extraordinary meeting on the investigation on #COVID19vaccine AstraZeneca and thromboembolic events. Once the meeting is over, we will communicate the conclusions on the Agency‚Äôs website","id":"1372527399821271043","conversation_id":"1372527399821271043","entities":{"mentions":{},"hashtags":[{"start":90,"end":105,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.5087,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":273,"reply_count":50,"like_count":471,"quote_count":56},"created_at":"2021-03-16T18:55:51.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) has made further progress on the investigation of #COVID19vaccine AstraZeneca and thromboembolic events. It will conclude and issue any necessary recommendations for further action on Thursday, 18 March. https://t.co/oE5U9eMwCt","id":"1371898021101907971","conversation_id":"1371898021101907971","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":81,"end":96,"tag":"COVID19vaccine"}],"urls":[{"start":235,"end":258,"url":"https://t.co/oE5U9eMwCt","expanded_url":"https://www.ema.europa.eu/en/news/investigation-covid-19-vaccine-astrazeneca-thromboembolic-events-continues","display_url":"ema.europa.eu/en/news/invest‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.4333,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1371810454314618889"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":379,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-16T13:11:09.000Z","author_id":"116716199","text":"RT @EU_Commission: Press conference by @EMA_News Executive Director Emer Cooke on the investigation on COVID-19 vaccine AstraZeneca and thr‚Ä¶","id":"1371811274657521665","conversation_id":"1371811274657521665","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"},{"start":39,"end":48,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":[{"start":68,"end":77,"probability":0.8183,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":289,"reply_count":30,"like_count":442,"quote_count":63},"created_at":"2021-03-16T11:54:56.000Z","author_id":"116716199","text":"EMA‚Äôs Executive Director, Emer Cooke, will update on the investigation on #COVID19vaccine AstraZeneca and thromboembolic events during a @EU_Commission press briefing today from 14:00 to 15:00 CET. \n‚û°Ô∏èFollow the live broadcast: https://t.co/es736JUX9k","id":"1371792095934091270","conversation_id":"1371792095934091270","entities":{"mentions":[{"start":137,"end":151,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":74,"end":89,"tag":"COVID19vaccine"}],"urls":[{"start":228,"end":251,"url":"https://t.co/es736JUX9k","expanded_url":"https://audiovisual.ec.europa.eu/en/ebs/live/2","display_url":"audiovisual.ec.europa.eu/en/ebs/live/2"}],"annotations":[{"start":0,"end":2,"probability":0.3596,"type":"Organization","normalized_text":"EMA"},{"start":26,"end":35,"probability":0.9893,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":421,"reply_count":70,"like_count":657,"quote_count":161},"created_at":"2021-03-15T17:13:55.000Z","author_id":"116716199","text":"EMA‚Äôs safety committee (#PRAC) continues investigation of the #COVID19vaccine Astra Zeneca and thromboembolic events. Check out the latest updates:  \nüëâhttps://t.co/5u3ltzNuYd","id":"1371509979388243969","conversation_id":"1371509979388243969","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":62,"end":77,"tag":"COVID19vaccine"}],"urls":[{"start":151,"end":174,"url":"https://t.co/5u3ltzNuYd","expanded_url":"https://www.ema.europa.eu/en/news/emas-safety-committee-continues-investigation-covid-19-vaccine-astrazeneca-thromboembolic-events","display_url":"ema.europa.eu/en/news/emas-s‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.4562,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1371439872829972481"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-15T13:28:15.000Z","author_id":"116716199","text":"RT @EP_Environment: üî¥ LIVE now: Debate on #COVID19 variants &amp; vaccines' efficiency https://t.co/gMoCriCSRJ","id":"1371453191880114181","conversation_id":"1371453191880114181","entities":{"mentions":[{"start":3,"end":18,"username":"EP_Environment","id":"951333319"}],"hashtags":[{"start":42,"end":50,"tag":"COVID19"}],"urls":[{"start":87,"end":110,"url":"https://t.co/gMoCriCSRJ","expanded_url":"https://twitter.com/i/broadcasts/1gqxvoOjEzkKB","display_url":"twitter.com/i/broadcasts/1‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1371405938712776704"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-15T10:27:10.000Z","author_id":"116716199","text":"RT @europarlAV: üî¥LIVE TODAYüî¥at 13:30 CET, @EP_Environment MEPs will address their questions to @EMA_News @ECDC_EU @WHO experts on the effic‚Ä¶","id":"1371407618598707205","conversation_id":"1371407618598707205","entities":{"mentions":[{"start":3,"end":14,"username":"europarlAV","id":"570018183"},{"start":42,"end":57,"username":"EP_Environment","id":"951333319"},{"start":95,"end":104,"username":"EMA_News","id":"116716199"},{"start":105,"end":113,"username":"ECDC_EU","id":"204752573"},{"start":114,"end":118,"username":"WHO","id":"14499829"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":10,"like_count":34,"quote_count":6},"created_at":"2021-03-12T15:25:34.000Z","author_id":"116716199","text":"Check out the highlights of the March 2021 meeting of EMA's Management Board: \nüëâhttps://t.co/DJ64xw7vAv https://t.co/tL30f0ez2n","id":"1370395551754297347","conversation_id":"1370395551754297347","entities":{"mentions":{},"hashtags":{},"urls":[{"start":80,"end":103,"url":"https://t.co/DJ64xw7vAv","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2021-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":104,"end":127,"url":"https://t.co/tL30f0ez2n","expanded_url":"https://twitter.com/EMA_News/status/1370395551754297347/photo/1","display_url":"pic.twitter.com/tL30f0ez2n"}],"annotations":[{"start":54,"end":75,"probability":0.3435,"type":"Other","normalized_text":"EMA's Management Board"}]},"attachments":{"media_keys":["3_1370395483693273090"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":6,"like_count":49,"quote_count":7},"created_at":"2021-03-12T12:48:42.000Z","author_id":"116716199","text":"Check out highlights from the March meeting of EMA‚Äôs safety committee, the #PRAC, which cover all aspects of safety monitoring of medicines, including #COVID19 treatments and vaccines. Read more:\nüëâhttps://t.co/tyCj1rDNeA https://t.co/xVVNUXXe66","id":"1370356073929060356","conversation_id":"1370356073929060356","entities":{"mentions":{},"hashtags":[{"start":75,"end":80,"tag":"PRAC"},{"start":151,"end":159,"tag":"COVID19"}],"urls":[{"start":197,"end":220,"url":"https://t.co/tyCj1rDNeA","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-march-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":221,"end":244,"url":"https://t.co/xVVNUXXe66","expanded_url":"https://twitter.com/EMA_News/status/1370356073929060356/photo/1","display_url":"pic.twitter.com/xVVNUXXe66"}],"annotations":[{"start":47,"end":49,"probability":0.4362,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1370355978022105089"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":99,"reply_count":5,"like_count":164,"quote_count":10},"created_at":"2021-03-12T09:30:00.000Z","author_id":"116716199","text":"üì¢Save the date! EMA organises 3rd public meeting on 26 March 2021 to inform citizens on approval, safety monitoring and impact of #COVID19vaccines in the EU. Register to join virtual room or watch live on the day. \nüëâhttps://t.co/IFdCpFyTlq https://t.co/aoJd3T3Sr3","id":"1370306069390487552","conversation_id":"1370306069390487552","entities":{"mentions":{},"hashtags":[{"start":130,"end":146,"tag":"COVID19vaccines"}],"urls":[{"start":216,"end":239,"url":"https://t.co/IFdCpFyTlq","expanded_url":"https://bit.ly/38nTe0V","display_url":"bit.ly/38nTe0V"},{"start":240,"end":263,"url":"https://t.co/aoJd3T3Sr3","expanded_url":"https://twitter.com/EMA_News/status/1370306069390487552/photo/1","display_url":"pic.twitter.com/aoJd3T3Sr3"}],"annotations":{}},"attachments":{"media_keys":["3_1370281656200929282"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":139,"reply_count":30,"like_count":237,"quote_count":18},"created_at":"2021-03-11T16:43:42.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/zvDr6kth7Y","id":"1370052823157780483","conversation_id":"1370052823157780483","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/zvDr6kth7Y","expanded_url":"https://twitter.com/EMA_News/status/1370052823157780483/photo/1","display_url":"pic.twitter.com/zvDr6kth7Y"}],"annotations":{}},"attachments":{"media_keys":["3_1370052691888631810"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1370035776587759630"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":97,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-11T16:19:43.000Z","author_id":"116716199","text":"RT @SKyriakidesEU: ‚úÖ @EU_Commission has granted conditional marketing authorisation to the @JNJNews #COVID19 vaccine. \n\nüìçFour vaccines are‚Ä¶","id":"1370046791270465547","conversation_id":"1370046791270465547","entities":{"mentions":[{"start":3,"end":17,"username":"SKyriakidesEU","id":"2476130260"},{"start":21,"end":35,"username":"EU_Commission","id":"157981564"},{"start":91,"end":99,"username":"JNJNews","id":"20457806"}],"hashtags":[{"start":100,"end":108,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1370035894942629894"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":469,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-03-11T16:18:05.000Z","author_id":"116716199","text":"RT @vonderleyen: More safe and effective vaccines are coming to the market. \n\nWe have just authorised the use of Johnson &amp; Johnson's vaccin‚Ä¶","id":"1370046379138162691","conversation_id":"1370046379138162691","entities":{"mentions":[{"start":3,"end":15,"username":"vonderleyen","id":"1146329871418843136"}],"hashtags":{},"urls":{},"annotations":[{"start":113,"end":129,"probability":0.3968,"type":"Person","normalized_text":"Johnson & Johnson"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":2,"like_count":65,"quote_count":3},"created_at":"2021-03-11T16:10:00.000Z","author_id":"116716199","text":"EMA and @GovCanHealth have now published the clinical data reviewed as part of the marketing authorisation of #COVID19vaccine Comirnaty.\nüëâ https://t.co/taKhQzIBL8 https://t.co/44RbnLDwtd","id":"1370044343042535431","conversation_id":"1370044343042535431","entities":{"mentions":[{"start":8,"end":21,"username":"GovCanHealth","id":"36375825"}],"hashtags":[{"start":110,"end":125,"tag":"COVID19vaccine"}],"urls":[{"start":139,"end":162,"url":"https://t.co/taKhQzIBL8","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/44RbnLDwtd","expanded_url":"https://twitter.com/EMA_News/status/1370044343042535431/photo/1","display_url":"pic.twitter.com/44RbnLDwtd"}],"annotations":{}},"attachments":{"media_keys":["3_1370043280923242502"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1160,"reply_count":78,"like_count":2000,"quote_count":466},"created_at":"2021-03-11T13:23:02.000Z","author_id":"116716199","text":"üì¢ EMA has just recommended granting a conditional marketing authorisation for #COVID19vaccine Janssen to prevent #COVID19 in people from 18 years of age. \nüëâ https://t.co/j7jetH1Tbx https://t.co/cKGKujrqYp","id":"1370002324605853701","conversation_id":"1370002324605853701","entities":{"mentions":{},"hashtags":[{"start":78,"end":93,"tag":"COVID19vaccine"},{"start":113,"end":121,"tag":"COVID19"}],"urls":[{"start":157,"end":180,"url":"https://t.co/j7jetH1Tbx","expanded_url":"https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":181,"end":204,"url":"https://t.co/cKGKujrqYp","expanded_url":"https://twitter.com/EMA_News/status/1370002324605853701/photo/1","display_url":"pic.twitter.com/cKGKujrqYp"}],"annotations":[{"start":95,"end":101,"probability":0.7693,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1370000430512627712"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":101,"reply_count":6,"like_count":232,"quote_count":16},"created_at":"2021-03-11T09:13:26.000Z","author_id":"116716199","text":"EMA has started a rolling review of the antibodies bamlanivimab and etesemivab, which are developed by Eli Lilly to be used in combination for the treatment of #COVID19. The review will also look at bamlanivimab used alone. \nüëâhttps://t.co/mt9uacnz4v https://t.co/6BrooVXK5A","id":"1369939509828329474","conversation_id":"1369939509828329474","entities":{"mentions":{},"hashtags":[{"start":160,"end":168,"tag":"COVID19"}],"urls":[{"start":226,"end":249,"url":"https://t.co/mt9uacnz4v","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-eli-lilly-antibodies-bamlanivimab-etesemivab-covid-19","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":250,"end":273,"url":"https://t.co/6BrooVXK5A","expanded_url":"https://twitter.com/EMA_News/status/1369939509828329474/photo/1","display_url":"pic.twitter.com/6BrooVXK5A"}],"annotations":[{"start":103,"end":111,"probability":0.9469,"type":"Person","normalized_text":"Eli Lilly"}]},"attachments":{"media_keys":["3_1369939439082946563"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":199,"reply_count":26,"like_count":276,"quote_count":73},"created_at":"2021-03-10T17:46:56.000Z","author_id":"116716199","text":"Preliminary view from EMA‚Äôs safety committee (#PRAC): there is no specific issue with a batch of #COVID19 Vaccine AstraZeneca that has been suspended in Austria after cases of multiple thrombosis were reported. \nüëâhttps://t.co/292s0fSNJs https://t.co/lh3BXG4e1m","id":"1369706348615766025","conversation_id":"1369706348615766025","entities":{"mentions":{},"hashtags":[{"start":46,"end":51,"tag":"PRAC"},{"start":97,"end":105,"tag":"COVID19"}],"urls":[{"start":213,"end":236,"url":"https://t.co/292s0fSNJs","expanded_url":"https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-prac-preliminary-view-suggests-no-specific-issue-batch-used-austria","display_url":"ema.europa.eu/en/news/covid-‚Ä¶"},{"start":237,"end":260,"url":"https://t.co/lh3BXG4e1m","expanded_url":"https://twitter.com/EMA_News/status/1369706348615766025/photo/1","display_url":"pic.twitter.com/lh3BXG4e1m"}],"annotations":[{"start":22,"end":24,"probability":0.4739,"type":"Organization","normalized_text":"EMA"},{"start":153,"end":159,"probability":0.9962,"type":"Place","normalized_text":"Austria"}]},"attachments":{"media_keys":["3_1369706105669099520"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":198,"reply_count":40,"like_count":313,"quote_count":36},"created_at":"2021-03-04T14:30:00.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/jmIdIBJNI0","id":"1367482465149804546","conversation_id":"1367482465149804546","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/jmIdIBJNI0","expanded_url":"https://twitter.com/EMA_News/status/1367482465149804546/photo/1","display_url":"pic.twitter.com/jmIdIBJNI0"}],"annotations":{}},"attachments":{"media_keys":["3_1367471980333723653"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":486,"reply_count":66,"like_count":919,"quote_count":259},"created_at":"2021-03-04T09:07:13.000Z","author_id":"116716199","text":"EMA has started a rolling review of Sputnik V, a #COVID19vaccine developed by Russia‚Äôs Gamaleya National Centre of Epidemiology and Microbiology. \nüëâ https://t.co/pHVqmSMAuW https://t.co/Bff87qJwOV","id":"1367401232885837827","conversation_id":"1367401232885837827","entities":{"mentions":{},"hashtags":[{"start":49,"end":64,"tag":"COVID19vaccine"}],"urls":[{"start":149,"end":172,"url":"https://t.co/pHVqmSMAuW","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-sputnik-v-covid-19-vaccine","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":173,"end":196,"url":"https://t.co/Bff87qJwOV","expanded_url":"https://twitter.com/EMA_News/status/1367401232885837827/photo/1","display_url":"pic.twitter.com/Bff87qJwOV"}],"annotations":[{"start":0,"end":2,"probability":0.3806,"type":"Organization","normalized_text":"EMA"},{"start":36,"end":44,"probability":0.368,"type":"Organization","normalized_text":"Sputnik V"},{"start":78,"end":83,"probability":0.9305,"type":"Place","normalized_text":"Russia"}]},"attachments":{"media_keys":["3_1367401162287251458"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":244,"reply_count":47,"like_count":522,"quote_count":106},"created_at":"2021-03-02T16:36:34.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) expected to give its recommendation for #COVID19vaccine from Janssen on 11 March 2021. \nüëâhttps://t.co/WlYiJcN4af","id":"1366789538522296327","conversation_id":"1366789538522296327","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":80,"end":95,"tag":"COVID19vaccine"}],"urls":[{"start":129,"end":152,"url":"https://t.co/WlYiJcN4af","expanded_url":"https://www.ema.europa.eu/en/events/extraordinary-meeting-committee-medicinal-products-human-use-chmp-11-march-2021","display_url":"ema.europa.eu/en/events/extr‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.4465,"type":"Organization","normalized_text":"EMA"},{"start":101,"end":107,"probability":0.8839,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":65,"reply_count":7,"like_count":127,"quote_count":6},"created_at":"2021-03-02T14:05:16.000Z","author_id":"116716199","text":"EMA and @GovCanHealth have collaboratively published the full clinical data reviewed as part of their authorisations of the Moderna #COVID19 vaccine. \nüëâ https://t.co/6TUmoQSnuW https://t.co/CL5QxF4RZu","id":"1366751461280014338","conversation_id":"1366751461280014338","entities":{"mentions":[{"start":8,"end":21,"username":"GovCanHealth","id":"36375825"}],"hashtags":[{"start":132,"end":140,"tag":"COVID19"}],"urls":[{"start":153,"end":176,"url":"https://t.co/6TUmoQSnuW","expanded_url":"https://www.ema.europa.eu/en/news/ema-health-canada-publish-clinical-data-used-support-their-authorisations-moderna-covid-19-vaccine","display_url":"ema.europa.eu/en/news/ema-he‚Ä¶"},{"start":177,"end":200,"url":"https://t.co/CL5QxF4RZu","expanded_url":"https://twitter.com/EMA_News/status/1366751461280014338/photo/1","display_url":"pic.twitter.com/CL5QxF4RZu"}],"annotations":{}},"attachments":{"media_keys":["3_1366751390492733446"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1365969685070643201"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":153,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-02-28T13:28:58.000Z","author_id":"116716199","text":"RT @eurordis: Today is @RareDiseaseDay!\n\n3‚É£0‚É£ million people in Europe &amp; 3‚É£0‚É£0‚É£ million people around the world live with a #raredisease.‚Ä¶","id":"1366017553672400897","conversation_id":"1366017553672400897","entities":{"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"},{"start":23,"end":38,"username":"rarediseaseday","id":"19982434"}],"hashtags":[{"start":128,"end":140,"tag":"raredisease"}],"urls":{},"annotations":[{"start":64,"end":69,"probability":0.9974,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":10,"like_count":67,"quote_count":2},"created_at":"2021-02-26T14:46:24.000Z","author_id":"116716199","text":"EMA has recommended granting a marketing authorisation in the EU for the first oral treatment for spinal muscular atrophy\nüëâ https://t.co/NkQ54IZPzD","id":"1365312263465402373","conversation_id":"1365312263465402373","entities":{"mentions":{},"hashtags":{},"urls":[{"start":124,"end":147,"url":"https://t.co/NkQ54IZPzD","expanded_url":"https://www.ema.europa.eu/en/news/first-oral-treatment-spinal-muscular-atrophy-sma-recommended-approval","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":4,"like_count":66,"quote_count":2},"created_at":"2021-02-26T13:13:03.000Z","author_id":"116716199","text":"EMA has started a new pilot project to enhance engagement with #patients at the start of review of all marketing authorisation applications for #OrphanMedicines  üëâ https://t.co/ph6e8ucSpo\n\n#RareDiseaseDay https://t.co/Hu9UlsfCO0","id":"1365288771240026115","conversation_id":"1365288771240026115","entities":{"mentions":{},"hashtags":[{"start":63,"end":72,"tag":"patients"},{"start":144,"end":160,"tag":"OrphanMedicines"},{"start":189,"end":204,"tag":"RareDiseaseDay"}],"urls":[{"start":164,"end":187,"url":"https://t.co/ph6e8ucSpo","expanded_url":"https://www.ema.europa.eu/en/documents/other/pilot-phase-chmp-early-contact-patient/consumer-organisations_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/documents/other/pilot-phase-chmp-early-contact-patient/consumer-organisations_en.pdf"},{"start":205,"end":228,"url":"https://t.co/Hu9UlsfCO0","expanded_url":"https://twitter.com/EMA_News/status/1365288771240026115/photo/1","display_url":"pic.twitter.com/Hu9UlsfCO0"}],"annotations":[{"start":0,"end":2,"probability":0.3907,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["16_1365288660187373569"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":5,"like_count":60,"quote_count":3},"created_at":"2021-02-26T11:37:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 6 #medicines for approval at its February 2021 meeting üëâ https://t.co/M76OzNS5Kh https://t.co/yg85eOan3Q","id":"1365264598224412672","conversation_id":"1365264598224412672","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":108,"end":131,"url":"https://t.co/M76OzNS5Kh","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":132,"end":155,"url":"https://t.co/yg85eOan3Q","expanded_url":"https://twitter.com/EMA_News/status/1365264598224412672/photo/1","display_url":"pic.twitter.com/yg85eOan3Q"}],"annotations":[{"start":0,"end":2,"probability":0.482,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1365263571236630532"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1362751391266181122"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-02-26T10:42:08.000Z","author_id":"116716199","text":"RT @rarediseaseday: THE EQUITY ‚öñÔ∏èTOOLKIT FOR PATIENT ADVOCATES IS OUT NOW! \n\nUse the #RareDiseaseDay toolkit to advocate for people living‚Ä¶","id":"1365250789636268034","conversation_id":"1365250789636268034","entities":{"mentions":[{"start":3,"end":18,"username":"rarediseaseday","id":"19982434"}],"hashtags":[{"start":85,"end":100,"tag":"RareDiseaseDay"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1357646537766100992"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":566,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-02-26T08:29:29.000Z","author_id":"116716199","text":"RT @rarediseaseday: üì¢ NEW! The official #RareDiseaseDay video is out NOW\n \nüéâWatch the 6 real life stories and be inspired to join the 2021‚Ä¶","id":"1365217407745351681","conversation_id":"1365217407745351681","entities":{"mentions":[{"start":3,"end":18,"username":"rarediseaseday","id":"19982434"}],"hashtags":[{"start":40,"end":55,"tag":"RareDiseaseDay"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":87,"reply_count":9,"like_count":160,"quote_count":20},"created_at":"2021-02-25T16:25:00.000Z","author_id":"116716199","text":"#COVID19vaccines: we have issued guidance for manufacturers planning to adapt vaccines to variants üëâ https://t.co/lXlayIYtKe https://t.co/MRHLI0WKUI","id":"1364974687927738369","conversation_id":"1364974687927738369","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":101,"end":124,"url":"https://t.co/lXlayIYtKe","expanded_url":"https://www.ema.europa.eu/en/news/adapting-covid-19-vaccines-sars-cov-2-variants-guidance-vaccine-manufacturers","display_url":"ema.europa.eu/en/news/adapti‚Ä¶"},{"start":125,"end":148,"url":"https://t.co/MRHLI0WKUI","expanded_url":"https://twitter.com/EMA_News/status/1364974687927738369/photo/1","display_url":"pic.twitter.com/MRHLI0WKUI"}],"annotations":{}},"attachments":{"media_keys":["3_1364973756293201924"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":106,"reply_count":26,"like_count":187,"quote_count":14},"created_at":"2021-02-25T14:31:34.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëá https://t.co/CIy9iVkLlk","id":"1364946140836360201","conversation_id":"1364946140836360201","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/CIy9iVkLlk","expanded_url":"https://twitter.com/EMA_News/status/1364946140836360201/photo/1","display_url":"pic.twitter.com/CIy9iVkLlk"}],"annotations":{}},"attachments":{"media_keys":["3_1364946080836816902"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":1,"like_count":20,"quote_count":1},"created_at":"2021-02-25T13:43:06.000Z","author_id":"116716199","text":"A series of #ICMRA workshops underlined international medicine regulators' commitment to align their approaches for regulation of #COVID19 vaccines and medicines. Read more about the outcomes of the discussions: \nüëâhttps://t.co/5wBL7vvTlA https://t.co/5rQZLdUJ2c","id":"1364933943917748231","conversation_id":"1364933943917748231","entities":{"mentions":{},"hashtags":[{"start":12,"end":18,"tag":"ICMRA"},{"start":130,"end":138,"tag":"COVID19"}],"urls":[{"start":214,"end":237,"url":"https://t.co/5wBL7vvTlA","expanded_url":"https://www.ema.europa.eu/en/news/international-cooperation-align-approaches-regulation-covid-19-vaccines-medicines","display_url":"ema.europa.eu/en/news/intern‚Ä¶"},{"start":238,"end":261,"url":"https://t.co/5rQZLdUJ2c","expanded_url":"https://twitter.com/EMA_News/status/1364933943917748231/photo/1","display_url":"pic.twitter.com/5rQZLdUJ2c"}],"annotations":{}},"attachments":{"media_keys":["3_1364933326579109890"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1364243273171271683"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-02-25T12:09:15.000Z","author_id":"116716199","text":"RT @eurordis: We look forward to working closely with @SKyriakidesEU &amp; @EU_Health to build a better future for all people living with a rar‚Ä¶","id":"1364910327100497920","conversation_id":"1364910327100497920","entities":{"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"},{"start":54,"end":68,"username":"SKyriakidesEU","id":"2476130260"},{"start":75,"end":85,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":101,"reply_count":15,"like_count":260,"quote_count":13},"created_at":"2021-02-24T15:50:34.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA starts a rolling review of regdanvimab, a monoclonal antibody developed by Celltrion for the treatment of #COVID19: \nüëâhttps://t.co/oXFZKXrQSE https://t.co/2389K3XzDo","id":"1364603635959742466","conversation_id":"1364603635959742466","entities":{"mentions":{},"hashtags":[{"start":113,"end":121,"tag":"COVID19"}],"urls":[{"start":125,"end":148,"url":"https://t.co/oXFZKXrQSE","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-celltrion-antibody-regdanvimab-covid-19","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":149,"end":172,"url":"https://t.co/2389K3XzDo","expanded_url":"https://twitter.com/EMA_News/status/1364603635959742466/photo/1","display_url":"pic.twitter.com/2389K3XzDo"}],"annotations":[{"start":82,"end":90,"probability":0.4587,"type":"Person","normalized_text":"Celltrion"}]},"attachments":{"media_keys":["3_1364603532335329282"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":7,"like_count":23,"quote_count":2},"created_at":"2021-02-22T14:08:00.000Z","author_id":"116716199","text":"What's on the agenda of the February meeting of EMA's human medicines committee: https://t.co/ylPJtPxGs7 \n #CHMP","id":"1363853047152181248","conversation_id":"1363853047152181248","entities":{"mentions":{},"hashtags":[{"start":107,"end":112,"tag":"CHMP"}],"urls":[{"start":81,"end":104,"url":"https://t.co/ylPJtPxGs7","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/chmp-agenda-22-25-february-2021-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":10,"like_count":50,"quote_count":1},"created_at":"2021-02-19T17:07:00.000Z","author_id":"116716199","text":"We had a great exchange with His Majesty the King of the Netherlands, King Willem-Alexander, who visited the Agency virtually today https://t.co/L5kpR1LuHk","id":"1362810930589888512","conversation_id":"1362810930589888512","entities":{"mentions":{},"hashtags":{},"urls":[{"start":132,"end":155,"url":"https://t.co/L5kpR1LuHk","expanded_url":"https://twitter.com/EMA_News/status/1362810930589888512/photo/1","display_url":"pic.twitter.com/L5kpR1LuHk"}],"annotations":[{"start":57,"end":67,"probability":0.7135,"type":"Place","normalized_text":"Netherlands"},{"start":70,"end":90,"probability":0.7646,"type":"Person","normalized_text":"King Willem-Alexander"}]},"attachments":{"media_keys":["3_1362810021453651971"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":173,"reply_count":36,"like_count":295,"quote_count":26},"created_at":"2021-02-18T14:07:20.000Z","author_id":"116716199","text":"#COVID19vaccines: where are we now? \nRolling reviews in progress, submitted applications, authorisations completed üëâ https://t.co/oAYj5T34oS","id":"1362403328630661120","conversation_id":"1362403328630661120","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/oAYj5T34oS","expanded_url":"https://twitter.com/EMA_News/status/1362403328630661120/photo/1","display_url":"pic.twitter.com/oAYj5T34oS"}],"annotations":{}},"attachments":{"media_keys":["3_1362402910383013891"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":133,"reply_count":8,"like_count":222,"quote_count":16},"created_at":"2021-02-18T09:47:00.000Z","author_id":"116716199","text":"EMA has published the full assessment report for #COVID19vaccine AstraZeneca, together with the product information in all official EU languages:\nüëâ https://t.co/WAP1UBgJGe https://t.co/iu4V1lfTim","id":"1362337812679376896","conversation_id":"1362337812679376896","entities":{"mentions":{},"hashtags":[{"start":49,"end":64,"tag":"COVID19vaccine"}],"urls":[{"start":148,"end":171,"url":"https://t.co/WAP1UBgJGe","expanded_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astrazeneca","display_url":"ema.europa.eu/en/medicines/h‚Ä¶"},{"start":172,"end":195,"url":"https://t.co/iu4V1lfTim","expanded_url":"https://twitter.com/EMA_News/status/1362337812679376896/photo/1","display_url":"pic.twitter.com/iu4V1lfTim"}],"annotations":[{"start":0,"end":2,"probability":0.5486,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1362336606364041216"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":587,"reply_count":80,"like_count":1530,"quote_count":273},"created_at":"2021-02-16T15:25:29.000Z","author_id":"116716199","text":"EMA has received an application for conditional marketing authorisation for #COVID19 Vaccine Janssen: \nüëâhttps://t.co/vBZXDaINdN https://t.co/PBFxayMMkL","id":"1361698219764445184","conversation_id":"1361698219764445184","entities":{"mentions":{},"hashtags":[{"start":76,"end":84,"tag":"COVID19"}],"urls":[{"start":104,"end":127,"url":"https://t.co/vBZXDaINdN","expanded_url":"https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-janssen","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/PBFxayMMkL","expanded_url":"https://twitter.com/EMA_News/status/1361698219764445184/photo/1","display_url":"pic.twitter.com/PBFxayMMkL"}],"annotations":[{"start":0,"end":2,"probability":0.5546,"type":"Organization","normalized_text":"EMA"},{"start":93,"end":99,"probability":0.5898,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":["3_1361698099664719875"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":10,"like_count":38,"quote_count":4},"created_at":"2021-02-12T12:02:03.000Z","author_id":"116716199","text":"During its February meeting, EMA‚Äôs safety committee, the #PRAC, carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines, including #COVID19 treatments and vaccines. Read more: https://t.co/Rfb007tHgt https://t.co/O4vpyhpurN","id":"1360197474867150848","conversation_id":"1360197474867150848","entities":{"mentions":{},"hashtags":[{"start":57,"end":62,"tag":"PRAC"},{"start":195,"end":203,"tag":"COVID19"}],"urls":[{"start":240,"end":263,"url":"https://t.co/Rfb007tHgt","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-february-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶","images":[{"url":"https://pbs.twimg.com/news_img/1482685307979976706/6g5p6PnS?format=png&name=orig","width":842,"height":1102},{"url":"https://pbs.twimg.com/news_img/1482685307979976706/6g5p6PnS?format=png&name=150x150","width":150,"height":150}],"status":200,"title":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 February 2021 - European Medicines Agency","description":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 February 2021","unwound_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-february-2021"},{"start":264,"end":287,"url":"https://t.co/O4vpyhpurN","expanded_url":"https://twitter.com/EMA_News/status/1360197474867150848/photo/1","display_url":"pic.twitter.com/O4vpyhpurN","images":{}}],"annotations":{}},"attachments":{"media_keys":["3_1360197419867250688"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":234,"reply_count":13,"like_count":492,"quote_count":83},"created_at":"2021-02-12T10:08:30.000Z","author_id":"116716199","text":"EMA has started a rolling review of CVnCoV, a #COVID19vaccine developed by CureVac AG:\nüëâhttps://t.co/risZxVYHuS https://t.co/n0nofi1hcU","id":"1360168899275325443","conversation_id":"1360168899275325443","entities":{"mentions":{},"hashtags":[{"start":46,"end":61,"tag":"COVID19vaccine"}],"urls":[{"start":88,"end":111,"url":"https://t.co/risZxVYHuS","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-curevacs-covid-19-vaccine-cvncov","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":112,"end":135,"url":"https://t.co/n0nofi1hcU","expanded_url":"https://twitter.com/EMA_News/status/1360168899275325443/photo/1","display_url":"pic.twitter.com/n0nofi1hcU"}],"annotations":[{"start":0,"end":2,"probability":0.3655,"type":"Person","normalized_text":"EMA"},{"start":36,"end":41,"probability":0.2313,"type":"Person","normalized_text":"CVnCoV"},{"start":75,"end":84,"probability":0.3677,"type":"Organization","normalized_text":"CureVac AG"}]},"attachments":{"media_keys":["3_1360168832439091200"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":96,"reply_count":7,"like_count":139,"quote_count":8},"created_at":"2021-02-10T16:55:04.000Z","author_id":"116716199","text":"EMA is responding to the #COVID19 mutations by developing regulatory guidance for manufacturers planning changes to the existing #COVID19vaccines in the #EU \nüëâ https://t.co/k7AGsFMZRX https://t.co/ajM3WlC0iG","id":"1359546439068766211","conversation_id":"1359546439068766211","entities":{"mentions":{},"hashtags":[{"start":25,"end":33,"tag":"COVID19"},{"start":129,"end":145,"tag":"COVID19vaccines"},{"start":153,"end":156,"tag":"EU"}],"urls":[{"start":160,"end":183,"url":"https://t.co/k7AGsFMZRX","expanded_url":"https://www.ema.europa.eu/en/news/ema-preparing-guidance-tackle-covid-19-variants","display_url":"ema.europa.eu/en/news/ema-pr‚Ä¶"},{"start":184,"end":207,"url":"https://t.co/ajM3WlC0iG","expanded_url":"https://twitter.com/EMA_News/status/1359546439068766211/photo/1","display_url":"pic.twitter.com/ajM3WlC0iG"}],"annotations":[{"start":0,"end":2,"probability":0.4779,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1359546373096488962"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":269,"reply_count":27,"like_count":396,"quote_count":101},"created_at":"2021-02-10T15:42:17.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Clarification - EMA has to date not received an application for a rolling review or a marketing authorisation for the #COVID19 Sputnik V vaccine, despite reports stating the opposite. \nüëâ Read more: https://t.co/vBOrX5732Q","id":"1359528122945843201","conversation_id":"1359528122945843201","entities":{"mentions":{},"hashtags":[{"start":121,"end":129,"tag":"COVID19"}],"urls":[{"start":201,"end":224,"url":"https://t.co/vBOrX5732Q","expanded_url":"https://www.ema.europa.eu/en/news/clarification-sputnik-v-vaccine-eu-approval-process","display_url":"ema.europa.eu/en/news/clarif‚Ä¶"}],"annotations":[{"start":19,"end":21,"probability":0.3988,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":5,"like_count":36,"quote_count":4},"created_at":"2021-02-08T15:32:34.000Z","author_id":"116716199","text":"Sharing expertise and best practices globally is key to make best use of observational studies of real-world data. Read the report from 5th #ICMRA regulatory workshop on observational research in the context of #COVID19:  \nüëâhttps://t.co/u8eVKbWC0g https://t.co/SHarEhVFv9","id":"1358800898122784773","conversation_id":"1358800898122784773","entities":{"mentions":{},"hashtags":[{"start":140,"end":146,"tag":"ICMRA"},{"start":211,"end":219,"tag":"COVID19"}],"urls":[{"start":224,"end":247,"url":"https://t.co/u8eVKbWC0g","expanded_url":"https://www.ema.europa.eu/en/news/international-regulators-working-together-enhance-collaboration-covid-19-observational-research","display_url":"ema.europa.eu/en/news/intern‚Ä¶"},{"start":248,"end":271,"url":"https://t.co/SHarEhVFv9","expanded_url":"https://twitter.com/EMA_News/status/1358800898122784773/photo/1","display_url":"pic.twitter.com/SHarEhVFv9"}],"annotations":{}},"attachments":{"media_keys":["3_1358800810541527042"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":90,"reply_count":12,"like_count":160,"quote_count":7},"created_at":"2021-02-05T16:50:00.000Z","author_id":"116716199","text":"‚ÄºÔ∏è The safety update on the #COVID19vaccine Moderna is now available. No changes are recommended in the use of this vaccine. \nüëâ Read more: https://t.co/DrbAnoAFlE https://t.co/rWjnqGqAai","id":"1357733222377877506","conversation_id":"1357733222377877506","entities":{"mentions":{},"hashtags":[{"start":28,"end":43,"tag":"COVID19vaccine"}],"urls":[{"start":139,"end":162,"url":"https://t.co/DrbAnoAFlE","expanded_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-moderna-february-2021_en.pdf","display_url":"ema.europa.eu/en/documents/c‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/documents/covid-19-vaccine-safety-update/covid-19-vaccine-safety-update-covid-19-vaccine-moderna-february-2021_en.pdf"},{"start":163,"end":186,"url":"https://t.co/rWjnqGqAai","expanded_url":"https://twitter.com/EMA_News/status/1357733222377877506/photo/1","display_url":"pic.twitter.com/rWjnqGqAai"}],"annotations":{}},"attachments":{"media_keys":["3_1357732409509298181"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":39,"reply_count":6,"like_count":83,"quote_count":4},"created_at":"2021-02-04T17:23:03.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) is reviewing available data to support national decision making on the possible use of monoclonal antibodies in #COVID19: \nüëâhttps://t.co/2wME3TXAse","id":"1357379152316411906","conversation_id":"1357379152316411906","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":152,"end":160,"tag":"COVID19"}],"urls":[{"start":164,"end":187,"url":"https://t.co/2wME3TXAse","expanded_url":"https://www.ema.europa.eu/en/news/ema-reviewing-data-monoclonal-antibody-use-covid-19","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.494,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":8,"like_count":75,"quote_count":7},"created_at":"2021-02-04T12:00:46.000Z","author_id":"116716199","text":"EMA is piloting a new ‚ÄòOPEN‚Äô initiative to increase international collaboration on the evaluation of #COVID19 vaccines and therapeutics. \nüëâ https://t.co/sZGnIQ244v https://t.co/wvLkYF4pCa","id":"1357298045826826245","conversation_id":"1357298045826826245","entities":{"mentions":{},"hashtags":[{"start":101,"end":109,"tag":"COVID19"}],"urls":[{"start":140,"end":163,"url":"https://t.co/sZGnIQ244v","expanded_url":"https://www.ema.europa.eu/en/news/ema-covid-19-assessments-open-non-eu-regulators","display_url":"ema.europa.eu/en/news/ema-co‚Ä¶"},{"start":164,"end":187,"url":"https://t.co/wvLkYF4pCa","expanded_url":"https://twitter.com/EMA_News/status/1357298045826826245/photo/1","display_url":"pic.twitter.com/wvLkYF4pCa"}],"annotations":[{"start":0,"end":2,"probability":0.6432,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1357297896325058561"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":213,"reply_count":17,"like_count":445,"quote_count":61},"created_at":"2021-02-03T17:08:21.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA starts a rolling review of Novavax #COVID19vaccine: üëâ https://t.co/qhuj1X7nuq","id":"1357013067041820673","conversation_id":"1357013067041820673","entities":{"mentions":{},"hashtags":[{"start":42,"end":57,"tag":"COVID19vaccine"}],"urls":[{"start":61,"end":84,"url":"https://t.co/qhuj1X7nuq","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-novavaxs-covid-19-vaccine-nvx-cov2373","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":94,"reply_count":15,"like_count":189,"quote_count":24},"created_at":"2021-02-01T15:45:22.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA starts a rolling review of REGN-COV2 antibody combination, which is being developed for the treatment and prevention of #COVID19: üëâ https://t.co/bsO67Hy8Ru https://t.co/W0Nd9MohIM","id":"1356267404364550146","conversation_id":"1356267404364550146","entities":{"mentions":{},"hashtags":[{"start":127,"end":135,"tag":"COVID19"}],"urls":[{"start":139,"end":162,"url":"https://t.co/bsO67Hy8Ru","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-regn-cov2-antibody-combination-casirivimab-imdevimab","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/W0Nd9MohIM","expanded_url":"https://twitter.com/EMA_News/status/1356267404364550146/photo/1","display_url":"pic.twitter.com/W0Nd9MohIM"}],"annotations":{}},"attachments":{"media_keys":["3_1356266959034314754"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1355218465532096515"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":115,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-29T18:26:29.000Z","author_id":"116716199","text":"RT @SKyriakidesEU: The @AstraZeneca #COVID19 vaccine has been authorised by @EU_Commission. We will continue our efforts around the clock t‚Ä¶","id":"1355220789767901186","conversation_id":"1355220789767901186","entities":{"mentions":[{"start":3,"end":17,"username":"SKyriakidesEU","id":"2476130260"},{"start":23,"end":35,"username":"AstraZeneca","id":"62465691"},{"start":76,"end":90,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":36,"end":44,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1355218893883764738"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1219,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-29T18:22:15.000Z","author_id":"116716199","text":"RT @vonderleyen: We have just authorised the @AstraZeneca vaccine on the EU market following a positive assessment by @EMA_News\n \nI expect‚Ä¶","id":"1355219722720206858","conversation_id":"1355219722720206858","entities":{"mentions":[{"start":3,"end":15,"username":"vonderleyen","id":"1146329871418843136"},{"start":45,"end":57,"username":"AstraZeneca","id":"62465691"},{"start":118,"end":127,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":2,"like_count":53,"quote_count":3},"created_at":"2021-01-29T17:44:19.000Z","author_id":"116716199","text":"Did you miss our press briefing on the Agency‚Äôs recommendation on the #COVID19vaccine AstraZeneca? You can watch it on EMA‚Äôs YouTube channel: https://t.co/hoszFs7Lx7","id":"1355210178182991880","conversation_id":"1355210178182991880","entities":{"mentions":{},"hashtags":[{"start":70,"end":85,"tag":"COVID19vaccine"}],"urls":[{"start":142,"end":165,"url":"https://t.co/hoszFs7Lx7","expanded_url":"https://youtu.be/oQNtvAMWdrY","display_url":"youtu.be/oQNtvAMWdrY"}],"annotations":[{"start":125,"end":131,"probability":0.5292,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":37,"quote_count":1},"created_at":"2021-01-29T17:15:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 13 #medicines for approval at its January 2021 meeting:  https://t.co/Tac0qiFKGE https://t.co/AO19XTaPPc","id":"1355202798451712001","conversation_id":"1355202798451712001","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":54,"end":64,"tag":"medicines"}],"urls":[{"start":108,"end":131,"url":"https://t.co/Tac0qiFKGE","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-29-january-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":132,"end":155,"url":"https://t.co/AO19XTaPPc","expanded_url":"https://twitter.com/EMA_News/status/1355202798451712001/photo/1","display_url":"pic.twitter.com/AO19XTaPPc"}],"annotations":[{"start":0,"end":2,"probability":0.4579,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1355202373191393282"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":3,"like_count":51,"quote_count":0},"created_at":"2021-01-29T15:57:25.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"I want to encourage people who have been vaccinated and their #HealthcareProfessionals to report any #SideEffects with #COVID19vaccines, which will be then collected and analysed through the EU #pharmacovigilance system.\"","id":"1355183274260373505","conversation_id":"1355183274260373505","entities":{"mentions":{},"hashtags":[{"start":90,"end":114,"tag":"HealthcareProfessionals"},{"start":129,"end":141,"tag":"SideEffects"},{"start":147,"end":163,"tag":"COVID19vaccines"},{"start":222,"end":240,"tag":"pharmacovigilance"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.964,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":1,"like_count":22,"quote_count":0},"created_at":"2021-01-29T15:53:25.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: \"The PRAC‚Äôs focus during the evaluation was the risk management plan. It describes the safety profile of the vaccine, all measures needed to ensure that it is used in a safe way, and additional data and studies needed for its ongoing safety monitoring\"","id":"1355182269422592003","conversation_id":"1355182269422592003","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9529,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":1,"like_count":53,"quote_count":4},"created_at":"2021-01-29T15:48:25.000Z","author_id":"116716199","text":"Bruno Sepodes, CHMP Vice-chair: \"The evaluation of overall safety and efficacy was based on clinical studies that included 24.000 people. We will also soon receive additional data coming from a study currently ongoing in the US.\"","id":"1355181009227149320","conversation_id":"1355181009227149320","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9648,"type":"Person","normalized_text":"Bruno Sepodes"},{"start":225,"end":226,"probability":0.9317,"type":"Place","normalized_text":"US"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":4,"like_count":60,"quote_count":4},"created_at":"2021-01-29T15:44:55.000Z","author_id":"116716199","text":"Bruno Sepodes, CHMP Vice-chair: \"After evaluation of all available data EMA's committee for human medicines (#CHMP) has agreed that the benefits of this #COVID19vaccine outweigh the known and any potential risks in people from 18 years of age.‚Äù","id":"1355180127181824001","conversation_id":"1355180127181824001","entities":{"mentions":{},"hashtags":[{"start":109,"end":114,"tag":"CHMP"},{"start":153,"end":168,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9842,"type":"Person","normalized_text":"Bruno Sepodes"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":1,"like_count":44,"quote_count":1},"created_at":"2021-01-29T15:41:49.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: \"We will continue to work hard, together with the Member States, @EU_Commission and our international partners, to play our part in fulfilling the needs of not only Europeans but people around world suffering as a result of the #COVID19 pandemic‚Äù","id":"1355179348354080777","conversation_id":"1355179348354080777","entities":{"mentions":[{"start":99,"end":113,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":262,"end":270,"tag":"COVID19"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9855,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":3,"like_count":79,"quote_count":1},"created_at":"2021-01-29T15:35:32.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: \"With EMA‚Äôs recommendation today, we are further expanding the range of #COVID19vaccines available to EU and EEA member states to bring the pandemic under control and protect their citizens.‚Äù","id":"1355177765931245568","conversation_id":"1355177765931245568","entities":{"mentions":{},"hashtags":[{"start":106,"end":122,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9916,"type":"Person","normalized_text":"Emer Cooke"},{"start":40,"end":42,"probability":0.3507,"type":"Person","normalized_text":"EMA"},{"start":136,"end":137,"probability":0.6016,"type":"Organization","normalized_text":"EU"},{"start":143,"end":145,"probability":0.6346,"type":"Organization","normalized_text":"EEA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":3,"like_count":62,"quote_count":4},"created_at":"2021-01-29T15:31:54.000Z","author_id":"116716199","text":"We are starting the press briefing on EMA‚Äôs recommendation of a conditional marketing authorisation in the EU for the #COVID19vaccine AstraZeneca: https://t.co/hoszFs7Lx7 https://t.co/BZ5LXEUzTv","id":"1355176851677831168","conversation_id":"1355176851677831168","entities":{"mentions":{},"hashtags":[{"start":118,"end":133,"tag":"COVID19vaccine"}],"urls":[{"start":147,"end":170,"url":"https://t.co/hoszFs7Lx7","expanded_url":"https://youtu.be/oQNtvAMWdrY","display_url":"youtu.be/oQNtvAMWdrY"},{"start":171,"end":194,"url":"https://t.co/BZ5LXEUzTv","expanded_url":"https://twitter.com/EMA_News/status/1355176851677831168/photo/1","display_url":"pic.twitter.com/BZ5LXEUzTv"}],"annotations":[{"start":38,"end":40,"probability":0.6603,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1355174435301580804"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":883,"reply_count":70,"like_count":1284,"quote_count":429},"created_at":"2021-01-29T15:11:02.000Z","author_id":"116716199","text":"üì¢ EMA has just recommended granting a conditional marketing authorisation for the #COVID19vaccine AstraZeneca to prevent #COVID19 in people from 18 years of age. üëâRead our press release: \nhttps://t.co/YDbOvZEMUN https://t.co/Sbj6TdlGTW","id":"1355171602531569664","conversation_id":"1355171602531569664","entities":{"mentions":{},"hashtags":[{"start":82,"end":97,"tag":"COVID19vaccine"},{"start":121,"end":129,"tag":"COVID19"}],"urls":[{"start":188,"end":211,"url":"https://t.co/YDbOvZEMUN","expanded_url":"https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶","status":200,"title":"EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU - European Medicines Agency","description":"EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU","unwound_url":"https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu"},{"start":212,"end":235,"url":"https://t.co/Sbj6TdlGTW","expanded_url":"https://twitter.com/EMA_News/status/1355171602531569664/photo/1","display_url":"pic.twitter.com/Sbj6TdlGTW"}],"annotations":{}},"attachments":{"media_keys":["3_1355171549863698438"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":109,"reply_count":13,"like_count":160,"quote_count":70},"created_at":"2021-01-29T13:42:45.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Update: EMA‚Äôs virtual press briefing to discuss the outcome of the evaluation of #COVID19 Vaccine AstraZeneca by EMA‚Äôs human medicines committee (#CHMP) is postponed until 16:30 (CET). Read more üëâhttps://t.co/gDYhx1JJng","id":"1355149383373889538","conversation_id":"1355149383373889538","entities":{"mentions":{},"hashtags":[{"start":84,"end":92,"tag":"COVID19"},{"start":149,"end":154,"tag":"CHMP"}],"urls":[{"start":199,"end":222,"url":"https://t.co/gDYhx1JJng","expanded_url":"https://www.ema.europa.eu/en/events/press-briefing-eu-recommendation-covid-19-vaccine-astrazeneca","display_url":"ema.europa.eu/en/events/pres‚Ä¶"}],"annotations":[{"start":93,"end":111,"probability":0.4196,"type":"Other","normalized_text":"Vaccine AstraZeneca"},{"start":116,"end":118,"probability":0.5605,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":250,"reply_count":11,"like_count":435,"quote_count":47},"created_at":"2021-01-29T08:21:05.000Z","author_id":"116716199","text":"Just published: The first safety update on a #COVID19vaccine is now available. It concludes that safety data collected on Comirnaty so far is consistent with the known safety profile of the vaccine, and no new #SideEffects were identified. \nRead more:  https://t.co/a8pyvZCEZJ https://t.co/mfU8ZdtRPG","id":"1355068435881979904","conversation_id":"1355068435881979904","entities":{"mentions":{},"hashtags":[{"start":45,"end":60,"tag":"COVID19vaccine"},{"start":210,"end":222,"tag":"SideEffects"}],"urls":[{"start":253,"end":276,"url":"https://t.co/a8pyvZCEZJ","expanded_url":"https://www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-update-published","display_url":"ema.europa.eu/en/news/first-‚Ä¶","status":200,"title":"First COVID-19 vaccine safety update published - European Medicines Agency","description":"First COVID-19 vaccine safety update published","unwound_url":"https://www.ema.europa.eu/en/news/first-covid-19-vaccine-safety-update-published"},{"start":277,"end":300,"url":"https://t.co/mfU8ZdtRPG","expanded_url":"https://twitter.com/EMA_News/status/1355068435881979904/photo/1","display_url":"pic.twitter.com/mfU8ZdtRPG"}],"annotations":{}},"attachments":{"media_keys":["3_1355068303329341440"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"quoted","id":"1354011072424980480"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":59,"reply_count":7,"like_count":69,"quote_count":6},"created_at":"2021-01-26T10:40:00.000Z","author_id":"116716199","text":"EMA‚Äôs Executive Director, Emer Cooke, will present the latest developments on #COVID19vaccines to @EP_Environment today from 16:45 to 18:15 CET. \n‚û°Ô∏èFollow the live broadcast: https://t.co/AdnoM4z4a9 https://t.co/nRoMsDWyc0","id":"1354016229686534144","conversation_id":"1354016229686534144","entities":{"mentions":[{"start":98,"end":113,"username":"EP_Environment","id":"951333319"}],"hashtags":[{"start":78,"end":94,"tag":"COVID19vaccines"}],"urls":[{"start":175,"end":198,"url":"https://t.co/AdnoM4z4a9","expanded_url":"https://multimedia.europarl.europa.eu/en/committee-on-environment-public-health-and-food-safety_20210126-1645-COMMITTEE-ENVI_vd","display_url":"multimedia.europarl.europa.eu/en/committee-o‚Ä¶"},{"start":199,"end":222,"url":"https://t.co/nRoMsDWyc0","expanded_url":"https://twitter.com/EP_Environment/status/1354011072424980480","display_url":"twitter.com/EP_Environment‚Ä¶"}],"annotations":[{"start":26,"end":35,"probability":0.9903,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":4,"like_count":46,"quote_count":6},"created_at":"2021-01-25T10:00:00.000Z","author_id":"116716199","text":"What's on the agenda of the January meeting of EMA's human medicines committee: https://t.co/HcKRnk2Yw6 #CHMP","id":"1353643777366216704","conversation_id":"1353643777366216704","entities":{"mentions":{},"hashtags":[{"start":104,"end":109,"tag":"CHMP"}],"urls":[{"start":80,"end":103,"url":"https://t.co/HcKRnk2Yw6","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-29-january-2021-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":47,"end":49,"probability":0.2974,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":8,"like_count":30,"quote_count":4},"created_at":"2021-01-21T10:30:00.000Z","author_id":"116716199","text":"EMA recommended 20 #veterinary #medicines for marketing authorisation in 2020. Don‚Äôt miss our annual veterinary medicines highlights here: https://t.co/3XXYL9pOZ8 https://t.co/0riGSfLHhU","id":"1352201775487586304","conversation_id":"1352201775487586304","entities":{"mentions":{},"hashtags":[{"start":19,"end":30,"tag":"veterinary"},{"start":31,"end":41,"tag":"medicines"}],"urls":[{"start":139,"end":162,"url":"https://t.co/3XXYL9pOZ8","expanded_url":"https://www.ema.europa.eu/en/news/veterinary-medicines-highlights-2020","display_url":"ema.europa.eu/en/news/veteri‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/0riGSfLHhU","expanded_url":"https://twitter.com/EMA_News/status/1352201775487586304/photo/1","display_url":"pic.twitter.com/0riGSfLHhU"}],"annotations":{}},"attachments":{"media_keys":["3_1352184303749386240"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":6,"like_count":79,"quote_count":5},"created_at":"2021-01-21T09:23:00.000Z","author_id":"116716199","text":"In 2020, EMA recommended 97 #medicines for marketing authorisation. Check out our annual human medicines highlights: https://t.co/yG1yI6lO6a https://t.co/e297UmAAw3","id":"1352184912791687168","conversation_id":"1352184912791687168","entities":{"mentions":{},"hashtags":[{"start":28,"end":38,"tag":"medicines"}],"urls":[{"start":117,"end":140,"url":"https://t.co/yG1yI6lO6a","expanded_url":"https://www.ema.europa.eu/en/news/human-medicines-highlights-2020","display_url":"ema.europa.eu/en/news/human-‚Ä¶"},{"start":141,"end":164,"url":"https://t.co/e297UmAAw3","expanded_url":"https://twitter.com/EMA_News/status/1352184912791687168/photo/1","display_url":"pic.twitter.com/e297UmAAw3"}],"annotations":{}},"attachments":{"media_keys":["3_1352183586225594368"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":7,"like_count":74,"quote_count":6},"created_at":"2021-01-19T15:24:59.000Z","author_id":"116716199","text":"EMA has endorsed a statement developed by the International Coalition of üíä Regulatory Authorities #ICMRA to inform and help healthcare professionals answer questions about the evaluation, approval &amp; monitoring of #COVID19vaccines.\n\nüëâ https://t.co/q2cDWsVzIT https://t.co/1cAsu5NyAH","id":"1351551232851193858","conversation_id":"1351551232851193858","entities":{"mentions":{},"hashtags":[{"start":98,"end":104,"tag":"ICMRA"},{"start":217,"end":233,"tag":"COVID19vaccines"}],"urls":[{"start":238,"end":261,"url":"https://t.co/q2cDWsVzIT","expanded_url":"https://www.ema.europa.eu/en/news/global-regulators-highlight-key-role-healthcare-professionals-fostering-confidence-covid-19-vaccines","display_url":"ema.europa.eu/en/news/global‚Ä¶"},{"start":262,"end":285,"url":"https://t.co/1cAsu5NyAH","expanded_url":"https://twitter.com/EMA_News/status/1351551232851193858/photo/1","display_url":"pic.twitter.com/1cAsu5NyAH"}],"annotations":[{"start":0,"end":2,"probability":0.426,"type":"Organization","normalized_text":"EMA"},{"start":46,"end":85,"probability":0.3366,"type":"Organization","normalized_text":"International Coalition of üíä Regulatory"}]},"attachments":{"media_keys":["3_1351550683372285955"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":7,"like_count":24,"quote_count":3},"created_at":"2021-01-15T11:27:05.000Z","author_id":"116716199","text":"At its January meeting, EMA's safety committee (PRAC) concluded the evaluation of a risk of acute adrenal insufficiency in children when switching to #Alkindi. \n\nMore information in the #PRAChighlights: \nüëâhttps://t.co/x82P2mbUv1\n\n#SafetyOfMedicines #pharmacovigilance https://t.co/g1v21S0AUl","id":"1350041811184586753","conversation_id":"1350041811184586753","entities":{"mentions":{},"hashtags":[{"start":150,"end":158,"tag":"Alkindi"},{"start":186,"end":201,"tag":"PRAChighlights"},{"start":230,"end":248,"tag":"SafetyOfMedicines"},{"start":249,"end":267,"tag":"pharmacovigilance"}],"urls":[{"start":205,"end":228,"url":"https://t.co/x82P2mbUv1","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-january-2021","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":268,"end":291,"url":"https://t.co/g1v21S0AUl","expanded_url":"https://twitter.com/EMA_News/status/1350041811184586753/photo/1","display_url":"pic.twitter.com/g1v21S0AUl"}],"annotations":{}},"attachments":{"media_keys":["3_1350041655597019137"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1349743499118333952"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-15T09:46:04.000Z","author_id":"116716199","text":"RT @ECDC_EU: Latest #COVID19 update (week 01/2021)\n\nGlobal:\n‚ñ™ 89 802 096 cases\n‚ñ™ 1 940 529 deaths\n\nEU/EEA:\n‚ñ™ 16 938 330 cases\n‚ñ™ 401 535 dea‚Ä¶","id":"1350016392037339136","conversation_id":"1350016392037339136","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":20,"end":28,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":58,"reply_count":10,"like_count":103,"quote_count":3},"created_at":"2021-01-14T10:20:22.000Z","author_id":"116716199","text":"You can find out more about the EU conditional marketing authorisations for #COVID19vaccines in this Lancet article:  https://t.co/mn7ua3cznB","id":"1349662634812071938","conversation_id":"1349662634812071938","entities":{"mentions":{},"hashtags":[{"start":76,"end":92,"tag":"COVID19vaccines"}],"urls":[{"start":118,"end":141,"url":"https://t.co/mn7ua3cznB","expanded_url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00085-4/fulltext#.YAAamvlR8lE.twitter","display_url":"thelancet.com/journals/lance‚Ä¶"}],"annotations":[{"start":32,"end":33,"probability":0.4513,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":125,"reply_count":7,"like_count":299,"quote_count":19},"created_at":"2021-01-13T16:32:11.000Z","author_id":"116716199","text":"The vaccine from Janssen-Cilag International N.V. is currently under rolling review. A date for submission of a marketing authorisation application has not been confirmed. As we have done for all #COVID19vaccines, we will communicate once such application is received.","id":"1349393817875705857","conversation_id":"1349393817875705857","entities":{"mentions":{},"hashtags":[{"start":196,"end":212,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":17,"end":48,"probability":0.1424,"type":"Organization","normalized_text":"Janssen-Cilag International N.V."}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1349300250939453441"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-13T10:56:46.000Z","author_id":"116716199","text":"RT @2021PortugalEU: Portuguese #Health Minister is today presiding over the first informal ministers meeting of #EU2021PT. EU Health Minist‚Ä¶","id":"1349309408241709056","conversation_id":"1349309408241709056","entities":{"mentions":{},"hashtags":[{"start":31,"end":38,"tag":"Health"},{"start":112,"end":121,"tag":"EU2021PT"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":435,"reply_count":51,"like_count":1023,"quote_count":177},"created_at":"2021-01-12T08:29:12.000Z","author_id":"116716199","text":"EMA receives the application for a conditional marketing authorisation of #COVID19 Vaccine AstraZeneca: https://t.co/FVoelj9uvP https://t.co/rpPoVEcNPk","id":"1348909884402786306","conversation_id":"1348909884402786306","entities":{"mentions":{},"hashtags":[{"start":74,"end":82,"tag":"COVID19"}],"urls":[{"start":104,"end":127,"url":"https://t.co/FVoelj9uvP","expanded_url":"https://www.ema.europa.eu/en/news/ema-receives-application-conditional-marketing-authorisation-covid-19-vaccine-astrazeneca","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/rpPoVEcNPk","expanded_url":"https://twitter.com/EMA_News/status/1348909884402786306/photo/1","display_url":"pic.twitter.com/rpPoVEcNPk"}],"annotations":[{"start":0,"end":2,"probability":0.5974,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1348909701174587393"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1347557242174808069"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":18,"quote_count":2},"created_at":"2021-01-08T15:02:12.000Z","author_id":"116716199","text":"@sunilguts European Public Assessment Report (EPAR) for Comirnaty is already published; EPAR for Moderna vaccine is expected to be published on Monday. Plus we are working hard to publish all data on which the marketing authorisation is based asap.","id":"1347559233991172105","conversation_id":"1347552402690494465","entities":{"mentions":[{"start":0,"end":10,"username":"sunilguts","id":"321372613"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"321372613"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":17,"like_count":158,"quote_count":5},"created_at":"2021-01-08T14:35:03.000Z","author_id":"116716199","text":"EMA evaluates thoroughly #COVID19vaccines. It is important that we evaluate data and move forward only when we find these data to be robust.","id":"1347552402690494465","conversation_id":"1347552402690494465","entities":{"mentions":{},"hashtags":[{"start":25,"end":41,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":0,"end":2,"probability":0.6403,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347542813840445440"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-08T14:10:02.000Z","author_id":"116716199","text":"@white_matrix The European Public Assessment Report (EPAR) for the Moderna vaccine is expected to be published on Monday.","id":"1347546105962262528","conversation_id":"1347542813840445440","entities":{"mentions":[{"start":0,"end":13,"username":"white_matrix","id":"1235942243762044929"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1235942243762044929"},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347537479944036358"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":1,"like_count":5,"quote_count":0},"created_at":"2021-01-08T13:39:05.000Z","author_id":"116716199","text":"@DBK118 Yes, the risk management plan for Comirnaty is available: https://t.co/t2GcCimD9M\nRMP will be made available for Moderna on Monday.","id":"1347538316309245953","conversation_id":"1347521512400683009","entities":{"mentions":[{"start":0,"end":7,"username":"DBK118","id":"1169872812154089472"}],"hashtags":{},"urls":[{"start":66,"end":89,"url":"https://t.co/t2GcCimD9M","expanded_url":"https://www.ema.europa.eu/en/documents/rmp/comirnaty-epar-risk-management-plan_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"}],"annotations":[{"start":42,"end":50,"probability":0.3688,"type":"Organization","normalized_text":"Comirnaty"},{"start":121,"end":127,"probability":0.2615,"type":"Organization","normalized_text":"Moderna"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1169872812154089472"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":4,"like_count":49,"quote_count":4},"created_at":"2021-01-08T13:30:27.000Z","author_id":"116716199","text":"Section 4.4 of the¬†#Comirnaty¬†product information says that cases of anaphylaxis have been reported. Appropriate medical treatment &amp; supervision should always be readily available if an anaphylactic reaction follows administration of the vaccine.¬†#EMAPublicMeeting2","id":"1347536145329119234","conversation_id":"1347536145329119234","entities":{"mentions":{},"hashtags":[{"start":19,"end":29,"tag":"Comirnaty"},{"start":251,"end":269,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347532958786326530"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":5,"quote_count":0},"created_at":"2021-01-08T13:24:46.000Z","author_id":"116716199","text":"@connorjoleary @ChemiWizard @culladgh @AUsunov The AstraZeneca vaccine is currently under rolling review. The company has not yet submitted a formal marketing authorisation application.","id":"1347534713137852416","conversation_id":"1347514179964514304","entities":{"mentions":[{"start":0,"end":14,"username":"connorjoleary","id":"894088369"},{"start":15,"end":27,"username":"ChemiWizard","id":"2438781801"},{"start":28,"end":37,"username":"culladgh","id":"1228119666167570433"},{"start":38,"end":46,"username":"AUsunov","id":"1355228610"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"894088369"},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347528070132097027"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":1,"like_count":13,"quote_count":0},"created_at":"2021-01-08T13:01:39.000Z","author_id":"116716199","text":"@pmcniffe @juneshannon EMA cannot provide medical advice to people. The use of¬†#COVID19vaccines¬†in patients with certain conditions should be decided in close consultation with a healthcare professional after considering the benefits &amp; risks in the product information of the vaccine.","id":"1347528894920974337","conversation_id":"1347519348450226176","entities":{"mentions":[{"start":0,"end":9,"username":"pmcniffe","id":"49062345"},{"start":10,"end":22,"username":"juneshannon","id":"22536315"}],"hashtags":[{"start":79,"end":95,"tag":"COVID19vaccines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"49062345"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":56,"quote_count":2},"created_at":"2021-01-08T12:59:41.000Z","author_id":"116716199","text":"Independent studies of #COVID19vaccines coordinated in the üá™üá∫ will give more information on the #COVID19vaccine‚Äôs long-term safety and effectiveness. Member States may also carry out their own additional studies at national level.\n#EMAPublicMeeting2","id":"1347528401163341824","conversation_id":"1347528401163341824","entities":{"mentions":{},"hashtags":[{"start":23,"end":39,"tag":"COVID19vaccines"},{"start":96,"end":111,"tag":"COVID19vaccine"},{"start":231,"end":249,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":[{"start":59,"end":62,"probability":0.5572,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347526794333843456"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":5,"quote_count":1},"created_at":"2021-01-08T12:55:12.000Z","author_id":"116716199","text":"@j_tiltman @vonderleyen @moderna_tx Vaccination is important to prevent people becoming ill with #COVID19. Vaccines alone will not allow us immediately to return to normal life. Other public health measures, e.g. masks &amp; social distancing remain important.","id":"1347527273759518721","conversation_id":"1346794649944530944","entities":{"mentions":[{"start":0,"end":10,"username":"j_tiltman","id":"3339476639"},{"start":11,"end":23,"username":"vonderleyen","id":"1146329871418843136"},{"start":24,"end":35,"username":"moderna_tx","id":"2227355222"}],"hashtags":[{"start":97,"end":105,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"3339476639"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":1,"like_count":73,"quote_count":5},"created_at":"2021-01-08T12:46:58.000Z","author_id":"116716199","text":"Key elements for vaccination strategies in üá™üá∫:\n\n‚û°Ô∏ècapacity to deliver #COVID19vaccines\n‚û°Ô∏èeasy &amp; affordable access for target populations;\n‚û°Ô∏èdeployment of vaccines with different characteristics and storage &amp; transport needs\n‚û°Ô∏èclear communication to citizens.\n\n#EMAPublicMeeting2","id":"1347525202687766529","conversation_id":"1347525202687766529","entities":{"mentions":{},"hashtags":[{"start":70,"end":86,"tag":"COVID19vaccines"},{"start":268,"end":286,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347524014428844033"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2021-01-08T12:45:28.000Z","author_id":"116716199","text":"@fenriswitch European Public Assessment Report (EPAR) for Cominarty is already published; EPAR for Moderna vaccine is expected to be published on Monday. Plus we are working hard to publish all data on which the marketing authorisation is based asap.","id":"1347524823883329539","conversation_id":"1347517083869962240","entities":{"mentions":[{"start":0,"end":12,"username":"fenriswitch","id":"258977025"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"258977025"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1347521512400683009"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":20,"quote_count":0},"created_at":"2021-01-08T12:38:45.000Z","author_id":"116716199","text":"The RMP contains important information about: \n\n‚û°Ô∏èthe vaccine‚Äôs safety\n‚û°Ô∏èhow to collect more information \n‚û°Ô∏èhow to reduce any risks. \n\nRMPs are continually updated as more information becomes available.","id":"1347523131825598465","conversation_id":"1347521512400683009","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":34,"quote_count":2},"created_at":"2021-01-08T12:37:26.000Z","author_id":"116716199","text":"To ensure each #COVID19vaccine is used safely and effectively, recommendations &amp; precautions are available for:\n‚úîÔ∏èhealthcare professionals, in the summary of product characteristics\n‚úîÔ∏èpatients, in the package leaflet. \nThese are available in all üá™üá∫ languages. #EMAPublicMeeting2","id":"1347522801473888257","conversation_id":"1347522801473888257","entities":{"mentions":{},"hashtags":[{"start":15,"end":30,"tag":"COVID19vaccine"},{"start":264,"end":282,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347521263363907584"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":1,"quote_count":0},"created_at":"2021-01-08T12:35:46.000Z","author_id":"116716199","text":"@fenriswitch EMA cannot provide medical advice to people. The use of¬†#COVID19vaccines¬†in patients with certain conditions should be decided in close consultation with a healthcare professional after considering the benefits &amp; risks in the product information.¬†#EMAPublicMeeting2","id":"1347522382160920577","conversation_id":"1347517083869962240","entities":{"mentions":[{"start":0,"end":12,"username":"fenriswitch","id":"258977025"}],"hashtags":[{"start":69,"end":85,"tag":"COVID19vaccines"},{"start":264,"end":282,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"258977025"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":21,"quote_count":1},"created_at":"2021-01-08T12:35:41.000Z","author_id":"116716199","text":"Established analysis techniques are in place to assess whether a suspected side effect is likely to be caused by the #COVID19vaccine.\n\nIf analysis concludes that a new side effect is caused by a vaccine, it will be included in the package leaflet.\n\n#EMAPublicMeeting2","id":"1347522362598633475","conversation_id":"1347522362598633475","entities":{"mentions":{},"hashtags":[{"start":117,"end":132,"tag":"COVID19vaccine"},{"start":249,"end":267,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":1,"like_count":62,"quote_count":6},"created_at":"2021-01-08T12:34:46.000Z","author_id":"116716199","text":"Anyone can report a suspected side effect with #COVID19vaccines to their national authority, healthcare professional &amp; vaccine manufacturer. \nAll reports are sent to EudraVigilance, the EU database of suspected side effects: https://t.co/3Vsjfa0ZVT\n#EMAPublicMeeting2","id":"1347522133312864262","conversation_id":"1347522133312864262","entities":{"mentions":{},"hashtags":[{"start":47,"end":63,"tag":"COVID19vaccines"},{"start":253,"end":271,"tag":"EMAPublicMeeting2"}],"urls":[{"start":229,"end":252,"url":"https://t.co/3Vsjfa0ZVT","expanded_url":"http://www.adrreports.eu/","display_url":"adrreports.eu"}],"annotations":[{"start":166,"end":179,"probability":0.3834,"type":"Place","normalized_text":"EudraVigilance"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":3,"like_count":81,"quote_count":2},"created_at":"2021-01-08T12:32:18.000Z","author_id":"116716199","text":"As for all medicines, safety monitoring of #COVID19vaccines after approval is needed to detect any new or changing side effects. A risk management plan, or simply an RMP, is in place for each vaccine. \n#EMAPublicMeeting2","id":"1347521512400683009","conversation_id":"1347521512400683009","entities":{"mentions":{},"hashtags":[{"start":43,"end":59,"tag":"COVID19vaccines"},{"start":202,"end":220,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1347518313102979074"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":6,"quote_count":0},"created_at":"2021-01-08T12:28:16.000Z","author_id":"116716199","text":"@ColonUfo @ECDC_EU European Public Assessment Report (EPAR) for Comirnaty is already published; EPAR for Moderna vaccine is expected to be published on Monday. Plus we are working hard to publish all data on which the marketing authorisation is based asap.","id":"1347520494367604736","conversation_id":"1347517083869962240","entities":{"mentions":[{"start":0,"end":9,"username":"ColonUfo","id":"1343902140964757507"},{"start":10,"end":18,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1343902140964757507"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1347519742714793986"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":1,"like_count":31,"quote_count":0},"created_at":"2021-01-08T12:25:45.000Z","author_id":"116716199","text":"A conditional marketing authorisation results in one authorisation valid throughout the üá™üá∫, allowing all Member States ‚Äì big or small ‚Äì to benefit from the joint work performed at EU level. A CMA ensures that no Member State is left behind. #EMAPublicMeeting2","id":"1347519863582035970","conversation_id":"1347519742714793986","entities":{"mentions":{},"hashtags":[{"start":241,"end":259,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":[{"start":182,"end":183,"probability":0.4076,"type":"Organization","normalized_text":"EU"},{"start":214,"end":225,"probability":0.568,"type":"Organization","normalized_text":"Member State"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":4,"like_count":47,"quote_count":2},"created_at":"2021-01-08T12:25:17.000Z","author_id":"116716199","text":"Conditional marketing authorisation is the EU‚Äôs regulatory mechanism for use in the current #COVID19 pandemic emergency, to grant all citizens in üá™üá∫ access to a vaccine and to support mass vaccination campaigns. #EMAPublicMeeting2","id":"1347519742714793986","conversation_id":"1347519742714793986","entities":{"mentions":{},"hashtags":[{"start":92,"end":100,"tag":"COVID19"},{"start":212,"end":230,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":[{"start":43,"end":44,"probability":0.7025,"type":"Organization","normalized_text":"EU"},{"start":146,"end":149,"probability":0.5954,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":50,"reply_count":6,"like_count":111,"quote_count":10},"created_at":"2021-01-08T12:23:43.000Z","author_id":"116716199","text":"There are limited data on immunocompromised people. Although these people may not respond as well to the vaccine, no particular safety concerns are anticipated. These citizens can still be vaccinated as they may be at higher risk from #COVID19. #EMAPublicMeeting2","id":"1347519348450226176","conversation_id":"1347519348450226176","entities":{"mentions":{},"hashtags":[{"start":235,"end":243,"tag":"COVID19"},{"start":245,"end":263,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":1,"like_count":75,"quote_count":3},"created_at":"2021-01-08T12:20:38.000Z","author_id":"116716199","text":"If fewer people are getting sick, particularly among elderly &amp; healthcare workers, the huge burden of #COVID19 on #healthcare systems will be reduced. If we can prevent people from having to go to hospital, more resources to treat other illnesses will be freed. #EMAPublicMeeting2","id":"1347518574278148097","conversation_id":"1347518574278148097","entities":{"mentions":{},"hashtags":[{"start":106,"end":114,"tag":"COVID19"},{"start":118,"end":129,"tag":"healthcare"},{"start":266,"end":284,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":2,"like_count":94,"quote_count":8},"created_at":"2021-01-08T12:19:56.000Z","author_id":"116716199","text":"Vaccination is important to prevent people becoming ill with #COVID19. Vaccines alone will not allow us immediately to return to normal life. Other public health measures, e.g. masks &amp; social distancing remain important. #EMAPublicMeeting2","id":"1347518399438585856","conversation_id":"1347518399438585856","entities":{"mentions":{},"hashtags":[{"start":61,"end":69,"tag":"COVID19"},{"start":225,"end":243,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":4,"like_count":40,"quote_count":5},"created_at":"2021-01-08T12:19:33.000Z","author_id":"116716199","text":"People vaccinated with these 2 #covid19vaccines in the clinical trial will continue to be followed for 2 years to gather more information on the duration of protection by #COVID19 and long-term safety. #EMAPublicMeeting2","id":"1347518301937819648","conversation_id":"1347518301937819648","entities":{"mentions":{},"hashtags":[{"start":31,"end":47,"tag":"covid19vaccines"},{"start":171,"end":179,"tag":"COVID19"},{"start":202,"end":220,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1347517083869962240"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":2,"like_count":36,"quote_count":0},"created_at":"2021-01-08T12:15:33.000Z","author_id":"116716199","text":"mRNA vaccines were studied in large clinical trials, involving many thousands of participants, including older people.\n#EMAPublicMeeting","id":"1347517297167097861","conversation_id":"1347517083869962240","entities":{"mentions":{},"hashtags":[{"start":119,"end":136,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":5,"like_count":210,"quote_count":4},"created_at":"2021-01-08T12:14:43.000Z","author_id":"116716199","text":"Very large trials showed that the mRNA vaccines are very effective at preventing #COVID19. Both showed &gt; 90% efficacy and adequate safety profile in clinical trials. #EMAPublicMeeting2","id":"1347517083869962240","conversation_id":"1347517083869962240","entities":{"mentions":{},"hashtags":[{"start":81,"end":89,"tag":"COVID19"},{"start":169,"end":187,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":73,"reply_count":4,"like_count":229,"quote_count":6},"created_at":"2021-01-08T12:13:46.000Z","author_id":"116716199","text":"mRNA from #COVID19vaccines doesn‚Äôt stay in the body but is broken down shortly after vaccination. #EMAPublicMeeting2","id":"1347516845461561346","conversation_id":"1347516845461561346","entities":{"mentions":{},"hashtags":[{"start":10,"end":26,"tag":"COVID19vaccines"},{"start":98,"end":116,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":43,"reply_count":5,"like_count":105,"quote_count":8},"created_at":"2021-01-08T12:11:43.000Z","author_id":"116716199","text":"Both #COVID19vaccines authorised in the üá™üá∫ are given as 2 injections, usually into the muscle of the upper arm:\n‚û°Ô∏èComirnaty (BioNTech/Pfizer) is given at least 21 days apart\n‚û°Ô∏èModerna COVID-19 vaccine is given 28 days apart\n#EMAPublicMeeting2","id":"1347516331135000578","conversation_id":"1347516331135000578","entities":{"mentions":{},"hashtags":[{"start":5,"end":21,"tag":"COVID19vaccines"},{"start":224,"end":242,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":598,"reply_count":68,"like_count":1439,"quote_count":277},"created_at":"2021-01-08T12:03:10.000Z","author_id":"116716199","text":"After having received more data from the company, EMA is expecting Astra Zeneca to submit a conditional marketing application for its #COVID19vaccine next week. Possible conclusion - end of Jan, depending on data and evaluation progress. #EMAPublicMeeting2","id":"1347514179964514304","conversation_id":"1347514179964514304","entities":{"mentions":{},"hashtags":[{"start":134,"end":149,"tag":"COVID19vaccine"},{"start":238,"end":256,"tag":"EMAPublicMeeting2"}],"urls":{},"annotations":[{"start":50,"end":52,"probability":0.5532,"type":"Organization","normalized_text":"EMA"},{"start":67,"end":78,"probability":0.501,"type":"Organization","normalized_text":"Astra Zeneca"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":1,"like_count":62,"quote_count":11},"created_at":"2021-01-08T12:00:36.000Z","author_id":"116716199","text":"‚ÄºÔ∏è We are now starting the 2nd EMA public meeting on approval &amp; roll-out of #COVID19vaccines in the üá™üá∫.\n\nFollow #EMAPublicMeeting2\n\nüî¥ Live: https://t.co/hEDln8t6J1","id":"1347513534771552257","conversation_id":"1347513534771552257","entities":{"mentions":{},"hashtags":[{"start":80,"end":96,"tag":"COVID19vaccines"},{"start":116,"end":134,"tag":"EMAPublicMeeting2"}],"urls":[{"start":144,"end":167,"url":"https://t.co/hEDln8t6J1","expanded_url":"https://www.youtube.com/watch?v=XC5dAk_7dOw&feature=youtu.be","display_url":"youtube.com/watch?v=XC5dAk‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":146,"reply_count":14,"like_count":313,"quote_count":101},"created_at":"2021-01-08T11:15:29.000Z","author_id":"116716199","text":"Update: EMA‚Äôs human medicines committee (#CHMP) has recommended updating the product information for the Comirnaty #COVID19vaccine to clarify that each vial contains 6 doses of the vaccine: https://t.co/bTEgnpdvFA https://t.co/0NZkVuYS4y","id":"1347502178781581312","conversation_id":"1347502178781581312","entities":{"mentions":{},"hashtags":[{"start":41,"end":46,"tag":"CHMP"},{"start":115,"end":130,"tag":"COVID19vaccine"}],"urls":[{"start":190,"end":213,"url":"https://t.co/bTEgnpdvFA","expanded_url":"https://www.ema.europa.eu/en/news/extra-dose-vials-comirnaty-covid-19-vaccine","display_url":"ema.europa.eu/en/news/extra-‚Ä¶"},{"start":214,"end":237,"url":"https://t.co/0NZkVuYS4y","expanded_url":"https://twitter.com/EMA_News/status/1347502178781581312/photo/1","display_url":"pic.twitter.com/0NZkVuYS4y"}],"annotations":{}},"attachments":{"media_keys":["3_1347502137878700032"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":62,"reply_count":2,"like_count":105,"quote_count":8},"created_at":"2021-01-08T10:00:31.000Z","author_id":"116716199","text":"Don't forget to follow the live broadcast of a 2nd EMA public meeting on approval &amp; roll-out of #COVID19vaccines in the üá™üá∫. \n\nüóìÔ∏èToday, 13h00 CET\n\nKeep an eye üîçon #EMAPublicMeeting2 to follow our live tweets. \n\nüî¥ https://t.co/hEDln8t6J1 https://t.co/hQnJa6ycPL","id":"1347483311250223104","conversation_id":"1347483311250223104","entities":{"mentions":{},"hashtags":[{"start":100,"end":116,"tag":"COVID19vaccines"},{"start":166,"end":184,"tag":"EMAPublicMeeting2"}],"urls":[{"start":216,"end":239,"url":"https://t.co/hEDln8t6J1","expanded_url":"https://www.youtube.com/watch?v=XC5dAk_7dOw&feature=youtu.be","display_url":"youtube.com/watch?v=XC5dAk‚Ä¶"},{"start":240,"end":263,"url":"https://t.co/hQnJa6ycPL","expanded_url":"https://twitter.com/EMA_News/status/1347483311250223104/photo/1","display_url":"pic.twitter.com/hQnJa6ycPL"}],"annotations":{}},"attachments":{"media_keys":["3_1347483080127340545"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1347192086928498689"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":71,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-07T14:51:14.000Z","author_id":"116716199","text":"RT @EU_Commission: All medicines and vaccines are closely monitored after they are authorised and put on the EU market.\n\nThe @EMA_News will‚Ä¶","id":"1347194084713238529","conversation_id":"1347194084713238529","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"},{"start":125,"end":134,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1346847278133366787"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":102,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-06T16:00:29.000Z","author_id":"116716199","text":"RT @EU_Health: üëçGood news: a second safe &amp; effective vaccine against COVID-19 is authorised for use in the EU\n\nRead more: https://t.co/azF2‚Ä¶","id":"1346849125048979458","conversation_id":"1346849125048979458","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1346842270952263680"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":139,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-06T15:37:28.000Z","author_id":"116716199","text":"RT @SKyriakidesEU: The @moderna_tx #COVID19 vaccine is approved for use by @EU_Commission, the second in üá™üá∫\n\nSwift vaccinations must now fo‚Ä¶","id":"1346843333398847488","conversation_id":"1346843333398847488","entities":{"mentions":[{"start":3,"end":17,"username":"SKyriakidesEU","id":"2476130260"},{"start":23,"end":34,"username":"moderna_tx","id":"2227355222"},{"start":75,"end":89,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":35,"end":43,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1346794649944530944"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1730,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2021-01-06T12:25:56.000Z","author_id":"116716199","text":"RT @vonderleyen: Good news for our efforts to bring more #COVID19 vaccines to Europeans!\n \n@EMA_News assessed that the @moderna_tx vaccine‚Ä¶","id":"1346795134038503425","conversation_id":"1346795134038503425","entities":{"mentions":[{"start":3,"end":15,"username":"vonderleyen","id":"1146329871418843136"},{"start":91,"end":100,"username":"EMA_News","id":"116716199"},{"start":119,"end":130,"username":"moderna_tx","id":"2227355222"}],"hashtags":[{"start":57,"end":65,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1562,"reply_count":66,"like_count":2861,"quote_count":723},"created_at":"2021-01-06T12:19:44.000Z","author_id":"116716199","text":"üì¢ EMA has recommended granting a conditional marketing authorisation for COVID-19 Vaccine Moderna to prevent #COVID19 in people from 18 years of age: https://t.co/l9KMZlx7wa https://t.co/BdvXanjOHN","id":"1346793570334867457","conversation_id":"1346793570334867457","entities":{"mentions":{},"hashtags":[{"start":109,"end":117,"tag":"COVID19"}],"urls":[{"start":150,"end":173,"url":"https://t.co/l9KMZlx7wa","expanded_url":"https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":174,"end":197,"url":"https://t.co/BdvXanjOHN","expanded_url":"https://twitter.com/EMA_News/status/1346793570334867457/photo/1","display_url":"pic.twitter.com/BdvXanjOHN"}],"annotations":{}},"attachments":{"media_keys":["3_1346793400608182272"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":240,"reply_count":26,"like_count":701,"quote_count":78},"created_at":"2021-01-06T09:17:49.000Z","author_id":"116716199","text":"The meeting of EMA‚Äôs human medicines committee (#CHMP) to discuss COVID-19 vaccine Moderna has started. We will communicate the outcome. Follow our updates on Twitter.","id":"1346747793432522752","conversation_id":"1346747793432522752","entities":{"mentions":{},"hashtags":[{"start":48,"end":53,"tag":"CHMP"}],"urls":{},"annotations":[{"start":15,"end":17,"probability":0.3869,"type":"Organization","normalized_text":"EMA"},{"start":159,"end":165,"probability":0.6299,"type":"Product","normalized_text":"Twitter"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1346469822238871553"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2021-01-05T14:58:17.000Z","author_id":"116716199","text":"@MarkusD_Hessen Thank you for your suggestion. We usually mention that the CHMP is EMA's human medicines committee: https://t.co/bkBRSVB5dT","id":"1346471082853691398","conversation_id":"1346468957117530122","entities":{"mentions":[{"start":0,"end":15,"username":"MarkusD_Hessen","id":"1133808929262198784"}],"hashtags":{},"urls":[{"start":116,"end":139,"url":"https://t.co/bkBRSVB5dT","expanded_url":"https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp","display_url":"ema.europa.eu/en/committees/‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1133808929262198784"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":84,"reply_count":19,"like_count":153,"quote_count":20},"created_at":"2021-01-05T14:49:50.000Z","author_id":"116716199","text":"The #CHMP discussion on COVID-19 vaccine Moderna will continue on Wednesday, 6th January 2021. Meanwhile, our experts are working hard to clarify all outstanding issues with the company.","id":"1346468957117530122","conversation_id":"1346468957117530122","entities":{"mentions":{},"hashtags":[{"start":4,"end":9,"tag":"CHMP"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":202,"reply_count":71,"like_count":286,"quote_count":150},"created_at":"2021-01-04T18:31:01.000Z","author_id":"116716199","text":"EMA's committee for human medicines (CHMP) discussion on COVID-19 vaccine Moderna has not concluded today. It will continue on Wednesday 6th January 2021. No further communication will be issued today by EMA.","id":"1346162232267329536","conversation_id":"1346162232267329536","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":120,"reply_count":22,"like_count":180,"quote_count":41},"created_at":"2020-12-30T17:04:37.000Z","author_id":"116716199","text":"üì¢ Update on EMA's rolling review of AstraZeneca‚Äôs COVID-19 vaccine: \nüëâhttps://t.co/pX3kq7LFDg","id":"1344328548543291394","conversation_id":"1344328548543291394","entities":{"mentions":{},"hashtags":{},"urls":[{"start":70,"end":93,"url":"https://t.co/pX3kq7LFDg","expanded_url":"https://www.ema.europa.eu/en/news/update-rolling-review-astrazenecas-covid-19-vaccine","display_url":"ema.europa.eu/en/news/update‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":174,"reply_count":18,"like_count":244,"quote_count":28},"created_at":"2020-12-28T09:28:00.000Z","author_id":"116716199","text":"üìÖ EMA will organise a second public meeting on 8 January 2021 to inform EU citizens about new #COVID19vaccines  \nüìùRegistration is open until 31 December: https://t.co/NjwVn6XhzQ \n#EMAPublicMeeting2 https://t.co/zA6fJzxP3a","id":"1343488862245576705","conversation_id":"1343488862245576705","entities":{"mentions":{},"hashtags":[{"start":94,"end":110,"tag":"COVID19vaccines"},{"start":179,"end":197,"tag":"EMAPublicMeeting2"}],"urls":[{"start":154,"end":177,"url":"https://t.co/NjwVn6XhzQ","expanded_url":"https://www.ema.europa.eu/en/news/ema-organises-second-public-meeting-about-new-covid-19-vaccines","display_url":"ema.europa.eu/en/news/ema-or‚Ä¶"},{"start":198,"end":221,"url":"https://t.co/zA6fJzxP3a","expanded_url":"https://twitter.com/EMA_News/status/1343488862245576705/photo/1","display_url":"pic.twitter.com/zA6fJzxP3a"}],"annotations":[{"start":3,"end":5,"probability":0.4424,"type":"Organization","normalized_text":"EMA"},{"start":73,"end":74,"probability":0.6457,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1341702090352173057"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":102,"reply_count":9,"like_count":155,"quote_count":25},"created_at":"2020-12-24T09:00:02.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA has published the assessment report for Comirnaty, the first #COVID19vaccine to be authorised in the EU, together with the product information in all official EU languages \nüëâ https://t.co/UKQK12cTRL https://t.co/ceV5SVzkbO","id":"1342032273139511296","conversation_id":"1342032273139511296","entities":{"mentions":{},"hashtags":[{"start":68,"end":83,"tag":"COVID19vaccine"}],"urls":[{"start":182,"end":205,"url":"https://t.co/UKQK12cTRL","expanded_url":"https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty","display_url":"ema.europa.eu/en/medicines/h‚Ä¶"},{"start":206,"end":229,"url":"https://t.co/ceV5SVzkbO","expanded_url":"https://twitter.com/EMA_News/status/1342032273139511296/photo/1","display_url":"pic.twitter.com/ceV5SVzkbO"}],"annotations":[{"start":47,"end":55,"probability":0.3411,"type":"Organization","normalized_text":"Comirnaty"},{"start":108,"end":109,"probability":0.4078,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1342030334347665408"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":96,"reply_count":9,"like_count":140,"quote_count":15},"created_at":"2020-12-23T08:23:34.000Z","author_id":"116716199","text":"üì¢EMA will organise a second public meeting on 8 January 2021 to inform EU citizens about the assessment, approval and roll-out of new #COVID19vaccines \nüëâhttps://t.co/NjwVn6XhzQ\n#EMAPublicMeeting2 https://t.co/x9R3CFcqw5","id":"1341660710351286273","conversation_id":"1341660710351286273","entities":{"mentions":{},"hashtags":[{"start":134,"end":150,"tag":"COVID19vaccines"},{"start":177,"end":195,"tag":"EMAPublicMeeting2"}],"urls":[{"start":153,"end":176,"url":"https://t.co/NjwVn6XhzQ","expanded_url":"https://www.ema.europa.eu/en/news/ema-organises-second-public-meeting-about-new-covid-19-vaccines","display_url":"ema.europa.eu/en/news/ema-or‚Ä¶"},{"start":196,"end":219,"url":"https://t.co/x9R3CFcqw5","expanded_url":"https://twitter.com/EMA_News/status/1341660710351286273/photo/1","display_url":"pic.twitter.com/x9R3CFcqw5"}],"annotations":[{"start":2,"end":4,"probability":0.4723,"type":"Organization","normalized_text":"EMA"},{"start":72,"end":73,"probability":0.6082,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1341660591459618816"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":1,"like_count":54,"quote_count":0},"created_at":"2020-12-22T14:53:13.000Z","author_id":"116716199","text":"Did you miss our press briefing yesterday on the Agency‚Äôs recommendation on the #COVID19vaccine developed by BioNTech/Pfizer? You can watch it on EMA‚Äôs YouTube channel: https://t.co/rfPVzSkFEh","id":"1341396377830625283","conversation_id":"1341396377830625283","entities":{"mentions":{},"hashtags":[{"start":80,"end":95,"tag":"COVID19vaccine"}],"urls":[{"start":169,"end":192,"url":"https://t.co/rfPVzSkFEh","expanded_url":"https://youtu.be/9waGXIEg4cg","display_url":"youtu.be/9waGXIEg4cg"}],"annotations":[{"start":109,"end":116,"probability":0.6345,"type":"Organization","normalized_text":"BioNTech"},{"start":118,"end":123,"probability":0.4207,"type":"Organization","normalized_text":"Pfizer"},{"start":152,"end":158,"probability":0.4444,"type":"Organization","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341027315950739458"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":3,"like_count":59,"quote_count":5},"created_at":"2020-12-21T14:31:33.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: I want to take this chance to encourage #patients and #HealthcareProfessionals to report any #SideEffects with #COVID19vaccines, which will be then collected and analysed through the EU system.","id":"1341028541257887744","conversation_id":"1341027315950739458","entities":{"mentions":{},"hashtags":[{"start":67,"end":76,"tag":"patients"},{"start":81,"end":105,"tag":"HealthcareProfessionals"},{"start":120,"end":132,"tag":"SideEffects"},{"start":138,"end":154,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9638,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341027315950739458"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":38,"quote_count":1},"created_at":"2020-12-21T14:31:15.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: The EU has an excellent safety surveillance system, with state-of-the-art analysis and detection, to ensure that we identify new or changing safety information.","id":"1341028463172567042","conversation_id":"1341027315950739458","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9506,"type":"Person","normalized_text":"Sabine Straus"},{"start":31,"end":32,"probability":0.4635,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341027315950739458"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":1,"like_count":33,"quote_count":0},"created_at":"2020-12-21T14:30:19.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: Additional resources have been mobilised to monitor and assess new safety information as it becomes available. For all #COVID19vaccines, strengthened reporting obligations for companies have been put in place.","id":"1341028227666632706","conversation_id":"1341027315950739458","entities":{"mentions":{},"hashtags":[{"start":146,"end":162,"tag":"COVID19vaccines"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9222,"type":"Person","normalized_text":"Sabine Straus"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":50,"reply_count":6,"like_count":117,"quote_count":4},"created_at":"2020-12-21T14:26:41.000Z","author_id":"116716199","text":"Sabine Straus, PRAC Chair: The PRAC is very aware of our responsibility to EU citizens to collect and analyse every piece of information on the safety of the vaccine. The safety profile of the #COVID19vaccine from the data we have assessed is reassuring.","id":"1341027315950739458","conversation_id":"1341027315950739458","entities":{"mentions":{},"hashtags":[{"start":193,"end":208,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9601,"type":"Person","normalized_text":"Sabine Straus"},{"start":75,"end":76,"probability":0.5285,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":81,"reply_count":1,"like_count":106,"quote_count":18},"created_at":"2020-12-21T14:25:11.000Z","author_id":"116716199","text":"Watch the press briefing on EMA‚Äôs recommendation of a conditional marketing authorisation in the üá™üá∫ for the #COVID19vaccine developed by BioNTech/ Pfizer: https://t.co/UWgmCbkrHt https://t.co/KHgoSAD8Bo","id":"1341026936324296706","conversation_id":"1341026936324296706","entities":{"mentions":{},"hashtags":[{"start":108,"end":123,"tag":"COVID19vaccine"}],"urls":[{"start":155,"end":178,"url":"https://t.co/UWgmCbkrHt","expanded_url":"https://www.ema.europa.eu/en/events/press-briefing","display_url":"ema.europa.eu/en/events/pres‚Ä¶"},{"start":179,"end":202,"url":"https://t.co/KHgoSAD8Bo","expanded_url":"https://twitter.com/EMA_News/status/1341026936324296706/photo/1","display_url":"pic.twitter.com/KHgoSAD8Bo"}],"annotations":[{"start":28,"end":30,"probability":0.6974,"type":"Organization","normalized_text":"EMA"},{"start":139,"end":154,"probability":0.2777,"type":"Organization","normalized_text":"BioNTech/ Pfizer"}]},"attachments":{"media_keys":["3_1341026912932687877"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":46,"reply_count":1,"like_count":90,"quote_count":11},"created_at":"2020-12-21T14:24:01.000Z","author_id":"116716199","text":"Harald Enzmann, CHMP Chair: The main #ClinicalTrial for this vaccine, which enrolled over 43,000 people, is one of the largest we have ever evaluated for a vaccine. https://t.co/qOyMcYLI4y","id":"1341026644979576834","conversation_id":"1341026644979576834","entities":{"mentions":{},"hashtags":[{"start":37,"end":51,"tag":"ClinicalTrial"}],"urls":[{"start":165,"end":188,"url":"https://t.co/qOyMcYLI4y","expanded_url":"https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"}],"annotations":[{"start":0,"end":13,"probability":0.9413,"type":"Person","normalized_text":"Harald Enzmann"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":862,"reply_count":34,"like_count":1431,"quote_count":286},"created_at":"2020-12-21T14:13:58.000Z","author_id":"116716199","text":"üì¢ EMA has just recommended granting a conditional marketing authorisation for the #COVID19vaccine developed by BioNTech/ Pfizer, to prevent #COVID19 in people from 16 years of age. \n\nüëâRead our press release: https://t.co/qOyMcYLI4y https://t.co/4c5ujZKQ6b","id":"1341024114933456902","conversation_id":"1341024114933456902","entities":{"mentions":{},"hashtags":[{"start":82,"end":97,"tag":"COVID19vaccine"},{"start":140,"end":148,"tag":"COVID19"}],"urls":[{"start":208,"end":231,"url":"https://t.co/qOyMcYLI4y","expanded_url":"https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":232,"end":255,"url":"https://t.co/4c5ujZKQ6b","expanded_url":"https://twitter.com/EMA_News/status/1341024114933456902/photo/1","display_url":"pic.twitter.com/4c5ujZKQ6b"}],"annotations":[{"start":112,"end":127,"probability":0.2401,"type":"Organization","normalized_text":"BioNTech/ Pfizer"}]},"attachments":{"media_keys":["3_1341023871219212289"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341022401375727616"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":2,"like_count":54,"quote_count":1},"created_at":"2020-12-21T14:11:39.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: We owe citizens transparency so they can decide on vaccination based on facts. EMA will publish information on the assessment, including all clinical data assessed in the application. This will allow further independent scrutiny from scientists.","id":"1341023529173725185","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.991,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341022401375727616"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":1,"like_count":15,"quote_count":0},"created_at":"2020-12-21T14:10:54.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: The conditional marketing authorisation ensures an agreed plan with legally binding obligations on companies, making sure that additional data will be generated and submitted to EMA after the approval.","id":"1341023341034020864","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9912,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341022401375727616"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":5,"like_count":97,"quote_count":2},"created_at":"2020-12-21T14:10:12.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: EMA‚Äôs scientific assessment is based on the strength of the scientific evidence on the vaccine‚Äôs safety, quality and efficacy, and nothing else. The evidence convincingly shows that benefits are greater than the risks of this #COVID19vaccine.","id":"1341023166387335170","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":[{"start":260,"end":275,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9913,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341022204608335874"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":3,"like_count":88,"quote_count":2},"created_at":"2020-12-21T14:07:10.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: I would like to celebrate and acknowledge the tireless work behind the scenes of a high number of experts from all üá™üá∫ Member States and my colleagues in EMA involved in the review of the #COVID19vaccine.","id":"1341022401375727616","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":[{"start":221,"end":236,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9927,"type":"Person","normalized_text":"Emer Cooke"},{"start":149,"end":166,"probability":0.4108,"type":"Organization","normalized_text":"üá™üá∫ Member States"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1341022012916051969"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":2,"like_count":87,"quote_count":1},"created_at":"2020-12-21T14:06:23.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: This is the result of unparalleled mobilisation and sharing of information between scientists, industry, regulators, healthcare professionals and patients around the globe.","id":"1341022204608335874","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9908,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":263,"reply_count":15,"like_count":595,"quote_count":101},"created_at":"2020-12-21T14:05:37.000Z","author_id":"116716199","text":"Emer Cooke, EMA's Exec. Director: EMA's scientific opinion paves the way for the first marketing authorisation of a #COVID19vaccine in the EU with the corresponding safeguards, controls and obligations.","id":"1341022012916051969","conversation_id":"1341022012916051969","entities":{"mentions":{},"hashtags":[{"start":116,"end":131,"tag":"COVID19vaccine"}],"urls":{},"annotations":[{"start":0,"end":9,"probability":0.9917,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":98,"reply_count":3,"like_count":161,"quote_count":38},"created_at":"2020-12-21T14:04:48.000Z","author_id":"116716199","text":"We are starting the press briefing on EMA‚Äôs recommendation of a conditional marketing authorisation in the üá™üá∫ for the #COVID19vaccine developed by BioNTech/ Pfizer. https://t.co/9XVvyzEU96","id":"1341021809290989568","conversation_id":"1341021809290989568","entities":{"mentions":{},"hashtags":[{"start":118,"end":133,"tag":"COVID19vaccine"}],"urls":[{"start":165,"end":188,"url":"https://t.co/9XVvyzEU96","expanded_url":"https://www.youtube.com/watch?v=9waGXIEg4cg&feature=youtu.be","display_url":"youtube.com/watch?v=9waGXI‚Ä¶"}],"annotations":[{"start":38,"end":40,"probability":0.6915,"type":"Organization","normalized_text":"EMA"},{"start":149,"end":156,"probability":0.6551,"type":"Organization","normalized_text":"BioNTech"},{"start":159,"end":164,"probability":0.3964,"type":"Organization","normalized_text":"Pfizer"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1340567613429096451"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":430,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-20T11:58:04.000Z","author_id":"116716199","text":"RT @EU_Commission: We are working with @EMA_News to ensure that #SafeVaccines are available as soon as possible.\n\nOnce on the market, they‚Ä¶","id":"1340627525861576706","conversation_id":"1340627525861576706","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"},{"start":39,"end":48,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":64,"end":77,"tag":"SafeVaccines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":7,"like_count":14,"quote_count":0},"created_at":"2020-12-18T13:30:05.000Z","author_id":"116716199","text":"Check out the highlights of the December 2020 meeting of EMA's Management Board: https://t.co/ewgqaAAI3T https://t.co/vf3PToZlin","id":"1339925908182974465","conversation_id":"1339925908182974465","entities":{"mentions":{},"hashtags":{},"urls":[{"start":81,"end":104,"url":"https://t.co/ewgqaAAI3T","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-december-2020-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":105,"end":128,"url":"https://t.co/vf3PToZlin","expanded_url":"https://twitter.com/EMA_News/status/1339925908182974465/photo/1","display_url":"pic.twitter.com/vf3PToZlin"}],"annotations":[{"start":57,"end":78,"probability":0.3059,"type":"Other","normalized_text":"EMA's Management Board"}]},"attachments":{"media_keys":["3_1339925852067418113"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":58,"reply_count":4,"like_count":106,"quote_count":24},"created_at":"2020-12-17T18:57:37.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Update on the assessment of the marketing authorisation application for Moderna‚Äôs mRNA-1273 #COVID19vaccine:  ‚û°Ô∏èhttps://t.co/AFPQpSUIbl","id":"1339645945315778560","conversation_id":"1339645945315778560","entities":{"mentions":{},"hashtags":[{"start":95,"end":110,"tag":"COVID19vaccine"}],"urls":[{"start":115,"end":138,"url":"https://t.co/AFPQpSUIbl","expanded_url":"https://www.ema.europa.eu/en/news/update-assessment-marketing-authorisation-application-modernas-mrna-1273-covid-19-vaccine","display_url":"ema.europa.eu/en/news/update‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":5,"like_count":56,"quote_count":3},"created_at":"2020-12-17T12:53:27.000Z","author_id":"116716199","text":"#DYK that EMA needs many detailed studies to confirm that a #COVID19vaccine is safe, provides adequate protection and is of suitable quality? \nRead about studies needed for #COVID19 vaccines approval: \nüëâhttps://t.co/HmsH4NuZ0A https://t.co/S9iNWDgf8t","id":"1339554298783539201","conversation_id":"1339554298783539201","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":60,"end":75,"tag":"COVID19vaccine"},{"start":173,"end":181,"tag":"COVID19"}],"urls":[{"start":203,"end":226,"url":"https://t.co/HmsH4NuZ0A","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-studies-approval","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":227,"end":250,"url":"https://t.co/S9iNWDgf8t","expanded_url":"https://twitter.com/EMA_News/status/1339554298783539201/photo/1","display_url":"pic.twitter.com/S9iNWDgf8t"}],"annotations":[{"start":10,"end":12,"probability":0.324,"type":"Person","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1339554222262661127"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":2,"like_count":86,"quote_count":5},"created_at":"2020-12-17T10:38:36.000Z","author_id":"116716199","text":"Normally, data for a üíä must be submitted at the start of EMA's evaluation of a marketing authorisation application. \n\nIn case of #RollingReview, EMA assesses data as they become available, in cycles, each lasting around 2 weeks. \nüëâhttps://t.co/wxpOGrPlu6 https://t.co/Iga8o9uRxW","id":"1339520362309152770","conversation_id":"1339520362309152770","entities":{"mentions":{},"hashtags":[{"start":129,"end":143,"tag":"RollingReview"}],"urls":[{"start":231,"end":254,"url":"https://t.co/wxpOGrPlu6","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring#scientific-evaluation-and-approval-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":255,"end":278,"url":"https://t.co/Iga8o9uRxW","expanded_url":"https://twitter.com/EMA_News/status/1339520362309152770/photo/1","display_url":"pic.twitter.com/Iga8o9uRxW"}],"annotations":{}},"attachments":{"media_keys":["3_1339520335767597056"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":110,"reply_count":9,"like_count":159,"quote_count":17},"created_at":"2020-12-17T08:23:37.000Z","author_id":"116716199","text":"‚ÄºÔ∏è #COVID19vaccines in the üá™üá∫ will only be authorised when the evidence shows that benefits of a vaccine in protecting people against #COVID19 are far greater than any side effects. \nüëâhttps://t.co/zwy3FHeDpn https://t.co/HygjDURBJ7","id":"1339486395602264064","conversation_id":"1339486395602264064","entities":{"mentions":{},"hashtags":[{"start":3,"end":19,"tag":"COVID19vaccines"},{"start":134,"end":142,"tag":"COVID19"}],"urls":[{"start":184,"end":207,"url":"https://t.co/zwy3FHeDpn","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":208,"end":231,"url":"https://t.co/HygjDURBJ7","expanded_url":"https://twitter.com/EMA_News/status/1339486395602264064/photo/1","display_url":"pic.twitter.com/HygjDURBJ7"}],"annotations":[{"start":27,"end":30,"probability":0.5688,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":["3_1339486237359534085"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":74,"reply_count":11,"like_count":120,"quote_count":16},"created_at":"2020-12-16T14:20:42.000Z","author_id":"116716199","text":"For #COVID19vaccines, speed of development and approval is much faster due to the #publichealthemergency, while the highest standards of quality, safety &amp; efficacy are ensured. Find out how: \nüëâhttps://t.co/zwy3FHeDpn https://t.co/cIBjhFEY1V","id":"1339213868149694464","conversation_id":"1339213868149694464","entities":{"mentions":{},"hashtags":[{"start":4,"end":20,"tag":"COVID19vaccines"},{"start":82,"end":104,"tag":"publichealthemergency"}],"urls":[{"start":197,"end":220,"url":"https://t.co/zwy3FHeDpn","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":221,"end":244,"url":"https://t.co/cIBjhFEY1V","expanded_url":"https://twitter.com/EMA_News/status/1339213868149694464/photo/1","display_url":"pic.twitter.com/cIBjhFEY1V"}],"annotations":{}},"attachments":{"media_keys":["3_1339213810394128386"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":130,"reply_count":125,"like_count":276,"quote_count":43},"created_at":"2020-12-16T11:17:55.000Z","author_id":"116716199","text":"#DYK that #COVID19vaccines go through the same steps as any normal vaccine? \n\nThey are first tested in the lab and in animals, and then in human volunteers: \nüëâhttps://t.co/FlCBPO6esB https://t.co/ky9Hv6IIst","id":"1339167869318344706","conversation_id":"1339167869318344706","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":10,"end":26,"tag":"COVID19vaccines"}],"urls":[{"start":159,"end":182,"url":"https://t.co/FlCBPO6esB","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-vaccines-key-facts","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/ky9Hv6IIst","expanded_url":"https://twitter.com/EMA_News/status/1339167869318344706/photo/1","display_url":"pic.twitter.com/ky9Hv6IIst"}],"annotations":{}},"attachments":{"media_keys":["3_1339167607958753280"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":7,"like_count":41,"quote_count":6},"created_at":"2020-12-16T10:08:39.000Z","author_id":"116716199","text":"üì¢ EMA plays an important role in the development, scientific evaluation, approval and monitoring of #COVID19vaccines in the üá™üá∫\n\nConsult our webpage to see how: \nüëâhttps://t.co/zwy3FHeDpn https://t.co/BZwuBH1SNd","id":"1339150439930093570","conversation_id":"1339150439930093570","entities":{"mentions":{},"hashtags":[{"start":100,"end":116,"tag":"COVID19vaccines"}],"urls":[{"start":162,"end":185,"url":"https://t.co/zwy3FHeDpn","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring","display_url":"ema.europa.eu/en/human-regul‚Ä¶","images":[{"url":"https://pbs.twimg.com/news_img/1493650207191490561/TwXteWIB?format=jpg&name=orig","width":1686,"height":1760},{"url":"https://pbs.twimg.com/news_img/1493650207191490561/TwXteWIB?format=jpg&name=150x150","width":150,"height":150}],"status":200,"title":"COVID-19 vaccines: development, evaluation, approval and monitoring - European Medicines Agency","description":"COVID-19 vaccines: development, evaluation, approval and monitoring","unwound_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-development-evaluation-approval-monitoring"},{"start":186,"end":209,"url":"https://t.co/BZwuBH1SNd","expanded_url":"https://twitter.com/EMA_News/status/1339150439930093570/photo/1","display_url":"pic.twitter.com/BZwuBH1SNd","images":{}}],"annotations":{}},"attachments":{"media_keys":["3_1339150354555015169"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":5,"like_count":68,"quote_count":9},"created_at":"2020-12-16T09:00:02.000Z","author_id":"116716199","text":"Do you have questions about #COVID19vaccines? EMA‚Äôs key facts may have some of the answers: \nüëâhttps://t.co/FlCBPO6esB https://t.co/NhJHn82LLc","id":"1339133171129065473","conversation_id":"1339133171129065473","entities":{"mentions":{},"hashtags":[{"start":28,"end":44,"tag":"COVID19vaccines"}],"urls":[{"start":94,"end":117,"url":"https://t.co/FlCBPO6esB","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-vaccines-key-facts","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":118,"end":141,"url":"https://t.co/NhJHn82LLc","expanded_url":"https://twitter.com/EMA_News/status/1339133171129065473/photo/1","display_url":"pic.twitter.com/NhJHn82LLc"}],"annotations":{}},"attachments":{"media_keys":["3_1339132463587745793"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1338825455525384193"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-16T08:52:23.000Z","author_id":"116716199","text":"RT @EUnetHTA: We are pleased to publish the minutes of the 13 July 2020 meeting held between the European Medicines Agency (EMA) and EUnetH‚Ä¶","id":"1339131246048391169","conversation_id":"1339131246048391169","entities":{"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"}],"hashtags":{},"urls":{},"annotations":[{"start":97,"end":121,"probability":0.4823,"type":"Other","normalized_text":"European Medicines Agency"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":208,"reply_count":21,"like_count":455,"quote_count":175},"created_at":"2020-12-15T13:24:34.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application: https://t.co/7UbMtZn8eK","id":"1338837357034868736","conversation_id":"1338837357034868736","entities":{"mentions":{},"hashtags":{},"urls":[{"start":105,"end":128,"url":"https://t.co/7UbMtZn8eK","expanded_url":"https://www.ema.europa.eu/en/news/update-assessment-biontech-pfizer-bnt162b2-vaccine-marketing-authorisation-application","display_url":"ema.europa.eu/en/news/update‚Ä¶"}],"annotations":[{"start":31,"end":38,"probability":0.5757,"type":"Organization","normalized_text":"BioNTech"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1338744852670976001"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":59,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-15T09:23:37.000Z","author_id":"116716199","text":"RT @EU_Commission: The European Medicines Agency has a solid track record in keeping Europe safe.\n\nThe @EMA_News constantly monitors the sa‚Ä¶","id":"1338776718216228867","conversation_id":"1338776718216228867","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"},{"start":103,"end":112,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":[{"start":23,"end":47,"probability":0.6159,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":85,"end":90,"probability":0.9575,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1337592841552490497"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-14T13:53:19.000Z","author_id":"116716199","text":"@Anja57045056 Please consult this webpage, where information is up-to-date: https://t.co/whFsC6Juwg","id":"1338482201072119810","conversation_id":"1337405686003736589","entities":{"mentions":{},"hashtags":{},"urls":[{"start":76,"end":99,"url":"https://t.co/whFsC6Juwg","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19","display_url":"ema.europa.eu/en/human-regul‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1280143549665890305"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":17,"like_count":49,"quote_count":10},"created_at":"2020-12-14T13:35:04.000Z","author_id":"116716199","text":"EMA held a public meeting on Friday 11 December to inform citizens about its role in the #COVID19 pandemic and the regulatory processes in the üá™üá∫ for the approval of #COVID19vaccines. The recording is available here: https://t.co/hbicN67GBA https://t.co/H4Ni1lne3u","id":"1338477608237936643","conversation_id":"1338477608237936643","entities":{"mentions":{},"hashtags":[{"start":89,"end":97,"tag":"COVID19"},{"start":166,"end":182,"tag":"COVID19vaccines"}],"urls":[{"start":217,"end":240,"url":"https://t.co/hbicN67GBA","expanded_url":"https://www.youtube.com/watch?v=awOTCqIynWI&feature=emb_logo","display_url":"youtube.com/watch?v=awOTCq‚Ä¶"},{"start":241,"end":264,"url":"https://t.co/H4Ni1lne3u","expanded_url":"https://twitter.com/EMA_News/status/1338477608237936643/photo/1","display_url":"pic.twitter.com/H4Ni1lne3u"}],"annotations":[{"start":0,"end":2,"probability":0.4706,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1338477448648929283"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1338170820305199105"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":58,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-14T13:29:37.000Z","author_id":"116716199","text":"RT @EU_Commission: Exceptionally high numbers of people are expected to receive the coronavirus vaccine at the same time. \n \nThe European M‚Ä¶","id":"1338476239762452481","conversation_id":"1338476239762452481","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1338027612698865665"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":103,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-14T13:29:18.000Z","author_id":"116716199","text":"RT @EU_Commission: How do COVID-19 vaccines work?\nHow are we making sure they are safe?\nHow are they developed, authorised and put on the m‚Ä¶","id":"1338476156316749824","conversation_id":"1338476156316749824","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":2,"like_count":26,"quote_count":7},"created_at":"2020-12-14T11:29:09.000Z","author_id":"116716199","text":"EMA will held the first EU #BigData Stakeholder Forum.\n\nüóìÔ∏èTuesday, 15 December 2020\n\nThis event will be held virtually and üé¶broadcast live: https://t.co/DPR7L0nSkQ https://t.co/c4hMHaczqe","id":"1338445921798004737","conversation_id":"1338445921798004737","entities":{"mentions":{},"hashtags":[{"start":27,"end":35,"tag":"BigData"}],"urls":[{"start":140,"end":163,"url":"https://t.co/DPR7L0nSkQ","expanded_url":"https://www.ema.europa.eu/en/events/eu-big-data-stakeholder-virtual-forum","display_url":"ema.europa.eu/en/events/eu-b‚Ä¶"},{"start":164,"end":187,"url":"https://t.co/c4hMHaczqe","expanded_url":"https://twitter.com/EMA_News/status/1338445921798004737/photo/1","display_url":"pic.twitter.com/c4hMHaczqe"}],"annotations":[{"start":0,"end":2,"probability":0.4073,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1338445856987615233"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1337680256900194305"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-14T10:23:29.000Z","author_id":"116716199","text":"RT @EU_Health: Our end of year festivities will look different this year, like much of 2020. \n\nWhilst vaccine development gives us reason t‚Ä¶","id":"1338429397066506240","conversation_id":"1338429397066506240","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1337432735623876612"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-14T10:23:16.000Z","author_id":"116716199","text":"RT @EU_Commission: We all dream about a swift return to normal life. \n\nVaccines are our chance to find a way out of the coronavirus pandemi‚Ä¶","id":"1338429342486048776","conversation_id":"1338429342486048776","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1337410948617949188"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-11T15:32:01.000Z","author_id":"116716199","text":"@fetterkoch96 Millions will get the vaccine in a short time; some of them will develop illnesses for other reasons. Established analysis techniques are in place to assess whether a side effect is likely to be caused by the vaccine.\nhttps://t.co/itypMgHa1w (slide 10)","id":"1337419877515190272","conversation_id":"1337405686003736589","entities":{"mentions":{},"hashtags":{},"urls":[{"start":232,"end":255,"url":"https://t.co/itypMgHa1w","expanded_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-monitoring-covid-19-vaccines-peter-arlett_en.pdf","display_url":"ema.europa.eu/en/documents/p‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1333888071616638979"},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1337407200705261569"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":1,"like_count":3,"quote_count":0},"created_at":"2020-12-11T15:09:47.000Z","author_id":"116716199","text":"@TrishnaBharadia Anyone can report a suspected side effect to their national authority/healthcare professional/vaccine manufacturer. All reports are sent to EudraVigilance, the EU database of suspected side effects:\nhttps://t.co/1XGvo3DWFe","id":"1337414282082996224","conversation_id":"1337405686003736589","entities":{"mentions":[{"start":0,"end":16,"username":"TrishnaBharadia","id":"2964964475"}],"hashtags":{},"urls":[{"start":216,"end":239,"url":"https://t.co/1XGvo3DWFe","expanded_url":"http://www.adrreports.eu/en/report_side_effect.html","display_url":"adrreports.eu/en/report_side‚Ä¶"}],"annotations":[{"start":157,"end":170,"probability":0.3445,"type":"Place","normalized_text":"EudraVigilance"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"2964964475"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":20,"like_count":23,"quote_count":7},"created_at":"2020-12-11T14:35:37.000Z","author_id":"116716199","text":"Send us comments! We will address as many as possible after the meeting, and our responses will be published on EMA‚Äôs website. https://t.co/5VmD0e7gHn #EMAPublicMeeting","id":"1337405686003736589","conversation_id":"1337405686003736589","entities":{"mentions":{},"hashtags":[{"start":151,"end":168,"tag":"EMAPublicMeeting"}],"urls":[{"start":127,"end":150,"url":"https://t.co/5VmD0e7gHn","expanded_url":"https://bit.ly/3qS2lyO","display_url":"bit.ly/3qS2lyO"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1337384557469970432"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":2,"quote_count":1},"created_at":"2020-12-11T13:42:36.000Z","author_id":"116716199","text":"@esno_web @SpringerNature We can address this question via email. Please send it to EMA: https://t.co/5VmD0e7gHn","id":"1337392340760190987","conversation_id":"1337384557469970432","entities":{"mentions":[{"start":0,"end":9,"username":"esno_web","id":"1185837546"},{"start":10,"end":25,"username":"SpringerNature","id":"253588542"}],"hashtags":{},"urls":[{"start":89,"end":112,"url":"https://t.co/5VmD0e7gHn","expanded_url":"https://bit.ly/3qS2lyO","display_url":"bit.ly/3qS2lyO"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1185837546"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":49,"reply_count":9,"like_count":106,"quote_count":4},"created_at":"2020-12-11T13:09:55.000Z","author_id":"116716199","text":"After authorisation, EMA is urging citizens not to get #COVID19vaccines from unauthorised websites &amp; vendors aiming to exploit fears during #COVID19. Citizens should follow official vaccination programmes rather than seeking out alternative sources of vaccines. #EMAPublicMeeting","id":"1337384117940461568","conversation_id":"1337384117940461568","entities":{"mentions":{},"hashtags":[{"start":55,"end":71,"tag":"COVID19vaccines"},{"start":144,"end":152,"tag":"COVID19"},{"start":266,"end":283,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":[{"start":21,"end":23,"probability":0.4375,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":20,"quote_count":1},"created_at":"2020-12-11T13:08:56.000Z","author_id":"116716199","text":"EMA talks to #patients and doctors, pharmacists and nurses, in EMA‚Äôs pandemic task force, in regular meetings and to test information materials. https://t.co/HU0LHfmdJQ #EMAPublicMeeting","id":"1337383869423685635","conversation_id":"1337383869423685635","entities":{"mentions":{},"hashtags":[{"start":13,"end":22,"tag":"patients"},{"start":169,"end":186,"tag":"EMAPublicMeeting"}],"urls":[{"start":145,"end":168,"url":"https://t.co/HU0LHfmdJQ","expanded_url":"https://www.ema.europa.eu/en/partners-networks/patients-consumers/getting-involved","display_url":"ema.europa.eu/en/partners-ne‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.3054,"type":"Person","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":5,"like_count":34,"quote_count":5},"created_at":"2020-12-11T13:08:23.000Z","author_id":"116716199","text":"Check EMA‚Äôs information about:\n‚û°Ô∏èhow #COVID19vaccines are being developed, approved &amp; monitored\n‚û°Ô∏èstudies needed for the approval of these vaccines in the EU.\nhttps://t.co/whFsC6Juwg #EMAPublicMeeting","id":"1337383730869121024","conversation_id":"1337383730869121024","entities":{"mentions":{},"hashtags":[{"start":37,"end":53,"tag":"COVID19vaccines"},{"start":187,"end":204,"tag":"EMAPublicMeeting"}],"urls":[{"start":163,"end":186,"url":"https://t.co/whFsC6Juwg","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19","display_url":"ema.europa.eu/en/human-regul‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":2,"like_count":68,"quote_count":7},"created_at":"2020-12-11T13:06:36.000Z","author_id":"116716199","text":"Once a #COVID19vaccine is authorised in the üá™üá∫, EMA will publish:\n‚û°Ô∏èProduct info\n‚û°Ô∏èSummary of assessment in lay language  \n‚û°Ô∏èEuropean Public Assessment Report\n‚û°Ô∏èFull risk management plan\n‚û°Ô∏èClinical data supporting authorisation\n‚û°Ô∏èRegular safety updates\n#EMAPublicMeeting","id":"1337383282338648065","conversation_id":"1337383282338648065","entities":{"mentions":{},"hashtags":[{"start":7,"end":22,"tag":"COVID19vaccine"},{"start":253,"end":270,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":1,"like_count":37,"quote_count":4},"created_at":"2020-12-11T13:05:09.000Z","author_id":"116716199","text":"EMA will provide an unprecedented level of transparency and data access for all #COVID19 medicines. Find out more about EMA‚Äôs communication and increased transparency measures in this presentation: https://t.co/QVdpeTjrpe #EMAPublicMeeting","id":"1337382916284952577","conversation_id":"1337382916284952577","entities":{"mentions":{},"hashtags":[{"start":80,"end":88,"tag":"COVID19"},{"start":222,"end":239,"tag":"EMAPublicMeeting"}],"urls":[{"start":198,"end":221,"url":"https://t.co/QVdpeTjrpe","expanded_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-transparency-engagement-communication-melanie-carr_en.pdf","display_url":"ema.europa.eu/en/documents/p‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.6853,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":3,"like_count":37,"quote_count":2},"created_at":"2020-12-11T13:03:58.000Z","author_id":"116716199","text":"Do you want to know more about safety of #COVID19vaccines? Consult this presentation: https://t.co/itypMgHa1w #EMAPublicMeeting","id":"1337382621286981633","conversation_id":"1337382621286981633","entities":{"mentions":{},"hashtags":[{"start":41,"end":57,"tag":"COVID19vaccines"},{"start":110,"end":127,"tag":"EMAPublicMeeting"}],"urls":[{"start":86,"end":109,"url":"https://t.co/itypMgHa1w","expanded_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-safety-monitoring-covid-19-vaccines-peter-arlett_en.pdf","display_url":"ema.europa.eu/en/documents/p‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":2,"like_count":20,"quote_count":1},"created_at":"2020-12-11T13:03:01.000Z","author_id":"116716199","text":"#COVID19vaccines safety gets stronger with your participation! Patients and healthcare professionals play a critical role in reporting suspected side effects. #EMAPublicMeeting","id":"1337382381414719490","conversation_id":"1337382381414719490","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"},{"start":159,"end":176,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":32,"quote_count":1},"created_at":"2020-12-11T13:02:03.000Z","author_id":"116716199","text":"Established side effects detected during #ClinicalTrials with #COVID19vaccines will be included in the package leaflet that is available to #patients. #EMAPublicMeeting","id":"1337382138077917184","conversation_id":"1337382138077917184","entities":{"mentions":{},"hashtags":[{"start":41,"end":56,"tag":"ClinicalTrials"},{"start":62,"end":78,"tag":"COVID19vaccines"},{"start":140,"end":149,"tag":"patients"},{"start":151,"end":168,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":2,"like_count":12,"quote_count":1},"created_at":"2020-12-11T12:57:40.000Z","author_id":"116716199","text":"EMA has a detailed plan to monitor #COVID19vaccines safety in practice and to act immediately to protect the health of EU citizens: https://t.co/QIl4Yeb6Cx #EMAPublicMeeting","id":"1337381035261235205","conversation_id":"1337381035261235205","entities":{"mentions":{},"hashtags":[{"start":35,"end":51,"tag":"COVID19vaccines"},{"start":156,"end":173,"tag":"EMAPublicMeeting"}],"urls":[{"start":132,"end":155,"url":"https://t.co/QIl4Yeb6Cx","expanded_url":"https://www.ema.europa.eu/en/news/ema-publishes-safety-monitoring-plan-guidance-risk-management-planning-covid-19-vaccines","display_url":"ema.europa.eu/en/news/ema-pu‚Ä¶","images":[{"url":"https://pbs.twimg.com/news_img/1452661236345286665/0Gmk7biD?format=png&name=orig","width":683,"height":512},{"url":"https://pbs.twimg.com/news_img/1452661236345286665/0Gmk7biD?format=png&name=150x150","width":150,"height":150}],"status":200,"title":"EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines - European Medicines Agency","description":"EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines","unwound_url":"https://www.ema.europa.eu/en/news/ema-publishes-safety-monitoring-plan-guidance-risk-management-planning-covid-19-vaccines"}],"annotations":[{"start":0,"end":2,"probability":0.4563,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":3,"like_count":34,"quote_count":5},"created_at":"2020-12-11T12:51:19.000Z","author_id":"116716199","text":"Do you want to know more about the evaluation and approval of #COVID19vaccines? Consult üîéthis presentation: \n‚û°Ô∏èhttps://t.co/g5myplBEbe \n#EMAPublicMeeting","id":"1337379434853265408","conversation_id":"1337379434853265408","entities":{"mentions":{},"hashtags":[{"start":62,"end":78,"tag":"COVID19vaccines"},{"start":136,"end":153,"tag":"EMAPublicMeeting"}],"urls":[{"start":111,"end":134,"url":"https://t.co/g5myplBEbe","expanded_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-eus-regulatory-process-evaluation-approval-vaccines-fergus-sweeney_en.pdf","display_url":"ema.europa.eu/en/documents/p‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":5,"like_count":49,"quote_count":1},"created_at":"2020-12-11T12:37:34.000Z","author_id":"116716199","text":"The üá™üá∫ has a strict and robust safety monitoring system to ensure #COVID19 vaccines‚Äô benefits are always higher than any potential risk. #EMAPublicMeeting","id":"1337375974531473408","conversation_id":"1337375974531473408","entities":{"mentions":{},"hashtags":[{"start":66,"end":74,"tag":"COVID19"},{"start":137,"end":154,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":[{"start":4,"end":7,"probability":0.3892,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":29,"quote_count":0},"created_at":"2020-12-11T12:34:14.000Z","author_id":"116716199","text":"Do you have more questions on how #COVID19 vaccines are developed? Check out this presentation: https://t.co/WZmVjqbhQ5 #EMAPublicMeeting","id":"1337375136752787461","conversation_id":"1337375136752787461","entities":{"mentions":{},"hashtags":[{"start":34,"end":42,"tag":"COVID19"},{"start":120,"end":137,"tag":"EMAPublicMeeting"}],"urls":[{"start":96,"end":119,"url":"https://t.co/WZmVjqbhQ5","expanded_url":"https://www.ema.europa.eu/en/documents/presentation/presentation-how-are-covid-19-vaccines-developed-marco-cavaleri_en.pdf","display_url":"ema.europa.eu/en/documents/p‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":4,"like_count":75,"quote_count":9},"created_at":"2020-12-11T12:15:15.000Z","author_id":"116716199","text":"#COVID19vaccines development and evaluation are compressed in time, but they will be approved according to the same high standards that apply to all üíä in the üá™üá∫. https://t.co/whFsC6Juwg #EMAPublicMeeting","id":"1337370358345838593","conversation_id":"1337370358345838593","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"COVID19vaccines"},{"start":186,"end":203,"tag":"EMAPublicMeeting"}],"urls":[{"start":162,"end":185,"url":"https://t.co/whFsC6Juwg","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19","display_url":"ema.europa.eu/en/human-regul‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":1,"like_count":19,"quote_count":0},"created_at":"2020-12-11T12:06:47.000Z","author_id":"116716199","text":"Views received during the public meeting will be shared with EMA and its experts and will be taken into consideration during the evaluation and continued monitoring of #COVID19vaccines. #EMAPublicMeeting","id":"1337368227685470208","conversation_id":"1337368227685470208","entities":{"mentions":{},"hashtags":[{"start":168,"end":184,"tag":"COVID19vaccines"},{"start":186,"end":203,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":[{"start":61,"end":63,"probability":0.3501,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":2,"like_count":23,"quote_count":1},"created_at":"2020-12-11T12:04:30.000Z","author_id":"116716199","text":"Follow our Twitter posts during the COVID-19 vaccines public meeting, by using the hashtag #EMAPublicMeeting.","id":"1337367655641206785","conversation_id":"1337367655641206785","entities":{"mentions":{},"hashtags":[{"start":91,"end":108,"tag":"EMAPublicMeeting"}],"urls":{},"annotations":[{"start":11,"end":17,"probability":0.7075,"type":"Product","normalized_text":"Twitter"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":3,"like_count":59,"quote_count":19},"created_at":"2020-12-11T12:03:58.000Z","author_id":"116716199","text":"We are starting the public meeting on #COVID19vaccines. \nJoin us to learn more of the EU scientific evaluation for #COVID19vaccines and to hear the voice of people on this subject: https://t.co/G5euT56KO3\n\n#EMAPublicMeeting","id":"1337367519984840706","conversation_id":"1337367519984840706","entities":{"mentions":{},"hashtags":[{"start":38,"end":54,"tag":"COVID19vaccines"},{"start":115,"end":131,"tag":"COVID19vaccines"},{"start":206,"end":223,"tag":"EMAPublicMeeting"}],"urls":[{"start":181,"end":204,"url":"https://t.co/G5euT56KO3","expanded_url":"https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu","display_url":"ema.europa.eu/en/events/publ‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":3,"like_count":22,"quote_count":0},"created_at":"2020-12-11T11:50:22.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 15 #medicines for approval at its December 2020 meeting https://t.co/lgTMdY4om6 https://t.co/i9z04sCa26","id":"1337364098967871488","conversation_id":"1337364098967871488","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":54,"end":64,"tag":"medicines"}],"urls":[{"start":107,"end":130,"url":"https://t.co/lgTMdY4om6","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-7-10-december-2020","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":131,"end":154,"url":"https://t.co/i9z04sCa26","expanded_url":"https://twitter.com/EMA_News/status/1337364098967871488/photo/1","display_url":"pic.twitter.com/i9z04sCa26"}],"annotations":[{"start":0,"end":2,"probability":0.4397,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1337364045431787527"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":46,"reply_count":5,"like_count":57,"quote_count":34},"created_at":"2020-12-11T08:00:00.000Z","author_id":"116716199","text":"Don't miss our public meeting on #COVID19vaccines\n\nüóìÔ∏è 11 Dec 2020, 13:00 - 16:30 CET\n\nThe event will beüî¥live broadcast. No registration needed: https://t.co/G5euT56KO3 \n\n#EMAPublicMeeting #VaccinesWork #VaccinesWork https://t.co/lCBPIRw8LA","id":"1337306123926433793","conversation_id":"1337306123926433793","entities":{"mentions":{},"hashtags":[{"start":33,"end":49,"tag":"COVID19vaccines"},{"start":170,"end":187,"tag":"EMAPublicMeeting"},{"start":188,"end":201,"tag":"VaccinesWork"},{"start":202,"end":215,"tag":"VaccinesWork"}],"urls":[{"start":144,"end":167,"url":"https://t.co/G5euT56KO3","expanded_url":"https://www.ema.europa.eu/en/events/public-stakeholder-meeting-development-authorisation-safe-effective-covid-19-vaccines-eu","display_url":"ema.europa.eu/en/events/publ‚Ä¶"},{"start":216,"end":239,"url":"https://t.co/lCBPIRw8LA","expanded_url":"https://twitter.com/EMA_News/status/1337306123926433793/photo/1","display_url":"pic.twitter.com/lCBPIRw8LA"}],"annotations":{}},"attachments":{"media_keys":["3_1337072815678304262"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1337060013697884161"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-10T15:52:41.000Z","author_id":"116716199","text":"RT @EU_Commission: Europe already has a robust system to ensure long-term vaccine safety.\n\nThe European Medicines Agency has a solid track‚Ä¶","id":"1337062691366707202","conversation_id":"1337062691366707202","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":[{"start":19,"end":24,"probability":0.977,"type":"Place","normalized_text":"Europe"},{"start":95,"end":119,"probability":0.5334,"type":"Organization","normalized_text":"European Medicines Agency"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336932410064302084"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":86,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-10T08:25:51.000Z","author_id":"116716199","text":"RT @EU_Commission: Vaccines are used worldwide to protect people from contracting infectious diseases. They also help prevent the spread of‚Ä¶","id":"1336950239761227776","conversation_id":"1336950239761227776","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336715856731103233"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T16:55:44.000Z","author_id":"116716199","text":"RT @europarlAV: üî¥Don't miss on 10th December, @EP_Environment will discuss the assessment &amp; authorization of vaccines against #COVID19 W/ E‚Ä¶","id":"1336716170746093577","conversation_id":"1336716170746093577","entities":{"mentions":[{"start":3,"end":14,"username":"europarlAV","id":"570018183"},{"start":46,"end":61,"username":"EP_Environment","id":"951333319"}],"hashtags":[{"start":130,"end":138,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336675100658176001"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":119,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T14:24:14.000Z","author_id":"116716199","text":"RT @EUCouncil: Developing a new vaccine usually takes years ‚Äì but not this time! üíâ\n\nWatch the video üëá to find out why and how the EU has be‚Ä¶","id":"1336678044929568768","conversation_id":"1336678044929568768","entities":{"mentions":[{"start":3,"end":13,"username":"EUCouncil","id":"206717989"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336642494910640133"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T13:03:34.000Z","author_id":"116716199","text":"RT @EU_ECHA: Products such as cosmeticsüíÑ, detergentsüßº&amp; the infill on artificial football pitches‚öΩcan contain #microplastics that end up in‚Ä¶","id":"1336657742975676418","conversation_id":"1336657742975676418","entities":{"mentions":[{"start":3,"end":11,"username":"EU_ECHA","id":"331604970"}],"hashtags":[{"start":113,"end":127,"tag":"microplastics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336570022093852673"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":105,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T11:38:19.000Z","author_id":"116716199","text":"RT @EU_Commission: Vaccines are our best chance to put an end to the pandemic.\n\nWe make sure they are safe and effective through a rigorous‚Ä¶","id":"1336636289534349313","conversation_id":"1336636289534349313","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336345959056494596"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":72,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T09:20:59.000Z","author_id":"116716199","text":"RT @EU_Commission: Vaccines undergo rigorous assessment before they can be made available in the EU.\n\nThe future coronavirus vaccine is no‚Ä¶","id":"1336601726716096512","conversation_id":"1336601726716096512","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336573797860855809"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T09:20:50.000Z","author_id":"116716199","text":"RT @EUCouncil: EU leaders will discuss coordination on vaccines and testing strategies at #EUCO in Brussels this 10-11 December. Subscribe‚Ä¶","id":"1336601688380231681","conversation_id":"1336601688380231681","entities":{"mentions":[{"start":3,"end":13,"username":"EUCouncil","id":"206717989"}],"hashtags":[{"start":90,"end":95,"tag":"EUCO"}],"urls":{},"annotations":[{"start":15,"end":16,"probability":0.668,"type":"Organization","normalized_text":"EU"},{"start":99,"end":106,"probability":0.9681,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336597606437416960"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-09T09:19:44.000Z","author_id":"116716199","text":"RT @edqm_news: EDQM and #EuropeanCommission build on 10 years of co-operation to support a more sustainable #blood supply and resilient blo‚Ä¶","id":"1336601412445351942","conversation_id":"1336601412445351942","entities":{"mentions":[{"start":3,"end":13,"username":"edqm_news","id":"2242197968"}],"hashtags":[{"start":24,"end":43,"tag":"EuropeanCommission"},{"start":108,"end":114,"tag":"blood"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336296826941673472"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":66,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T14:48:21.000Z","author_id":"116716199","text":"RT @EU_Commission: When a vaccinated person is exposed to the coronavirus, their natural defences recognise the virus and are ready to kill‚Ä¶","id":"1336321724548145154","conversation_id":"1336321724548145154","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336294366298697730"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":383,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T14:47:49.000Z","author_id":"116716199","text":"RT @EU_Health: We know #VaccinesWork: they eradicated smallpox and have virtually eliminated other diseases like polio.\n\nSafe and effective‚Ä¶","id":"1336321588552077315","conversation_id":"1336321588552077315","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":23,"end":36,"tag":"VaccinesWork"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":2,"like_count":45,"quote_count":3},"created_at":"2020-12-08T13:23:49.000Z","author_id":"116716199","text":"üì¢ We have just published a joint strategy that sets the direction for EMA and EU medicines regulatory agencies to 2025: https://t.co/U3LtGoeK9L https://t.co/FeHno1gXyK","id":"1336300450497355777","conversation_id":"1336300450497355777","entities":{"mentions":{},"hashtags":{},"urls":[{"start":120,"end":143,"url":"https://t.co/U3LtGoeK9L","expanded_url":"https://www.ema.europa.eu/en/news/joint-strategy-sets-direction-ema-eu-medicines-regulatory-agencies-2025","display_url":"ema.europa.eu/en/news/joint-‚Ä¶"},{"start":144,"end":167,"url":"https://t.co/FeHno1gXyK","expanded_url":"https://twitter.com/EMA_News/status/1336300450497355777/photo/1","display_url":"pic.twitter.com/FeHno1gXyK"}],"annotations":[{"start":71,"end":73,"probability":0.6863,"type":"Organization","normalized_text":"EMA"},{"start":79,"end":80,"probability":0.8355,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1336300294867738627"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336218221951725568"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T09:38:48.000Z","author_id":"116716199","text":"RT @EU_Health: The European Vaccination Information Portal (#EVIP) has been updated withüÜïmultilingual content on #coronavirus &amp; the steps t‚Ä¶","id":"1336243824952274944","conversation_id":"1336243824952274944","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":60,"end":65,"tag":"EVIP"},{"start":113,"end":125,"tag":"coronavirus"}],"urls":{},"annotations":[{"start":15,"end":57,"probability":0.3245,"type":"Other","normalized_text":"The European Vaccination Information Portal"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1336207634408607745"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":53,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T08:42:44.000Z","author_id":"116716199","text":"RT @EU_Commission: Safety &amp; effectiveness ‚Äì these are the 2 watchwords when it comes to vaccines.\n\nAll vaccines go through rigorous scienti‚Ä¶","id":"1336229716093710336","conversation_id":"1336229716093710336","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1335978246794567684"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T08:40:51.000Z","author_id":"116716199","text":"RT @EU_Health: How do we protect the most vulnerable from the #coronavirus?\n\nJoin us and Commissioner @SKyriakidesEU &amp; many others in a web‚Ä¶","id":"1336229240396713986","conversation_id":"1336229240396713986","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":102,"end":116,"username":"SKyriakidesEU","id":"2476130260"}],"hashtags":[{"start":62,"end":74,"tag":"coronavirus"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1335968055835435015"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":115,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-08T08:08:49.000Z","author_id":"116716199","text":"RT @EU_Commission: A vaccine for coronavirus is on its way. And the EU has a rigorous authorisation process in place to ensure it is safe a‚Ä¶","id":"1336221180861231107","conversation_id":"1336221180861231107","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":[{"start":68,"end":69,"probability":0.6193,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":6,"like_count":11,"quote_count":1},"created_at":"2020-12-07T12:28:41.000Z","author_id":"116716199","text":"What's on the agenda of the December meeting of EMA's human medicines committee: https://t.co/uzAU47n3Ll #CHMP","id":"1335924187609903104","conversation_id":"1335924187609903104","entities":{"mentions":{},"hashtags":[{"start":105,"end":110,"tag":"CHMP"}],"urls":[{"start":81,"end":104,"url":"https://t.co/uzAU47n3Ll","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-7-10-december-2020-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":48,"end":50,"probability":0.2865,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1334401425162506241"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":68,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-07T12:00:49.000Z","author_id":"116716199","text":"RT @EU_Health: #Coronavirus: the solution will come through vaccination &amp; there is light at the end of the tunnel\n\nBut to get there, we nee‚Ä¶","id":"1335917176201555972","conversation_id":"1335917176201555972","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":27,"tag":"Coronavirus"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1333749824898916356"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":11,"quote_count":0},"created_at":"2020-12-07T11:49:56.000Z","author_id":"116716199","text":"EMA has contributed to two regulatory training modules to the ADVANCE course on advanced therapy medicinal products: https://t.co/3dvmk4KEeV #ATMP https://t.co/mzL8owXp0Y","id":"1335914434984861696","conversation_id":"1335914434984861696","entities":{"mentions":{},"hashtags":[{"start":141,"end":146,"tag":"ATMP"}],"urls":[{"start":117,"end":140,"url":"https://t.co/3dvmk4KEeV","expanded_url":"https://loom.ly/rwwW9Lg","display_url":"loom.ly/rwwW9Lg","status":200,"unwound_url":"https://eatris.eu/events/eatris-ai-symposium-how-the-emerging-role-of-artificial-intelligence-ai-in-translational-medicine-can-jump-start-a-new-era-in-medical-care/"},{"start":147,"end":170,"url":"https://t.co/mzL8owXp0Y","expanded_url":"https://twitter.com/ADVANCE_atmp/status/1333749824898916356","display_url":"twitter.com/ADVANCE_atmp/s‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.6751,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1334496096555577350"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":78,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-03T15:04:29.000Z","author_id":"116716199","text":"RT @ECDC_EU: #JustPublished\nUpdated weekly üö¶ maps are now online!\n\nThese maps aim to support the @EUCouncil Recommendation on a coordinated‚Ä¶","id":"1334513844278923268","conversation_id":"1334513844278923268","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":97,"end":107,"username":"EUCouncil","id":"206717989"}],"hashtags":[{"start":13,"end":27,"tag":"JustPublished"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":10,"like_count":78,"quote_count":11},"created_at":"2020-12-01T13:15:58.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA starts a rolling review of Janssen‚Äôs #COVID19vaccine: üëâhttps://t.co/4M4ffy1YpK","id":"1333761759136649218","conversation_id":"1333761759136649218","entities":{"mentions":{},"hashtags":[{"start":44,"end":59,"tag":"COVID19vaccine"}],"urls":[{"start":62,"end":85,"url":"https://t.co/4M4ffy1YpK","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-janssens-covid-19-vaccine-ad26cov2s","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"}],"annotations":[{"start":34,"end":40,"probability":0.8146,"type":"Person","normalized_text":"Janssen"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1333733516635418626"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-01T11:56:56.000Z","author_id":"116716199","text":"RT @EU_Commission: The EU has a rigourous process in place to ensure the same high standards for any vaccine on Europe's market.\n\nThis is n‚Ä¶","id":"1333741870644670464","conversation_id":"1333741870644670464","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":[{"start":23,"end":24,"probability":0.4886,"type":"Organization","normalized_text":"EU"},{"start":112,"end":117,"probability":0.9715,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":172,"reply_count":22,"like_count":249,"quote_count":62},"created_at":"2020-12-01T11:00:40.000Z","author_id":"116716199","text":"‚ÄºÔ∏è BioNTech/Pfizer and Moderna have submitted to EMA applications for their #Covid19vaccines. \nüëâhttps://t.co/oiSxaqec3L https://t.co/0KeX14cjQ2","id":"1333727712331112449","conversation_id":"1333727712331112449","entities":{"mentions":{},"hashtags":[{"start":76,"end":92,"tag":"Covid19vaccines"}],"urls":[{"start":96,"end":119,"url":"https://t.co/oiSxaqec3L","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines-covid-19#medicines-undergoing-evaluation-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":120,"end":143,"url":"https://t.co/0KeX14cjQ2","expanded_url":"https://twitter.com/EMA_News/status/1333727712331112449/photo/1","display_url":"pic.twitter.com/0KeX14cjQ2"}],"annotations":[{"start":12,"end":17,"probability":0.6772,"type":"Organization","normalized_text":"Pfizer"},{"start":23,"end":29,"probability":0.5766,"type":"Organization","normalized_text":"Moderna"}]},"attachments":{"media_keys":["3_1333727636821069824"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1333657154792919040"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":56,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-12-01T09:51:06.000Z","author_id":"116716199","text":"RT @EU_Health: #WorldAidsDay: despite significant progress in recent years, HIV still remains a major public health concern &amp; earlier diagn‚Ä¶","id":"1333710205591433216","conversation_id":"1333710205591433216","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":28,"tag":"WorldAidsDay"}],"urls":{},"annotations":[{"start":76,"end":78,"probability":0.7042,"type":"Other","normalized_text":"HIV"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1333073861609447425"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":211,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-30T09:23:12.000Z","author_id":"116716199","text":"RT @EU_Commission: The year behind us is a story of endurance.\n\nWe have adapted to unforeseen and dramatic circumstances, and worked to get‚Ä¶","id":"1333340795664027651","conversation_id":"1333340795664027651","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":5,"like_count":38,"quote_count":9},"created_at":"2020-11-27T15:13:53.000Z","author_id":"116716199","text":"Global regulators urge the continuation of #COVID19vaccine trials for longer-term safety and efficacy follow-up: \nüëâhttps://t.co/7HGs9d38FD #ClinicalTrials #COVID19 https://t.co/Uj7wxL3u33","id":"1332341884124082176","conversation_id":"1332341884124082176","entities":{"mentions":{},"hashtags":[{"start":43,"end":58,"tag":"COVID19vaccine"},{"start":139,"end":154,"tag":"ClinicalTrials"},{"start":155,"end":163,"tag":"COVID19"}],"urls":[{"start":115,"end":138,"url":"https://t.co/7HGs9d38FD","expanded_url":"https://www.ema.europa.eu/en/news/global-regulators-urge-continuation-covid-19-vaccine-trials-longer-term-safety-efficacy-follow","display_url":"ema.europa.eu/en/news/global‚Ä¶"},{"start":164,"end":187,"url":"https://t.co/Uj7wxL3u33","expanded_url":"https://twitter.com/EMA_News/status/1332341884124082176/photo/1","display_url":"pic.twitter.com/Uj7wxL3u33"}],"annotations":{}},"attachments":{"media_keys":["3_1332340582203711493"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":6,"like_count":35,"quote_count":19},"created_at":"2020-11-27T11:45:46.000Z","author_id":"116716199","text":"PRAC meeting highlights Nov-Dec: EMA's safety committee, the PRAC, concluded a review that confirms a link between the use of chloroquine &amp; hydroxychloroquine and the risk of psychiatric disorders &amp; suicidal behaviour:  https://t.co/KV5y9zSUdN #pharmacovigilance https://t.co/9txYSeDSec","id":"1332289507824201736","conversation_id":"1332289507824201736","entities":{"mentions":{},"hashtags":[{"start":252,"end":270,"tag":"pharmacovigilance"}],"urls":[{"start":228,"end":251,"url":"https://t.co/KV5y9zSUdN","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-23-26-november-2020","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":271,"end":294,"url":"https://t.co/9txYSeDSec","expanded_url":"https://twitter.com/EMA_News/status/1332289507824201736/photo/1","display_url":"pic.twitter.com/9txYSeDSec"}],"annotations":{}},"attachments":{"media_keys":["3_1332289320414273543"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":1,"like_count":54,"quote_count":1},"created_at":"2020-11-26T10:51:58.000Z","author_id":"116716199","text":"EMA has published a paper on the recent fee waiver for academic organisations developing #OrphanMedicines. An important milestone to further encourage the development of medicines for #RareDiseases. Read more here: https://t.co/eq1KPwskqS https://t.co/xuZzy18GsP","id":"1331913584578883591","conversation_id":"1331913584578883591","entities":{"mentions":{},"hashtags":[{"start":89,"end":105,"tag":"OrphanMedicines"},{"start":184,"end":197,"tag":"RareDiseases"}],"urls":[{"start":215,"end":238,"url":"https://t.co/eq1KPwskqS","expanded_url":"https://www.nature.com/articles/d41573-020-00205-x","display_url":"nature.com/articles/d4157‚Ä¶"},{"start":239,"end":262,"url":"https://t.co/xuZzy18GsP","expanded_url":"https://twitter.com/EMA_News/status/1331913584578883591/photo/1","display_url":"pic.twitter.com/xuZzy18GsP"}],"annotations":[{"start":0,"end":2,"probability":0.5855,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1331913480270647328"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1330877658272571396"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-25T15:19:40.000Z","author_id":"116716199","text":"RT @edqm_news: #EDQM releases updated European #Pharmacopoeia #PhEur vaccines package for #COVID19 #vaccine developers\nhttps://t.co/rtEPn1b‚Ä¶","id":"1331618562428039168","conversation_id":"1331618562428039168","entities":{"mentions":[{"start":3,"end":13,"username":"edqm_news","id":"2242197968"}],"hashtags":[{"start":15,"end":20,"tag":"EDQM"},{"start":47,"end":61,"tag":"Pharmacopoeia"},{"start":62,"end":68,"tag":"PhEur"},{"start":90,"end":98,"tag":"COVID19"},{"start":99,"end":107,"tag":"vaccine"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1331602718532771841"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-25T15:19:27.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (25.11.2020)\n\nGlobal:\n‚ñ™ 59 879 877 cases\n‚ñ™ 1 410 082 deaths\n\nEU/EEA/UK:\n‚ñ™ 12 359 852 cases\n‚ñ™ 302 641 d‚Ä¶","id":"1331618510653501442","conversation_id":"1331618510653501442","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6804,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1331580942671097857"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":90,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-25T13:17:30.000Z","author_id":"116716199","text":"RT @EU_Health: #HealthUnion: launch of the #EUPharmaStrategy to: \n\nüëâ Improve patients‚Äô access to affordable medicines\nüëâ Address unmet medic‚Ä¶","id":"1331587819794477063","conversation_id":"1331587819794477063","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":27,"tag":"HealthUnion"},{"start":43,"end":60,"tag":"EUPharmaStrategy"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":2,"like_count":57,"quote_count":6},"created_at":"2020-11-25T12:34:29.000Z","author_id":"116716199","text":"Have your voice heard ‚ÄºÔ∏è Register to make an intervention during the EMA public meeting on 11 Dec that will inform citizens about our role in the #COVID19 pandemic and  regulatory procedures in the üá™üá∫https://t.co/zugwhqViLl https://t.co/qhfdbQAcDv","id":"1331576994908278784","conversation_id":"1331576994908278784","entities":{"mentions":{},"hashtags":[{"start":146,"end":154,"tag":"COVID19"}],"urls":[{"start":200,"end":223,"url":"https://t.co/zugwhqViLl","expanded_url":"https://ec.europa.eu/eusurvey/runner/SpeakerApplicationForm_EMAPublicStakeholderMeetingCOVID-19","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":224,"end":247,"url":"https://t.co/qhfdbQAcDv","expanded_url":"https://twitter.com/EMA_News/status/1331576994908278784/photo/1","display_url":"pic.twitter.com/qhfdbQAcDv"}],"annotations":{}},"attachments":{"media_keys":["3_1331576768797564928"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":4,"like_count":37,"quote_count":2},"created_at":"2020-11-23T15:09:35.000Z","author_id":"116716199","text":"There are over 6,000 #RareDiseases that affect about 30 million people in the üá™üá∫. On Monday, 30 Nov, EMA is organising a workshop on regulatory support for development of #OrphanMedicines: \nüëâhttps://t.co/bFIag7koda https://t.co/jWsFrZX86O","id":"1330891251172913154","conversation_id":"1330891251172913154","entities":{"mentions":{},"hashtags":[{"start":21,"end":34,"tag":"RareDiseases"},{"start":171,"end":187,"tag":"OrphanMedicines"}],"urls":[{"start":191,"end":214,"url":"https://t.co/bFIag7koda","expanded_url":"https://www.ema.europa.eu/en/news/workshop-regulatory-support-development-orphan-medicines","display_url":"ema.europa.eu/en/news/worksh‚Ä¶"},{"start":215,"end":238,"url":"https://t.co/jWsFrZX86O","expanded_url":"https://twitter.com/EMA_News/status/1330891251172913154/photo/1","display_url":"pic.twitter.com/jWsFrZX86O"}],"annotations":{}},"attachments":{"media_keys":["16_1330891141852635137"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":3,"like_count":28,"quote_count":0},"created_at":"2020-11-23T13:34:48.000Z","author_id":"116716199","text":"#AMR is a major threat to #publichealth. Continued research in all aspects of #AntimicrobialResistance is crucial for fighting #superbugs. https://t.co/RIBFraLTrz","id":"1330867397520191490","conversation_id":"1330867397520191490","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"AMR"},{"start":26,"end":39,"tag":"publichealth"},{"start":78,"end":102,"tag":"AntimicrobialResistance"},{"start":127,"end":137,"tag":"superbugs"}],"urls":[{"start":139,"end":162,"url":"https://t.co/RIBFraLTrz","expanded_url":"https://twitter.com/EMA_News/status/1330867397520191490/photo/1","display_url":"pic.twitter.com/RIBFraLTrz"}],"annotations":{}},"attachments":{"media_keys":["3_1330867337117970432"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":18,"quote_count":5},"created_at":"2020-11-20T13:18:41.000Z","author_id":"116716199","text":"How can EU veterinarians find out which antibiotics they should use? Have a look üîéat the AMEG infographic , available in all üá™üá∫ languages! https://t.co/BEo8jdIIuW #EAAD2020 https://t.co/SSmqUxO4rF","id":"1329776178480226305","conversation_id":"1329776178480226305","entities":{"mentions":{},"hashtags":[{"start":163,"end":172,"tag":"EAAD2020"}],"urls":[{"start":139,"end":162,"url":"https://t.co/BEo8jdIIuW","expanded_url":"https://www.ema.europa.eu/en/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":173,"end":196,"url":"https://t.co/SSmqUxO4rF","expanded_url":"https://twitter.com/EMA_News/status/1329776178480226305/photo/1","display_url":"pic.twitter.com/SSmqUxO4rF"}],"annotations":{}},"attachments":{"media_keys":["3_1329776110243110912"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":1,"like_count":10,"quote_count":0},"created_at":"2020-11-20T11:24:03.000Z","author_id":"116716199","text":"Global health leaders and decision-makers can increase incentives for new #antibiotics and reward companies that develop them. #AMR #OneHealth #ICMRA https://t.co/muG9PdZZ58","id":"1329747327603646466","conversation_id":"1329747327603646466","entities":{"mentions":{},"hashtags":[{"start":74,"end":86,"tag":"antibiotics"},{"start":127,"end":131,"tag":"AMR"},{"start":132,"end":142,"tag":"OneHealth"},{"start":143,"end":149,"tag":"ICMRA"}],"urls":[{"start":150,"end":173,"url":"https://t.co/muG9PdZZ58","expanded_url":"https://twitter.com/EMA_News/status/1329747327603646466/photo/1","display_url":"pic.twitter.com/muG9PdZZ58"}],"annotations":{}},"attachments":{"media_keys":["3_1329747318069977088"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":24,"quote_count":2},"created_at":"2020-11-20T08:00:09.000Z","author_id":"116716199","text":"As a #patient, by using #antibiotics responsibly you can protect people who are especially vulnerable to infections. #EAAD2020 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/BZsqwgHDRN https://t.co/weSibXMjjQ","id":"1329696016640192514","conversation_id":"1329696016640192514","entities":{"mentions":{},"hashtags":[{"start":5,"end":13,"tag":"patient"},{"start":24,"end":36,"tag":"antibiotics"},{"start":117,"end":126,"tag":"EAAD2020"},{"start":127,"end":150,"tag":"KeepAntibioticsWorking"},{"start":151,"end":172,"tag":"AntibioticResistance"},{"start":173,"end":177,"tag":"AMR"}],"urls":[{"start":178,"end":201,"url":"https://t.co/BZsqwgHDRN","expanded_url":"https://www.ema.europa.eu/en/news/ema-marks-european-antibiotic-awareness-day","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":202,"end":225,"url":"https://t.co/weSibXMjjQ","expanded_url":"https://twitter.com/EMA_News/status/1329696016640192514/photo/1","display_url":"pic.twitter.com/weSibXMjjQ"}],"annotations":{}},"attachments":{"media_keys":["3_1329696006548705281"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1329427193974370306"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":74,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-19T16:32:28.000Z","author_id":"116716199","text":"RT @ECDC_EU: #JustPublished\nUpdated weekly üö¶ maps are now online!\n\nThese maps aim to support the @EUCouncil Recommendation on a coordinated‚Ä¶","id":"1329462559146176521","conversation_id":"1329462559146176521","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":97,"end":107,"username":"EUCouncil","id":"206717989"}],"hashtags":[{"start":13,"end":27,"tag":"JustPublished"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":13,"quote_count":4},"created_at":"2020-11-19T14:09:32.000Z","author_id":"116716199","text":"#DYK Sales of veterinary antibiotics in üá™üá∫ declined by more than 34% (2011-2018)? Since 2011, some European countries have reduced by more than 50% their sales of veterinary antibiotics: https://t.co/cSaXwZagZe #EAAD2020 #ESVAC https://t.co/NFpxIyLogt","id":"1329426585380925442","conversation_id":"1329426585380925442","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":211,"end":220,"tag":"EAAD2020"},{"start":221,"end":227,"tag":"ESVAC"}],"urls":[{"start":187,"end":210,"url":"https://t.co/cSaXwZagZe","expanded_url":"https://www.ema.europa.eu/en/documents/report/sales-veterinary-antimicrobial-agents-31-european-countries-2018-trends-2010-2018-tenth-esvac-report_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":228,"end":251,"url":"https://t.co/NFpxIyLogt","expanded_url":"https://twitter.com/EMA_News/status/1329426585380925442/photo/1","display_url":"pic.twitter.com/NFpxIyLogt"}],"annotations":[{"start":40,"end":43,"probability":0.9057,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":["3_1329420768330059778"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2020-11-19T13:18:03.000Z","author_id":"116716199","text":"Global medicines regulators have a role in combating #AntimicrobialResistance. Through #ICMRA, we have joined the international regulatory community in the fight against #AMR. #OneHealth https://t.co/yzhwHDLXg0 https://t.co/rB1yn8J4dA","id":"1329413629234589698","conversation_id":"1329413629234589698","entities":{"mentions":{},"hashtags":[{"start":53,"end":77,"tag":"AntimicrobialResistance"},{"start":87,"end":93,"tag":"ICMRA"},{"start":170,"end":174,"tag":"AMR"},{"start":176,"end":186,"tag":"OneHealth"}],"urls":[{"start":187,"end":210,"url":"https://t.co/yzhwHDLXg0","expanded_url":"http://www.icmra.info/drupal/en/home","display_url":"icmra.info/drupal/en/home"},{"start":211,"end":234,"url":"https://t.co/rB1yn8J4dA","expanded_url":"https://twitter.com/EMA_News/status/1329413629234589698/photo/1","display_url":"pic.twitter.com/rB1yn8J4dA"}],"annotations":{}},"attachments":{"media_keys":["3_1329413619289829377"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":85,"reply_count":1,"like_count":121,"quote_count":27},"created_at":"2020-11-19T11:50:15.000Z","author_id":"116716199","text":"üì¢EMA will organise a public meeting on 11 Dec to inform citizens about the üá™üá∫ regulatory processes for the approval of #COVID19vaccines and the Agency‚Äôs role in their development, evaluation, approval &amp; monitoring: https://t.co/40hqgJ5SpM https://t.co/BmPm3r012J","id":"1329391536719732737","conversation_id":"1329391536719732737","entities":{"mentions":{},"hashtags":[{"start":119,"end":135,"tag":"COVID19vaccines"}],"urls":[{"start":219,"end":242,"url":"https://t.co/40hqgJ5SpM","expanded_url":"https://www.ema.europa.eu/en/news/ema-organises-public-meeting-covid-19-vaccines","display_url":"ema.europa.eu/en/news/ema-or‚Ä¶"},{"start":243,"end":266,"url":"https://t.co/BmPm3r012J","expanded_url":"https://twitter.com/EMA_News/status/1329391536719732737/photo/1","display_url":"pic.twitter.com/BmPm3r012J"}],"annotations":{}},"attachments":{"media_keys":["3_1329391301847101441"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":19,"quote_count":1},"created_at":"2020-11-19T11:15:02.000Z","author_id":"116716199","text":"#DYK that as a #veterinarian you can have a role in promoting the responsible use of #antibiotics with animal owners? #EAAD2020 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/2Or7jUn6Fq","id":"1329382673723383808","conversation_id":"1329382673723383808","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":15,"end":28,"tag":"veterinarian"},{"start":85,"end":97,"tag":"antibiotics"},{"start":118,"end":127,"tag":"EAAD2020"},{"start":128,"end":151,"tag":"KeepAntibioticsWorking"},{"start":152,"end":173,"tag":"AntibioticResistance"},{"start":174,"end":178,"tag":"AMR"}],"urls":[{"start":179,"end":202,"url":"https://t.co/2Or7jUn6Fq","expanded_url":"https://twitter.com/EMA_News/status/1329382673723383808/photo/1","display_url":"pic.twitter.com/2Or7jUn6Fq"}],"annotations":{}},"attachments":{"media_keys":["3_1329382664474943488"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":45,"quote_count":1},"created_at":"2020-11-19T08:00:06.000Z","author_id":"116716199","text":"You should use antibiotics only when and as prescribed by your doctor. If you need more information, talk to your doctor or pharmacist: https://t.co/BZsqwgHDRN #EAAD2020 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/ljoOfQvDaD","id":"1329333613989662721","conversation_id":"1329333613989662721","entities":{"mentions":{},"hashtags":[{"start":160,"end":169,"tag":"EAAD2020"},{"start":170,"end":193,"tag":"KeepAntibioticsWorking"},{"start":194,"end":215,"tag":"AntibioticResistance"},{"start":216,"end":220,"tag":"AMR"}],"urls":[{"start":136,"end":159,"url":"https://t.co/BZsqwgHDRN","expanded_url":"https://www.ema.europa.eu/en/news/ema-marks-european-antibiotic-awareness-day","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":221,"end":244,"url":"https://t.co/ljoOfQvDaD","expanded_url":"https://twitter.com/EMA_News/status/1329333613989662721/photo/1","display_url":"pic.twitter.com/ljoOfQvDaD"}],"annotations":{}},"attachments":{"media_keys":["3_1329333603965263876"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1329054315579895809"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-18T14:27:38.000Z","author_id":"116716199","text":"RT @ECDC_EU: Interested in #AntimicrobialResistance? Want to get informed and get involved in the fight against #AMR?\n\nCheck out our #EAAD‚Ä¶","id":"1329068755977048064","conversation_id":"1329068755977048064","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":27,"end":51,"tag":"AntimicrobialResistance"},{"start":112,"end":116,"tag":"AMR"},{"start":133,"end":138,"tag":"EAAD"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":23,"quote_count":1},"created_at":"2020-11-18T13:10:36.000Z","author_id":"116716199","text":"The world needs new #antibiotics to help us fight #AntibioticResistance. Pharmaceutical companies need to boost their research and development efforts. #EAAD2020 #KeepAntibioticsWorking #AMR https://t.co/nNg5etwL14 https://t.co/uyiR2NHZrp","id":"1329049368666796034","conversation_id":"1329049368666796034","entities":{"mentions":{},"hashtags":[{"start":20,"end":32,"tag":"antibiotics"},{"start":50,"end":71,"tag":"AntibioticResistance"},{"start":152,"end":161,"tag":"EAAD2020"},{"start":162,"end":185,"tag":"KeepAntibioticsWorking"},{"start":186,"end":190,"tag":"AMR"}],"urls":[{"start":191,"end":214,"url":"https://t.co/nNg5etwL14","expanded_url":"https://antibiotic.ecdc.europa.eu/en/european-antibiotic-awareness-day-eaad-2020","display_url":"antibiotic.ecdc.europa.eu/en/european-an‚Ä¶"},{"start":215,"end":238,"url":"https://t.co/uyiR2NHZrp","expanded_url":"https://twitter.com/EMA_News/status/1329049368666796034/photo/1","display_url":"pic.twitter.com/uyiR2NHZrp"}],"annotations":{}},"attachments":{"media_keys":["3_1329049358931816449"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1328974254596034560"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-18T12:52:43.000Z","author_id":"116716199","text":"RT @ECDC_EU: #EAAD is here and we have lots of interesting things to share with you!\n\nCheck our new page, dedicated to this year's digital‚Ä¶","id":"1329044866760929280","conversation_id":"1329044866760929280","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":18,"tag":"EAAD"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1329000330986663939"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":103,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-18T12:52:24.000Z","author_id":"116716199","text":"RT @ECDC_EU: We are now facing the possibility of a future where #antibiotics will no longer be effective due to the #AntimicrobialResistan‚Ä¶","id":"1329044785689219072","conversation_id":"1329044785689219072","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":65,"end":77,"tag":"antibiotics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":20,"quote_count":0},"created_at":"2020-11-18T12:05:18.000Z","author_id":"116716199","text":"As a #healthcareprofessional you can promote the responsible use of #antibiotics and explain to your patients that taking antibiotics and #AntibioticResistance are related. #EAAD2020 #KeepAntibioticsWorking #AMR https://t.co/BZsqwgHDRN https://t.co/2xDMBVMKNe","id":"1329032934746181632","conversation_id":"1329032934746181632","entities":{"mentions":{},"hashtags":[{"start":5,"end":28,"tag":"healthcareprofessional"},{"start":68,"end":80,"tag":"antibiotics"},{"start":138,"end":159,"tag":"AntibioticResistance"},{"start":173,"end":182,"tag":"EAAD2020"},{"start":183,"end":206,"tag":"KeepAntibioticsWorking"},{"start":207,"end":211,"tag":"AMR"}],"urls":[{"start":212,"end":235,"url":"https://t.co/BZsqwgHDRN","expanded_url":"https://www.ema.europa.eu/en/news/ema-marks-european-antibiotic-awareness-day","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":236,"end":259,"url":"https://t.co/2xDMBVMKNe","expanded_url":"https://twitter.com/EMA_News/status/1329032934746181632/photo/1","display_url":"pic.twitter.com/2xDMBVMKNe"}],"annotations":{}},"attachments":{"media_keys":["3_1329032924847599619"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":2,"like_count":71,"quote_count":6},"created_at":"2020-11-18T11:01:57.000Z","author_id":"116716199","text":"Antibiotics don‚Äôt work against viral infections. Don‚Äôt use them to treat a cold or flu. #EAAD2020 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/BZsqwgHDRN https://t.co/SXjOITYdwr","id":"1329016991265525760","conversation_id":"1329016991265525760","entities":{"mentions":{},"hashtags":[{"start":88,"end":97,"tag":"EAAD2020"},{"start":98,"end":121,"tag":"KeepAntibioticsWorking"},{"start":122,"end":143,"tag":"AntibioticResistance"},{"start":144,"end":148,"tag":"AMR"}],"urls":[{"start":149,"end":172,"url":"https://t.co/BZsqwgHDRN","expanded_url":"https://www.ema.europa.eu/en/news/ema-marks-european-antibiotic-awareness-day","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":173,"end":196,"url":"https://t.co/SXjOITYdwr","expanded_url":"https://twitter.com/EMA_News/status/1329016991265525760/photo/1","display_url":"pic.twitter.com/SXjOITYdwr"}],"annotations":{}},"attachments":{"media_keys":["3_1329016981597589511"]}},{"source":"Meltwater Social","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":5,"like_count":43,"quote_count":0},"created_at":"2020-11-18T09:46:38.000Z","author_id":"116716199","text":"üì£Today marks #EAAD2020. We all have a role to play when it comes to the responsible use of #antibiotics. #AMR is a high priority for EMA and its new Executive Director, Emer Cooke. \n‚û°Ô∏è https://t.co/nNg5etwL14 #AntibioticResistance #KeepAntibioticsWorking https://t.co/iTda5W2N2C","id":"1328998037545492481","conversation_id":"1328998037545492481","entities":{"mentions":{},"hashtags":[{"start":13,"end":22,"tag":"EAAD2020"},{"start":91,"end":103,"tag":"antibiotics"},{"start":105,"end":109,"tag":"AMR"},{"start":209,"end":230,"tag":"AntibioticResistance"},{"start":231,"end":254,"tag":"KeepAntibioticsWorking"}],"urls":[{"start":185,"end":208,"url":"https://t.co/nNg5etwL14","expanded_url":"https://antibiotic.ecdc.europa.eu/en/european-antibiotic-awareness-day-eaad-2020","display_url":"antibiotic.ecdc.europa.eu/en/european-an‚Ä¶"},{"start":255,"end":278,"url":"https://t.co/iTda5W2N2C","expanded_url":"https://twitter.com/EMA_News/status/1328998037545492481/photo/1","display_url":"pic.twitter.com/iTda5W2N2C"}],"annotations":[{"start":170,"end":179,"probability":0.9794,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":["3_1328998026317352961"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1328292875814248449"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-17T13:52:13.000Z","author_id":"116716199","text":"RT @EU_Health: How resilient have European health systems been to the COVID-19 crisis?\n\nJoin us, @SandraGallina and @OECD_Social in the pre‚Ä¶","id":"1328697452199862274","conversation_id":"1328697452199862274","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":97,"end":111,"username":"SandraGallina","id":"3746400628"},{"start":116,"end":128,"username":"OECD_Social","id":"85526005"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1328345447363121157"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-16T14:52:34.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (16.11.2020)\n\nGlobal:\n‚ñ™ 54 576 428 cases\n‚ñ™ 1 319 792 deaths\n\nEU/EEA/UK:\n‚ñ™ 10 727 551 cases\n‚ñ™ 267 394 d‚Ä¶","id":"1328350251871252482","conversation_id":"1328350251871252482","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6706,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":55,"reply_count":11,"like_count":167,"quote_count":31},"created_at":"2020-11-16T12:43:01.000Z","author_id":"116716199","text":"EMA is welcoming Emer Cooke who today took office as Executive Director of the Agency: \nüëâhttps://t.co/icf3mKI19W https://t.co/tTTOX6pxym","id":"1328317650750017536","conversation_id":"1328317650750017536","entities":{"mentions":{},"hashtags":{},"urls":[{"start":89,"end":112,"url":"https://t.co/icf3mKI19W","expanded_url":"https://www.ema.europa.eu/en/news/emer-cooke-takes-office-head-ema","display_url":"ema.europa.eu/en/news/emer-c‚Ä¶"},{"start":113,"end":136,"url":"https://t.co/tTTOX6pxym","expanded_url":"https://twitter.com/EMA_News/status/1328317650750017536/photo/1","display_url":"pic.twitter.com/tTTOX6pxym"}],"annotations":[{"start":0,"end":2,"probability":0.3797,"type":"Person","normalized_text":"EMA"},{"start":17,"end":26,"probability":0.9899,"type":"Person","normalized_text":"Emer Cooke"}]},"attachments":{"media_keys":["3_1328317493149102081"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":1,"like_count":75,"quote_count":15},"created_at":"2020-11-16T11:19:39.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA starts a rolling review of a 3rd #COVID19vaccine. First batch of data come from lab studies. Much of the evidence on the vaccine's safety and effectiveness is still to be submitted. https://t.co/2TTpxHnEsY #UnitedAgainstCoronavirus https://t.co/uAxBZ3qv8R","id":"1328296670984024067","conversation_id":"1328296670984024067","entities":{"mentions":{},"hashtags":[{"start":40,"end":55,"tag":"COVID19vaccine"},{"start":213,"end":238,"tag":"UnitedAgainstCoronavirus"}],"urls":[{"start":189,"end":212,"url":"https://t.co/2TTpxHnEsY","expanded_url":"https://www.ema.europa.eu/en/news/ema-starts-rolling-review-mrna-covid-19-vaccine-moderna-biotech-spain-sl","display_url":"ema.europa.eu/en/news/ema-st‚Ä¶"},{"start":239,"end":262,"url":"https://t.co/uAxBZ3qv8R","expanded_url":"https://twitter.com/EMA_News/status/1328296670984024067/photo/1","display_url":"pic.twitter.com/uAxBZ3qv8R"}],"annotations":{}},"attachments":{"media_keys":["3_1328296532165206019"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1328019084689207296"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-16T09:04:21.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (15.11.2020)\n\nGlobal:\n‚ñ™ 54 110 061 cases\n‚ñ™ 1 313 835 deaths\n\nEU/EEA/UK:\n‚ñ™ 10 560 273 cases\n‚ñ™ 265 184 d‚Ä¶","id":"1328262622106570753","conversation_id":"1328262622106570753","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6746,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":47,"quote_count":10},"created_at":"2020-11-13T13:49:00.000Z","author_id":"116716199","text":"‚ÄºÔ∏è EMA publishes a safety monitoring plan and guidance on risk management planning for #COVID19vaccines: \nüëâhttps://t.co/QIl4Yeb6Cx #pharmacovigilance #COVID19 https://t.co/OsJ31UNGMW","id":"1327247090276249601","conversation_id":"1327247090276249601","entities":{"mentions":{},"hashtags":[{"start":87,"end":103,"tag":"COVID19vaccines"},{"start":131,"end":149,"tag":"pharmacovigilance"},{"start":150,"end":158,"tag":"COVID19"}],"urls":[{"start":107,"end":130,"url":"https://t.co/QIl4Yeb6Cx","expanded_url":"https://www.ema.europa.eu/en/news/ema-publishes-safety-monitoring-plan-guidance-risk-management-planning-covid-19-vaccines","display_url":"ema.europa.eu/en/news/ema-pu‚Ä¶"},{"start":159,"end":182,"url":"https://t.co/OsJ31UNGMW","expanded_url":"https://twitter.com/EMA_News/status/1327247090276249601/photo/1","display_url":"pic.twitter.com/OsJ31UNGMW"}],"annotations":[{"start":3,"end":5,"probability":0.4949,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1327246920834756615"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":21,"like_count":20,"quote_count":3},"created_at":"2020-11-13T11:56:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 5 #medicines for approval at its November 2020 meeting https://t.co/ypVvJ6XfsZ https://t.co/DVv3eHNse3","id":"1327218653637521409","conversation_id":"1327218653637521409","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":106,"end":129,"url":"https://t.co/ypVvJ6XfsZ","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-november-2020","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":130,"end":153,"url":"https://t.co/DVv3eHNse3","expanded_url":"https://twitter.com/EMA_News/status/1327218653637521409/photo/1","display_url":"pic.twitter.com/DVv3eHNse3"}],"annotations":[{"start":0,"end":2,"probability":0.4608,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1327217253763444738"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":6,"like_count":99,"quote_count":13},"created_at":"2020-11-13T10:56:48.000Z","author_id":"116716199","text":"Today is Guido Rasi's last day as Executive Director of EMA. Thank you, Guido, for your leadership and commitment! https://t.co/C3EEjahnGd https://t.co/Sqw6lzQtXy","id":"1327203757558558720","conversation_id":"1327203757558558720","entities":{"mentions":{},"hashtags":{},"urls":[{"start":115,"end":138,"url":"https://t.co/C3EEjahnGd","expanded_url":"https://www.ema.europa.eu/en/news/message-emas-outgoing-executive-director","display_url":"ema.europa.eu/en/news/messag‚Ä¶"},{"start":139,"end":162,"url":"https://t.co/Sqw6lzQtXy","expanded_url":"https://twitter.com/EMA_News/status/1327203757558558720/photo/1","display_url":"pic.twitter.com/Sqw6lzQtXy"}],"annotations":[{"start":9,"end":18,"probability":0.9826,"type":"Person","normalized_text":"Guido Rasi"},{"start":72,"end":76,"probability":0.9855,"type":"Person","normalized_text":"Guido"}]},"attachments":{"media_keys":["3_1327203475713912833"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326935592660328448"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":64,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-13T08:37:17.000Z","author_id":"116716199","text":"RT @ECDC_EU: #JustPublished!\nRapid Risk Assessment: Detection of new #SARSCoV2 variants related to #mink.\n\nOn 5 Nov., #Denmark reported 214‚Ä¶","id":"1327168646347710464","conversation_id":"1327168646347710464","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":27,"tag":"JustPublished"},{"start":69,"end":78,"tag":"SARSCoV2"},{"start":99,"end":104,"tag":"mink"},{"start":118,"end":126,"tag":"Denmark"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326872706147627008"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-12T17:28:29.000Z","author_id":"116716199","text":"RT @EUombudsman: üÜï We have just launched our third üá™üá∫ 'Award for Good Administration' #EOaward üèÖ\n\nDo you know of any work or projects by EU‚Ä¶","id":"1326939940635209735","conversation_id":"1326939940635209735","entities":{"mentions":[{"start":3,"end":15,"username":"EUombudsman","id":"873777758"}],"hashtags":[{"start":86,"end":94,"tag":"EOaward"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":20,"quote_count":3},"created_at":"2020-11-12T13:47:37.000Z","author_id":"116716199","text":"See in this EMA report what steps are proposed to ensure that pregnant ü§∞ and breastfeeding women have the right information when taking decisions on their use of medicines üíä: https://t.co/5CF04160nJ https://t.co/AGLjC22LjI","id":"1326884354900062208","conversation_id":"1326884354900062208","entities":{"mentions":{},"hashtags":{},"urls":[{"start":175,"end":198,"url":"https://t.co/5CF04160nJ","expanded_url":"https://www.ema.europa.eu/en/documents/report/report-workshop-benefit-risk-medicines-used-during-pregnancy-breastfeeding_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":199,"end":222,"url":"https://t.co/AGLjC22LjI","expanded_url":"https://twitter.com/EMA_News/status/1326884354900062208/photo/1","display_url":"pic.twitter.com/AGLjC22LjI"}],"annotations":{}},"attachments":{"media_keys":["3_1326884341197254656"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326881828091924480"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-12T13:43:29.000Z","author_id":"116716199","text":"RT @edqm_news: #COVID19 #vaccines: release of guidelines critical for co-ordinated independent batch control by OMCLs\nEDQM has published 3‚Ä¶","id":"1326883314133819393","conversation_id":"1326883314133819393","entities":{"mentions":[{"start":3,"end":13,"username":"edqm_news","id":"2242197968"}],"hashtags":[{"start":15,"end":23,"tag":"COVID19"},{"start":24,"end":33,"tag":"vaccines"}],"urls":{},"annotations":[{"start":112,"end":121,"probability":0.7975,"type":"Person","normalized_text":"OMCLs EDQM"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1323988987715997698"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-12T13:31:55.000Z","author_id":"116716199","text":"RT @IDFEuropeBXL: üì¢Our virtual #WorldDiabetesDay symposium will be on November 17th, 9.30-10.45‚ùóÔ∏è\n\nRegister now üëâhttps://t.co/T4fHP1BQH3\nLe‚Ä¶","id":"1326880403874062336","conversation_id":"1326880403874062336","entities":{"mentions":[{"start":3,"end":16,"username":"IDFEuropeBXL","id":"848831221"}],"hashtags":[{"start":31,"end":48,"tag":"WorldDiabetesDay"}],"urls":[{"start":113,"end":136,"url":"https://t.co/T4fHP1BQH3","expanded_url":"https://bit.ly/34W22tR","display_url":"bit.ly/34W22tR"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326551811587670028"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-12T08:18:56.000Z","author_id":"116716199","text":"RT @DSMeu: üá™üá∫‚öïÔ∏è A stronger #HealthUnion = a secure &amp; patient-oriented use of #health data üåê\n\nWith a European Health Data Space we can have:‚Ä¶","id":"1326801640624676864","conversation_id":"1326801640624676864","entities":{"mentions":{},"hashtags":[{"start":27,"end":39,"tag":"HealthUnion"},{"start":81,"end":88,"tag":"health"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326539264952168455"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-12T08:18:44.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (11.11.2020)\n\nGlobal:\n‚ñ™ 51 552 875 cases\n‚ñ™ 1 274 311 deaths\n\nEU/EEA/UK:\n‚ñ™ 9 650 447 cases\n‚ñ™ 251 064 de‚Ä¶","id":"1326801589592596480","conversation_id":"1326801589592596480","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6662,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326490245878206464"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":52,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-11T15:16:37.000Z","author_id":"116716199","text":"RT @EU_Health: Today, we‚Äôre proposing the first building blocks of a more secure, better-prepared and more resilient EU in the area of heal‚Ä¶","id":"1326544367809568771","conversation_id":"1326544367809568771","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326492983320047618"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":70,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-11T12:46:02.000Z","author_id":"116716199","text":"RT @vonderleyen: Our #HealthUnion will be based on:\n\nüî∏A stronger health security framework to reinforce preparedness &amp; response.\n\nüî∏A reinfo‚Ä¶","id":"1326506472356909056","conversation_id":"1326506472356909056","entities":{"mentions":[{"start":3,"end":15,"username":"vonderleyen","id":"1146329871418843136"}],"hashtags":[{"start":21,"end":33,"tag":"HealthUnion"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1326205468491063299"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-11T08:32:57.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (10.11.2020)\n\nGlobal:\n‚ñ™ 50 994 215 cases\n‚ñ™ 1 264 077 deaths\n\nEU/EEA/UK:\n‚ñ™ 9 444 285 cases\n‚ñ™ 246 405 de‚Ä¶","id":"1326442777882845184","conversation_id":"1326442777882845184","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6028,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":0,"like_count":44,"quote_count":5},"created_at":"2020-11-10T15:36:43.000Z","author_id":"116716199","text":"Do you have questions about #COVID19vaccines? EMA‚Äôs key facts webpage may have some of the answers: \nüëâhttps://t.co/FlCBPO6esB https://t.co/D0dMbnB2my","id":"1326187037649756167","conversation_id":"1326187037649756167","entities":{"mentions":{},"hashtags":[{"start":28,"end":44,"tag":"COVID19vaccines"}],"urls":[{"start":102,"end":125,"url":"https://t.co/FlCBPO6esB","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/covid-19-vaccines-key-facts","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":126,"end":149,"url":"https://t.co/D0dMbnB2my","expanded_url":"https://twitter.com/EMA_News/status/1326187037649756167/photo/1","display_url":"pic.twitter.com/D0dMbnB2my"}],"annotations":{}},"attachments":{"media_keys":["3_1326186852898967553"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":2,"like_count":7,"quote_count":1},"created_at":"2020-11-10T09:20:26.000Z","author_id":"116716199","text":"üì¢ Find out more about a new opportunity for specialists in #pharmacovigilance to join EMA‚Äôs safety committee, the #PRAC. Expressions of interest can be submitted to @EU_Health by 20 Nov 2020\nüëâhttps://t.co/8cZ1miweBs https://t.co/ISlYyOmwi7","id":"1326092339597729792","conversation_id":"1326092339597729792","entities":{"mentions":[{"start":165,"end":175,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":59,"end":77,"tag":"pharmacovigilance"},{"start":114,"end":119,"tag":"PRAC"}],"urls":[{"start":192,"end":215,"url":"https://t.co/8cZ1miweBs","expanded_url":"https://www.ema.europa.eu/en/news/call-independent-scientific-experts-join-emas-pharmacovigilance-risk-assessment-committee-prac-0","display_url":"ema.europa.eu/en/news/call-i‚Ä¶"},{"start":216,"end":239,"url":"https://t.co/ISlYyOmwi7","expanded_url":"https://twitter.com/EMA_News/status/1326092339597729792/photo/1","display_url":"pic.twitter.com/ISlYyOmwi7"}],"annotations":{}},"attachments":{"media_keys":["3_1326092123544948736"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1325489522067517440"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-09T15:13:06.000Z","author_id":"116716199","text":"RT @ECDC_EU: Having lots of questions on #COVID19?\n\nWe have prepared some Q&amp;A's for you!\nKnow more about #SARSCOV2 virus, travelling in tim‚Ä¶","id":"1325818706136543232","conversation_id":"1325818706136543232","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":41,"end":49,"tag":"COVID19"},{"start":109,"end":118,"tag":"SARSCOV2"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1325776634499244032"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-09T15:12:45.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (09.11.2020)\n\nGlobal:\n‚ñ™ 50 414 235 cases\n‚ñ™ 1 255 831 deaths\n\nEU/EEA/UK:\n‚ñ™ 9 245 073 cases\n‚ñ™ 243 470 de‚Ä¶","id":"1325818615493431299","conversation_id":"1325818615493431299","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.5195,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1324773545134772224"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-09T15:12:24.000Z","author_id":"116716199","text":"RT @EUjamrai: üì¢A contest. More than 600 applications. Only 1 winner! We called to action creative minds from all over the world to design t‚Ä¶","id":"1325818528839196673","conversation_id":"1325818528839196673","entities":{"mentions":[{"start":3,"end":12,"username":"EUjamrai","id":"925330504630591488"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":1,"like_count":3,"quote_count":0},"created_at":"2020-11-09T10:53:27.000Z","author_id":"116716199","text":"What's on the agenda of the November meeting of EMA's human medicines committee: https://t.co/JHOviHijBx #CHMP","id":"1325753363087110147","conversation_id":"1325753363087110147","entities":{"mentions":{},"hashtags":[{"start":105,"end":110,"tag":"CHMP"}],"urls":[{"start":81,"end":104,"url":"https://t.co/JHOviHijBx","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-9-12-november-2020-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":48,"end":50,"probability":0.295,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":2,"like_count":23,"quote_count":2},"created_at":"2020-11-09T09:57:28.000Z","author_id":"116716199","text":"International regulators (#ICMRA) and @WHO join forces to ensure that #patients have access to safe and effective medicines üíä against #COVID19 as early as possible. Read their joint statement: \nüëâhttps://t.co/A1yeF72KPw\n#UnitedAgainstCoronavirus https://t.co/5nwaGg0hjH","id":"1325739272868163586","conversation_id":"1325739272868163586","entities":{"mentions":[{"start":38,"end":42,"username":"WHO","id":"14499829"}],"hashtags":[{"start":26,"end":32,"tag":"ICMRA"},{"start":70,"end":79,"tag":"patients"},{"start":134,"end":142,"tag":"COVID19"},{"start":219,"end":244,"tag":"UnitedAgainstCoronavirus"}],"urls":[{"start":195,"end":218,"url":"https://t.co/A1yeF72KPw","expanded_url":"https://www.ema.europa.eu/en/news/international-regulators-who-join-forces-address-covid-19-challenges","display_url":"ema.europa.eu/en/news/intern‚Ä¶"},{"start":245,"end":268,"url":"https://t.co/5nwaGg0hjH","expanded_url":"https://twitter.com/EMA_News/status/1325739272868163586/photo/1","display_url":"pic.twitter.com/5nwaGg0hjH"}],"annotations":{}},"attachments":{"media_keys":["3_1325739225866768385"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1324732169374343171"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-06T16:56:44.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (06.11.2020)\n\nGlobal:\n‚ñ™ 48 763 203 cases\n‚ñ™ 1 234 371 deaths\n\nEU/EEA/UK:\n‚ñ™ 8 528 088 cases\n‚ñ™ 235 648 de‚Ä¶","id":"1324757623862972416","conversation_id":"1324757623862972416","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1324700582960123904"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-06T14:06:40.000Z","author_id":"116716199","text":"RT @ECDC_EU: Most important information on #COVID19 in your language!\nClick here: https://t.co/8jROjlSvH2 and learn more!\n\n#StrongerTogethe‚Ä¶","id":"1324714821191929857","conversation_id":"1324714821191929857","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":43,"end":51,"tag":"COVID19"}],"urls":[{"start":82,"end":105,"url":"https://t.co/8jROjlSvH2","expanded_url":"https://bit.ly/34T1IME","display_url":"bit.ly/34T1IME"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1323901654379466758"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-06T12:12:20.000Z","author_id":"116716199","text":"RT @edqm_news: New EDQM document on recombinant viral vectored vaccines to support #COVID19 #vaccine developers\n\nhttps://t.co/GTxTzLpyGj ht‚Ä¶","id":"1324686051173146624","conversation_id":"1324686051173146624","entities":{"mentions":[{"start":3,"end":13,"username":"edqm_news","id":"2242197968"}],"hashtags":[{"start":83,"end":91,"tag":"COVID19"},{"start":92,"end":100,"tag":"vaccine"}],"urls":[{"start":113,"end":136,"url":"https://t.co/GTxTzLpyGj","expanded_url":"https://www.edqm.eu/en/news/new-edqm-document-recombinant-viral-vectored-vaccines-support-covid-19-vaccine-developers","display_url":"edqm.eu/en/news/new-ed‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1324377069128765440"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-05T16:17:14.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (05.11.2020)\n\nGlobal:\n‚ñ™ 48 171 563 cases\n‚ñ™ 1 226 241 deaths\n\nEU/EEA/UK:\n‚ñ™ 8 261 087 cases\n‚ñ™ 232 600 de‚Ä¶","id":"1324385295303888902","conversation_id":"1324385295303888902","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6089,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":1,"like_count":40,"quote_count":1},"created_at":"2020-11-05T15:05:00.000Z","author_id":"116716199","text":"EMA plays an important role in the development, scientific evaluation, approval and monitoring of #COVID19vaccines in the EU üá™üá∫. Consult our webpage to see how: https://t.co/zwy3FGX20N https://t.co/wOL68CdTcs","id":"1324367114866601985","conversation_id":"1324367114866601985","entities":{"mentions":{},"hashtags":[{"start":98,"end":114,"tag":"COVID19vaccines"}],"urls":[{"start":161,"end":184,"url":"https://t.co/zwy3FGX20N","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-development-evaluation-approval-monitoring","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":185,"end":208,"url":"https://t.co/wOL68CdTcs","expanded_url":"https://twitter.com/EMA_News/status/1324367114866601985/photo/1","display_url":"pic.twitter.com/wOL68CdTcs"}],"annotations":[{"start":0,"end":2,"probability":0.3027,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1324365726539546625"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1323990101211418625"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-11-04T14:17:35.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (04.11.2020)\n\nGlobal:\n‚ñ™ 47 594 234 cases\n‚ñ™ 1 215 892 deaths\n\nEU/EEA/UK:\n‚ñ™ 8 008 149 cases\n‚ñ™ 228 182 de‚Ä¶","id":"1323992793807790080","conversation_id":"1323992793807790080","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.5892,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":39,"reply_count":11,"like_count":44,"quote_count":9},"created_at":"2020-10-30T13:52:59.000Z","author_id":"116716199","text":"‚ÄºÔ∏è Extra transparency measures: EMA publishes clinical data submitted for the authorisation of Veklury (#remdesivir) and information on the #COVID19 treatments &amp; vaccines that have received scientific advice from the Agency: \n\nüëâhttps://t.co/WK5jjlmqYG https://t.co/1vD5Gslmr4","id":"1322174666165932032","conversation_id":"1322174666165932032","entities":{"mentions":{},"hashtags":[{"start":104,"end":115,"tag":"remdesivir"},{"start":140,"end":148,"tag":"COVID19"}],"urls":[{"start":232,"end":255,"url":"https://t.co/WK5jjlmqYG","expanded_url":"https://www.ema.europa.eu/en/news/extra-transparency-measures-covid-19-vaccines-therapeutics","display_url":"ema.europa.eu/en/news/extra-‚Ä¶"},{"start":256,"end":279,"url":"https://t.co/1vD5Gslmr4","expanded_url":"https://twitter.com/EMA_News/status/1322174666165932032/photo/1","display_url":"pic.twitter.com/1vD5Gslmr4"}],"annotations":{}},"attachments":{"media_keys":["3_1322174621307883522"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":16,"quote_count":1},"created_at":"2020-10-30T11:25:28.000Z","author_id":"116716199","text":"At its monthly meeting, EMA‚Äôs safety committee (#PRAC) reviewed the guidance for companies on how to prepare risk management plans for #COVID19vaccines. The \noverview of the meeting: \nüëâhttps://t.co/RcGtrsBIp7\n#safetyofmedicines #pharmacovigilance https://t.co/1k6Liq5TJy","id":"1322137540325969920","conversation_id":"1322137540325969920","entities":{"mentions":{},"hashtags":[{"start":48,"end":53,"tag":"PRAC"},{"start":135,"end":151,"tag":"COVID19vaccines"},{"start":209,"end":227,"tag":"safetyofmedicines"},{"start":228,"end":246,"tag":"pharmacovigilance"}],"urls":[{"start":185,"end":208,"url":"https://t.co/RcGtrsBIp7","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-26-29-october-2020","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/1k6Liq5TJy","expanded_url":"https://twitter.com/EMA_News/status/1322137540325969920/photo/1","display_url":"pic.twitter.com/1k6Liq5TJy"}],"annotations":[{"start":24,"end":26,"probability":0.543,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1322137265573867522"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1321420796686905346"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-29T09:53:02.000Z","author_id":"116716199","text":"RT @EU_Health: The rise in #COVID19 infection rates across Europe is alarming\n\nCssr @SKyriakidesEU underlines that decisive &amp; immediate act‚Ä¶","id":"1321751890716143619","conversation_id":"1321751890716143619","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":84,"end":98,"username":"SKyriakidesEU","id":"2476130260"}],"hashtags":[{"start":27,"end":35,"tag":"COVID19"}],"urls":{},"annotations":[{"start":59,"end":64,"probability":0.9941,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1321463920155123713"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-29T09:52:14.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (28.10.2020)\n\nGlobal:\n‚ñ™ 44 052 388 cases\n‚ñ™ 1 168 076 deaths\n\nEU/EEA/UK:\n‚ñ™ 6 466 450 cases\n‚ñ™ 213 207 de‚Ä¶","id":"1321751691201597440","conversation_id":"1321751691201597440","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.6305,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":9,"quote_count":2},"created_at":"2020-10-29T08:56:51.000Z","author_id":"116716199","text":"Follow the üé¶live broadcast of EMA's 25th anniversary symposium on new approaches in patient-focused #CancerDrug development: \nüëâhttps://t.co/dKsEiURABm https://t.co/OHTjtjeWns","id":"1321737750199021568","conversation_id":"1321737750199021568","entities":{"mentions":{},"hashtags":[{"start":100,"end":111,"tag":"CancerDrug"}],"urls":[{"start":127,"end":150,"url":"https://t.co/dKsEiURABm","expanded_url":"https://www.ema.europa.eu/en/events/ema-25th-anniversary-symposium-new-approaches-patient-focused-cancer-drug-development","display_url":"ema.europa.eu/en/events/ema-‚Ä¶"},{"start":151,"end":174,"url":"https://t.co/OHTjtjeWns","expanded_url":"https://twitter.com/EMA_News/status/1321737750199021568/photo/1","display_url":"pic.twitter.com/OHTjtjeWns"}],"annotations":[{"start":31,"end":33,"probability":0.4425,"type":"Other","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1321737725930835968"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1321416894109331458"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-28T13:33:07.000Z","author_id":"116716199","text":"RT @SKyriakidesEU: The rise in üá™üá∫ #COVID19 infections is alarming. Member States must take decisive action now to protect lives and livelih‚Ä¶","id":"1321444889838702595","conversation_id":"1321444889838702595","entities":{"mentions":[{"start":3,"end":17,"username":"SKyriakidesEU","id":"2476130260"}],"hashtags":[{"start":34,"end":42,"tag":"COVID19"}],"urls":{},"annotations":[{"start":31,"end":34,"probability":0.6294,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1321418061140889600"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-28T13:32:49.000Z","author_id":"116716199","text":"RT @EU_Health: #Coronavirus resurgence: unfortunately, the relaxation of measures during the summer wasn't always accompanied by steps to b‚Ä¶","id":"1321444812839636993","conversation_id":"1321444812839636993","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":27,"tag":"Coronavirus"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1320800508064518154"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-27T09:33:53.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (26.10.2020)\n\nGlobal:\n‚ñ™ 43 140 173 cases\n‚ñ™ 1 155 235 deaths\n\nEU/EEA/UK:\n‚ñ™ 6 077 377 cases\n‚ñ™ 209 542 de‚Ä¶","id":"1321022295922671616","conversation_id":"1321022295922671616","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.5899,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1320681436081475588"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-26T14:50:41.000Z","author_id":"116716199","text":"RT @EU_Health: What should a European Health Union look like?\n\nJoin VP @MargSchinas &amp; @SKyriakidesEU as they reflect on lessons learned fro‚Ä¶","id":"1320739635736227840","conversation_id":"1320739635736227840","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":71,"end":83,"username":"MargSchinas","id":"820190174"},{"start":90,"end":104,"username":"SKyriakidesEU","id":"2476130260"}],"hashtags":{},"urls":{},"annotations":[{"start":29,"end":49,"probability":0.4975,"type":"Organization","normalized_text":"European Health Union"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1320689596984864769"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-26T14:50:26.000Z","author_id":"116716199","text":"RT @ECDC_EU: #JustPublished! \n\nKey aspects regarding the introduction and prioritisation of #COVID19 #vaccination in the EU/EEA and the UK.‚Ä¶","id":"1320739571798335492","conversation_id":"1320739571798335492","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":13,"end":27,"tag":"JustPublished"},{"start":92,"end":100,"tag":"COVID19"},{"start":101,"end":113,"tag":"vaccination"}],"urls":{},"annotations":[{"start":136,"end":137,"probability":0.9449,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1318879997659140097"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-23T08:08:29.000Z","author_id":"116716199","text":"RT @EU_Health: ‚ö†Ô∏èReminder: The safety requirements for #COVID19 vaccines remain as high as for any other vaccine in the EU, &amp; the context o‚Ä¶","id":"1319551251554717696","conversation_id":"1319551251554717696","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":55,"end":63,"tag":"COVID19"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1319279803543945217"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-23T08:08:04.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today's #COVID19 update (22.10.2020)\n\nGlobal:\n‚ñ™ 41 299 301 cases\n‚ñ™ 1 132 500 deaths\n\nEU/EEA/UK:\n‚ñ™ 5 339 149 cases\n‚ñ™ 204 661 de‚Ä¶","id":"1319551150325104640","conversation_id":"1319551150325104640","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":21,"end":29,"tag":"COVID19"}],"urls":{},"annotations":[{"start":105,"end":106,"probability":0.641,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1319289263750430725"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":107,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-23T08:07:50.000Z","author_id":"116716199","text":"RT @ECDC_EU: Updated weekly üö¶ maps now online! \n\nThese maps aim to support the @EUCouncil Recommendation on a coordinated approach to the r‚Ä¶","id":"1319551087947505664","conversation_id":"1319551087947505664","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":79,"end":89,"username":"EUCouncil","id":"206717989"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":6,"quote_count":1},"created_at":"2020-10-22T16:44:26.000Z","author_id":"116716199","text":"#DYK that the older population in the üá™üá∫ is expected to grow from 84 ml in 2008 to 141 ml by 2050, acc to @Eurostat? \nEMA published a reflection paper on how üíä can be better designed for older people: \nüëâhttps://t.co/BvwmwANY01 https://t.co/DsFsCR8yFj","id":"1319318709832474624","conversation_id":"1319318709832474624","entities":{"mentions":[{"start":106,"end":115,"username":"EuroStat","id":"156845666"}],"hashtags":[{"start":0,"end":4,"tag":"DYK"}],"urls":[{"start":203,"end":226,"url":"https://t.co/BvwmwANY01","expanded_url":"https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf","display_url":"ema.europa.eu/en/documents/s‚Ä¶"},{"start":227,"end":250,"url":"https://t.co/DsFsCR8yFj","expanded_url":"https://twitter.com/EMA_News/status/1319318709832474624/photo/1","display_url":"pic.twitter.com/DsFsCR8yFj"}],"annotations":{}},"attachments":{"media_keys":["3_1319318443825528835"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1319274563855736845"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2020-10-22T14:28:13.000Z","author_id":"116716199","text":"RT @PGEU: At the #EMA25years virtual conference, our Secretary General @IlariaPassarani highlighted PGEU's support for an expanded role of‚Ä¶","id":"1319284427969605633","conversation_id":"1319284427969605633","entities":{"mentions":[{"start":3,"end":8,"username":"PGEU","id":"459292439"},{"start":71,"end":87,"username":"IlariaPassarani","id":"1106659014"}],"hashtags":[{"start":17,"end":28,"tag":"EMA25years"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2020-10-22T14:26:35.000Z","author_id":"116716199","text":"Jose Drabwell, @ipopi_info: It's also up to #patients', consumers' and #healthcareprofessionals' organisations to widen the knowledge of the clinical trials database. It's an important access to data. #clinicaltrials #EMA25Years","id":"1319284018563567617","conversation_id":"1319284018563567617","entities":{"mentions":[{"start":15,"end":26,"username":"ipopi_info","id":"1117085011"}],"hashtags":[{"start":44,"end":53,"tag":"patients"},{"start":71,"end":95,"tag":"healthcareprofessionals"},{"start":201,"end":216,"tag":"clinicaltrials"},{"start":217,"end":228,"tag":"EMA25Years"}],"urls":{},"annotations":[{"start":0,"end":12,"probability":0.9278,"type":"Person","normalized_text":"Jose Drabwell"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":1,"like_count":10,"quote_count":1},"created_at":"2020-10-22T14:11:00.000Z","author_id":"116716199","text":"Nancy De Briyne,¬†@FVEurope: New¬†#veterinary¬†legislation brings tools to boost innovation in veterinary medicine, which hopefully translates into new¬†üíä¬†for animals. It will bring steps fwd when it comes to¬†#AMR, as it will improve the use¬†of #antibiotics¬†in animals.¬†#EMA25Years","id":"1319280097522708482","conversation_id":"1319280097522708482","entities":{"mentions":[{"start":17,"end":26,"username":"FVEurope","id":"1549866445"}],"hashtags":[{"start":32,"end":43,"tag":"veterinary"},{"start":205,"end":209,"tag":"AMR"},{"start":241,"end":253,"tag":"antibiotics"},{"start":266,"end":277,"tag":"EMA25Years"}],"urls":{},"annotations":[{"start":0,"end":14,"probability":0.8511,"type":"Person","normalized_text":"Nancy De Briyne"}]},"attachments":{"media_keys":{}}}]
